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Abstract 
Adipose tissue (AT) functions as an active endocrine organ and an energy 
reserve compartment for storing lipids. It’s now well accepted that adipose 
tissue expandability, remodelling and effective storage of excess lipids in the 
form of triglycerides (TAGs) play an important role in maintaining metabolic 
homeostasis. To understand healthy AT expansion and function, we used human 
derived in-vitro adipocyte models to interrogate pathways of interest, as well as 
Next Generation Sequencing methods. We first sought to validate and 
functionally characterize two GWAS candidate genes involved in lipid 
metabolism and expressed in adipose; FIT2 (Fat Storage Inducing 
Transmembrane Protein 2) and FTO (Fat Mass and Obesity Associated). The 
FIT2 gene is associated with type 2 diabetes in the East Asian population and 
plays a role in transporting TAGs from ER to lipid droplets. On the other hand, 
FTO is an obesity associated gene in multiple ethnicities and regulates 
mitochondrial energy expenditure through central and peripheral mechanisms. 
Our observations suggest that improved TAG storage via FIT2 protein as well 
as improved mitochondrial oxidative capacity via FTO protein can promote 
insulin sensitivity in primary human adipocytes. Next, using RNA sequencing 
data from AT, we observed positive enrichment in the extracellular matrix 
(ECM) and fibrosis components in omental AT depots from T2DM when 
compared to NT2DM subjects. Excessive ECM and fibrosis components have 
been shown to inhibit obesity associated adipose tissue expansion and 
inflammation in the obese, but the differences identified in the OM depot among 
obese T2DM and obese NT2DM subjects are novel. Overall, our work 
contributes insights into the molecular and transcriptomic determinants of 
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HMOX1 heme oxygenase (decycling) 1 
HO1 Heme Oxygenase 1 
HRP horse radish peroxidase 
HSPG2 heparan sulfate proteoglycan 2 
IBMX 3-isobutyl-1-methylxanthine 
IκKB/IKBKB Inhibitor Of Kappa Light Polypeptide Gene Enhancer In 
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ITGA10 integrin, alpha 10 
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ITGA2 integrin, alpha 2 (CD49B, alpha 2 subunit of VLA-2 
receptor) 
ITGA3 integrin, alpha 3 (antigen CD49C, alpha 3 subunit of 
VLA-3 receptor) 
ITGA4 integrin, alpha 4 (antigen CD49D, alpha 4 subunit of 
VLA-4 receptor) 
ITGA7 integrin, alpha 7 
ITGB1 integrin, beta 1 (fibronectin receptor, beta polypeptide, 
antigen CD29 includes MDF2, MSK12) 
  XXV  
 
ITGB3 integrin, beta 3 (platelet glycoprotein IIIa, antigen CD61) 
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ITGB5 integrin, beta 5 
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KEGG Kyoto Encyclopedia of Genes and Genomes 
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LAMA3 laminin, alpha 3 
LAMB1 laminin, beta 1 
LAMB2 laminin, beta 2 (laminin S) 
LAMB3 laminin, beta 3 
LAMC2 laminin, gamma 2 
LPL lipoprotein lipase 
MCP1 monocyte Chemotactic Protein 1 
MET met proto-oncogene (hepatocyte growth factor receptor) 
MHO metabolically healthy obese 
MMP Matrix Metallopeptidase 
mRNA messenger RNA 
MSR1 macrophage scavenger receptor 1 
mTOR mechanistic target of rapamycin (serine/threonine kinase) 
MTUS1 mitochondrial tumor suppressor 1 
MYF5 myogenic factor 5 
NADH nicotinamide adenine dinucleotide 
NEAA non-essential amino acids 
NFκB1 Nuclear Factor Of Kappa Light Polypeptide Gene 
Enhancer In B-Cells 1 
NR1H3 nuclear receptor subfamily 1, group H, member 3 
NRF2/NFE2L2 Nuclear Factor, Erythroid 2-Like 2 
NRIP1 nuclear receptor interacting protein 1 
NT2DM non type 2 diabetes or non-type 2 diabetics 
OCR oxygen consumption rate 
OFD1 oral-facial-digital syndrome 1 
OM omental 
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PAX7 paired box 7 
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PDGFRα platelet-derived growth factor receptor, alpha polypeptide 
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PGC1α/PPARGC1A Peroxisome Proliferator-Activated Receptor Gamma, 
Coactivator 1 Alpha 
PKA/PRKACA Protein Kinase, CAMP-Dependent, Catalytic, Alpha 
PLIN1 perilipin 
PLIN2 adipose differentiation-related protein 
PLIN4 KIAA1881 
PLIN5 lipid storage droplet protein 5 
PNPLA2 patatin-like phospholipase domain containing 2 
PPARα peroxisome proliferator-activated receptor alpha 
PPARγ peroxisome proliferator-activated receptor gamma 
PPP2R2C protein phosphatase 2 (formerly 2A), regulatory subunit 
B, gamma isoform 
PRDM16 PR domain containing 16 
PTPN2 protein tyrosine phosphatase, non-receptor type 2 
PVDF polyvinylidene fluoride 
RBP4 retinol binding protein 4, plasma 
RELN reelin 
RNA ribonucleic acid 
ROS reactive oxygen species 
SAT subcutaneous adipose tissue 
SC subcutaneous 
SCARB1 scavenger receptor class B, member 1 
SDC4 syndecan 4 
SDS sodium dodecyl sulfate 
SGBS Simpson Golabi Behmel Syndrome 
siRNA small interfering RNA 
SNP single nucleotide polymorphism 
SPP1 secreted phosphoprotein 1 
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SV2B synaptic vesicle glycoprotein 2B; hypothetical protein 
LOC100128403 
SVF stromal vascular fraction 
T2DM type 2 diabetes or type 2 diabetics 
T3 triiodothyronine 
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TBS tris buffered saline 
TCA tricarboxylic acid (TCA) 
TGF transforming growth factor 
THBS1 thrombospondin 1 
THBS2 thrombospondin 2 
THBS3 thrombospondin 3 
THBS4 thrombospondin 4 
TIP47/PLIN3 Perilipin 3 
TLR4 toll-like receptor 4 
TNC tenascin C 
TNF Tumor Necrosis Factor 
TNN tenascin N 
TNXB tenascin XB; tenascin XA pseudogene 
UCP1 uncoupling protein 1 (mitochondrial, proton carrier) 
UPR unfolded protein response 
VAT visceral adipose tissue 
VEGF Vascular Endothelial Growth Factor 
VWF Von Willebrand factor 
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1.1 Type 2 diabetes and obesity 
Diabetes mellitus is a group of metabolic diseases in which there is 
hyperglycemia, due to either the pancreas not producing enough insulin (insulin 
deficiency) or the cells of the body not responding properly to the insulin 
produced (insulin resistance), or both [1]. If left untreated, diabetes can cause 
many complications, including cardiovascular disease, stroke, chronic kidney 
failure, foot ulcers, and damage to the eyes [2]. 
Type 2 diabetes mellitus (T2DM) is the most common form of adult onset 
(observed usually at age of 40 years and above) diabetes in the world with strong 
genetic, ethnic and environmental influence. Owing to polygenic nature and 
involvement of multiple tissues and proteins in its pathogenesis, diabetes has no 
cure yet and a major focus in metabolism research has been towards better 
management and longer healthy lifespan of the patients. Currently, T2DM 
affects almost 387 million (8.3% of total population) people worldwide, and this 
figure is expected to increase to 592 million by the year 2035 with 
approximately 46.3% of patients remaining undiagnosed. T2DM as a disease 
also levies huge financial burden (612 billion USD in 2014) on the patients and 
thus there is a constant requirement for better research, healthcare management 
guidelines and strategies for early diagnosis of T2DM [3]. Worldwide 
demographics show that the Western Pacific region has the highest number of 
diabetic individuals (138 million) followed by Southeast Asian population 
which includes approximately 70 million diabetic adults. Within Singapore, 
12.3% of the total population (18-69 years old) is diabetic (increased from 4.7% 
in the year 1984, figure 1). 
 3 
 
D ia b e t e s  p r e v a le n c e











































D ia b e t e s  (S in g a p o re )
D ia b e te s  (U S A )
Figure 1: Diabetes burden in Singapore and United States of America (USA). 
Adapted from Diabetes Atlas, International Diabetes Federation (edition 1-6). 
Dots and squares represent the percentage of diabetic individuals calculated 
based on the national population.  
Ethnic Asians are predisposed to cardio-metabolic disorders at an earlier age as 
well as lower Body Mass Index (BMI) [4], primarily due to the differences in 
their body fat distribution [5]. Epidemiology studies indicate that at a given 
BMI, Asians tend to accumulate greater amounts of central or abdominal fat 
when compared to western population which accelerates the development of 
insulin resistance and associated complications [5, 6]. This phenomenon is 
exemplified in the Singaporean population (figure 1 and 2) as they have a 
similar prevalence of diabetes when compared to United States of America 
(USA), even though the percentage of the obese and overweight population is 
lower than that of USA. Hence, there exists a discordance between obesity or 
amount of adipose tissue depot and incidence of insulin resistance or diabetes 
in various ethnic groups. Thus, studying adipose tissue depots in adult humans 
might provide clues for understanding the reasons behind variances in the 
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Figure 2: Prevalence of obesity and overweight adults in Singapore and USA. 
Bars represent the percentage of obese and overweight people calculated based 
on national population. Data adapted from WHO Global Database for Body 
Mass Index. Overweight and obesity were defined as BMI ≥ 25.0 and BMI ≥ 30 
respectively. Obesity percentage in Singapore increases to 23% if BMI ≥ 27.5 
is used for defining obesity (Asian cut-off). 
1.2 Functional categories of adipocytes and anatomical distribution of 
adipose tissue 
In adult humans, white adipose tissue (WAT) forms majority of adipose and is 
important in maintaining metabolic homeostasis along with brown adipose 
tissue (BAT). Adipocytes are functional lipid storing cells inside adipose tissue 
and three types of functionally different adipocytes found in humans are white, 
brown and beige [7, 8] (figure 3). Depending on anatomical location, 
mammalian white adipocytes are typically distributed into subcutaneous (SAT 
or SC) and omental (OM) or visceral adipose tissue depots (VAT). SAT lies 
underneath the skin performing a more protective and thermoregulatory 
function whereas VAT is located inside the abdominal cavity, enveloping the 
abdominal organs. Additionally, BAT is involved in heat production via 
mitochondrial uncoupling and was known to predominantly exist only in 
intrascapular region of neonates and infants. However, recently Kirsi A et al 
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used positron emission tomography and observed UCP1 expressing functional 
brown adipose tissue in the paracervical and supraclavicular region of adult 
humans [9]. Functionally, brown adipocytes actively express UCP1 protein and 
have a large number of mitochondria and smaller lipid droplets compared to 
white adipocytes [8]. Beige adipocytes are embedded in white adipose tissue 
(WAT) of adult humans and possess inducible browning phenotype [10]; an 
ability to transform from white adipocyte to brown adipocyte upon stimulation 
with cold, β3-adrenergic receptor agonist, PPARγ agonist, FGF21 and irisin.  
Figure 3: Types of adipocytes in mammals.  
Adipocytes are classified as either white, brown or beige depending on their 
phenotype and functions. Brown and beige adipocytes differentiate from 
PAX7+/Myf5+ and PAX7-/Myf5+ precursors respectively, whereas white 
adipocytes differentiate from PAX7-/Myf5- lineage.  
Adipose tissue depots are known to have distinct characteristics in terms of 
metabolism and endocrine capacity. Between SAT and VAT, the latter 
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removal also proved to have more beneficial effects in terms of metabolic 
markers when compared to removal of subcutaneous fat [11, 12]. Interestingly, 
adipocytes isolated from respective depots and cultured in vitro maintain their 
phenotype to an extent and hence used as valid experimental models. For 
instance, upon stimulation with rosiglitazone and insulin, OM adipocytes 
isolated from adipose tissue secrete less adiponectin compared to SC adipocytes 
[13] which is a characteristic feature of OM adipose tissue [14]. 
1.3 Main functions of adipose tissue 
Conventionally, adipose tissue was considered as merely a storage organ for 
excess nutrients in the form of lipid droplets which could be utilized during 
periods of fasting/starvation via lipolysis. Over the years, more complex 
functions of fat (mentioned below) were slowly understood. Figure 4 
summarizes known functions of adipose tissue. Adipose tissue functions 
include: 
1. Endocrine function: secretion of hormones such as leptin [15, 16] and 
adiponectin [17] which regulate food intake and fuel utilization. 
2. Regulation of angiogenesis to support adipocyte growth within the 
tissue [18]. 
3. Regulation of inflammation and macrophage infiltration [19]. 
4. Metabolic functions including lipogenesis, lipid storage and lipolysis.  
In healthy individuals, the degree of lipid storage or breakdown is controlled 
primarily by insulin and glucagon hormones. During the fed state, insulin 
promotes the storage of dietary lipids in adipose tissue. Free fatty acids after 
being absorbed are converted to TAGs (triacylglycerol/triglycerides) in the liver 
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and transported to the adipose tissue after being packaged inside lipoproteins. 
Inside adipose, lipase enzyme in the plasma membrane of adipocytes breaks 
these TAGs to free fatty acids which eventually enter inside ER as fatty acyl-
CoA. In ER, these fatty acyl-CoA are converted back to TAGs (re-esterification) 
and stored in lipid droplets. Adipocytes also synthesize free fatty acids such as 
palmitic acid from acetyl-CoA by the process of de novo lipogenesis. During 
fasting state, glucagon hormone is secreted from pancreatic alpha cells, which 
in turn activates lipolysis of stored TAGs in adipocytes. Free fatty acids released 
upon lipolysis are distributed to energy deficient tissues such as skeletal muscle. 
Here, these free fatty acids are oxidized into acetyl-CoA in mitochondria via β-
oxidation pathway to generate energy in the form of ATP. 
Figure 4: Illustration of functions of adipose tissue.  
Adipocytes actively store lipids in form of triglycerides or TAGs (lipogenesis) 
inside stable lipid droplets which are catabolized by lipolysis. In healthy 
adipose tissue, insulin switches the adipocytes from lipolytic to lypogenic to 
promote fuel storage. Adiponectin and leptin regulate apatite and energy 
balance via central and peripheral mechanisms. Adopted from Trayhurn, Paul 
et al, 2013 [20].  
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1.4 Adipose tissue expandability hypothesis 
“The adipose tissue expandability hypothesis states that the capacity of an 
individual to expand their fat mass to store lipid is a more important determinant 
of obesity-associated metabolic problems than the absolute amount of adipose 
tissue an individual possesses” [21, 22]. In a situation where an individual fails 
to maintain adipose tissue functions due to impaired expansion, usually due to 
excessive obesity, ectopic lipids begin to accumulate in tissues such as liver, 
heart and skeletal muscle which accelerates development of metabolic 
syndrome. 
Obesity and insulin resistance were always believed to exist hand in hand, but 
multiple clinical and animal model observations now establish that link between 
obesity and insulin resistance is not directly proportional. In humans, it is well 
recognised that metabolically healthy obese (MHO) are protected from insulin 
resistance and its complications, even though they are extremely obese [23, 24]. 
Conversely, some individuals with lipodystrophy syndrome who are unable to 
store lipids properly in adipose tissue, suffer from insulin resistance, 
dyslipidaemia and other metabolic complications [25]. Moreover, TZDs 
(thiazolidinediones), a class of antidiabetic drugs are known to increase body 
weight and improve insulin sensitivity simultaneously [26].  
Animal model studies support this hypothesis as well. Adiponectin is an insulin 
sensitizing, anti-inflammatory adipokine which exerts favourable effects on 
lipid and glucose homeostasis via multiple mechanisms [27]. Mice with 
adiponectin overexpression (AdTG-ob/ob) do not exhibit ectopic lipid 
deposition or insulin resistance even with 50% extra body weight compared to 
ob/ob mice who extremely overweight and become diabetic at an early age [28]. 
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These mice have increased SC and reduced OM adipose tissue depots with 
smaller adipocytes when compared to ob/ob mice. Similar phenomenon is 
observed in MHO individuals, who have increased circulating adiponectin [24] 
and maintain metabolic homeostasis and even in humans, expansion of SC 
depot decreases odds of insulin resistance whereas expansion of OM depot 
increases odds of insulin resistance [29]. Additional evidence comes from 
adipose tissue transplantation studies. Reversal of hyperglycaemia, insulin 
deficiency as well as insulin resistance is seen in lipoatrophic diabetic mice 
(ZIP/F-1) on being transplanted with healthy adipose tissue from wild type mice 
[30]. 
1.4.1 Mechanisms involved in healthy adipose tissue expansion or adipose 
tissue remodelling during obesity 
Massive non-neoplastic expansion of adipose tissue with increasing weight is 
one of its exceptional ability [31]. Several interlinked properties of adipose 
tissue biology confer this unique ability and determine the metabolic outcome. 
They are: 
1. Hypertrophy (increase in size) and hyperplasia (increase in number) of 
adipocytes. 
2. Modifications in ECM to support growing adipocytes. 
3. Angiogenesis 
4. Macrophage mobilization to remove excess lipids and dead cells 
(discussed in section 1.5.2).  
5. Lipid mobilization into lipid droplets. 
6. Adipokine secretion. 
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1.4.1.1 Hypertrophy and hyperplasia 
Weight gain and weight loss have distinct effects on adipocyte phenotype. As 
an individual becomes obese, adipocytes or fat cells increase in size to 
accommodate extra nutrients and upon reaching a threshold, they start dividing 
to proliferate in number [32]. Hypertrophy has a greater pathogenic effect then 
hyperplasia [33] and different adipose depots may react differently in response 
to obesity environment. In ad libidum fed male wistar rats, intra-abdominal 
adipose tissue growth is due to hypertrophy whereas retroperitoneal and 
inguinal adipose depot grow by hyperplasia [34]. Studies also support the idea 
that total number of preadipocytes are fixed after birth, but the percentage of 
adipocytes maturing from these depend on obesity [35]. Similarly, weight loss 
affects adipocyte size as well. Subjects with hyperplastic obesity who undergo 
jejuno-ileostomy for weight loss have smaller adipocytes after 21 months of 
surgery with no change in number of adipocytes [36].  
1.4.1.2 Extracellular matrix components and angiogenesis 
In addition to adipocyte size and number, vasculature and ECM components are 
equally crucial for healthy adipose tissue [37, 38]. ECM (figure 5) is a mesh like 
structure enveloping and supporting all the cells within. Primary functions of 
ECM include adhesion (during cell migration), providing tensile strength, 
comprehensive strength, elasticity, supporting angiogenesis as well as binding 
and signalling of growth factors, hormones, cytokines etc. [39]. Angiogenesis 
is a process of formation of new blood vessels from existing ones harbored in 
ECM and its significance in maintaining healthy adipose tissue have been 
confirmed in adipose tissue from ob/ob mice as well as human subjects [40]. 
Obese insulin resistant individuals tend to have a reduced number of capillaries 
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and larger blood vessels when compared to lean subjects and these differences 
in angiogenesis were attributed to differences in ECM [41]. 
Figure 5: Basic components of ECM.  
ECM composition is tissue specific and varies with obesity and age in adipose 
tissue. Macromolecules including fibrous proteins and proteoglycans support 
internal cellular components and enzymes such as MMPs which are usually 
involved in degeneration of ECM, particularly important for a process like bone 
resorption, migration and tissue remodeling.  
Maria A. Rupnick et al [18] treated ob/ob mice with anti-angiogenic agents and 
observed dose dependent reduction in weight and adipose tissue mass along 
with increased apoptosis, vascular abnormalities and shift from carbohydrate 
utilization to fatty acid utilization indicating adipose tissue dysfunction. In 
db/db mice, administration of antibodies against vascular endothelial growth 
factor (VEGF) lead to a reduction in angiogenic/adipogenic clusters  or in other 
words adipogenesis [42]. Sufficient vasculature is key to prevent hypoxia or 
lack of oxygen; which is a common observation in obese individuals [43] due 
to an imbalance between increasing adipose tissue mass and insufficient growth 
in the vasculature. Hypoxia-inducible factor 1α (HIF1α) gets activated due to 
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towards fibrosis (possibly by activation of lysyl oxidase and subsequent 
crosslinking of collagen I and collagen III to form fibrillary collagen) with 
increased local inflammation [39, 44]. Fibrosis inhibits healthy expansion of 
adipose tissue and accelerates obesity associated metabolic disorders [20, 45]. 
1.4.1.3 Lipid mobilization into lipid droplets 
Formation of lipid droplets occurs since most primitive species and is important 
for survival during fasting and starvation. From an evolutionary perspective, 
they are highly conserved in their constitution and mechanism of formation 
from invertebrates to animals. In mammals, although adipocytes are primary 
site for lipid storage, they are present in all metabolically active tissues such as 
skeletal muscle, adipose tissue and liver.  
Lipid droplets store triglycerides (TAGs), retinyl esters and cholesteryl esters 
surrounded by a phospholipid monolayer and almost 90% of them are found in 
the proximity of endoplasmic reticulum (ER). Three mechanisms primarily 
involved in lipid droplet biology include; (I) transfer of newly formed TAG in 
ER and other constituents into lipid droplets, (II) transfer of lipids from small 
to large droplets (III) fusion of smaller droplets to form bigger droplets. 
Particularly, members of perilipin family, i.e. PLIN2 (adipophilin, ADRP), 
PLIN1 (perilipin), TIP-47 (PLIN3), S3-12 (PLIN4) and PLIN5 are actively 
involved in regulation of lipid droplets [46]. Additionally, several proteins 
present at the junction of ER and lipid droplet mediate the transport of new 
synthesized TAGs into lipid droplets. Seipin and FIT1/2 are two such proteins 
responsible for the formation of bigger sized lipid droplets [47-50] and failure 
to partition triglycerides effectively is thought to be detrimental to adipose tissue 
health [48, 51, 52]. Knockdown of seipin in 3T3-L1 adipocytes leads to 
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increased oleate accumulation and clustering of smaller lipid droplets into 
bigger ones accompanied by insulin resistance [49]. Furthermore, Berardinelli-
Seip Congenital Lipodystrophy 2 (BSCL2)/Seipin mutants in humans are 
lipodystrophic with fatty liver and severe insulin resistance along with complete 
loss of adipose tissue [50, 53]. The role of lipid droplet proteins in maintaining 
adipose tissue health is now increasingly appreciated and studied in the context 
of adipose tissue expandability. 
1.5 Mechanisms involved in adipose tissue dysfunction during obesity 
Mechanisms involved adipose tissue dysfunction are: 
1. Accumulation of pathogenic lipid species. 
2. Production of reactive oxygen species (ROS). 
3. Activation of inflammatory pathways. 
4. Upregulation of unfolded protein response (UPR). 
These are highly interconnected pathways responsible for the development of 
insulin resistance and other complications in T2DM. Mechanism which is 
induced at first during overfeeding and obesity was a long standing debate. But, 
very recently a study involving overfeeding of individuals with approximately 
6000 Kilo-calorie/day for a week observed significant upregulation of ROS 
production in their subcutaneous adipose tissue even when inflammation or ER 
stress was not observed [54], suggesting ROS production to be the first 
pathogenic mechanism.  
1.5.1 Accumulation of pathogenic lipid species 
Diacylglycerols (DAGs), ceramides and sphingolipids are lipid intermediates 
[55, 56] elevated during free fatty acid excess and are known to be pathogenic 
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in nature. Free fatty acids lead to increased ROS production, ER stress and 
inflammation in 3T3-L1 adipocytes as well as mice [57]. Excessive DAGs result 
in insulin resistance by activating protein kinase Cθ which phosphorylates IRS-
1 protein at serine residue and in turn inhibit insulin mediated tyrosine 
phosphorylation of IRS proteins (figure 6). The importance of regulating the 
amount of DAG formation have been worked out in several studies. 
Figure 6: Mechanism of lipid induced insulin resistance. 
Elevated DAGs and free fatty acids activate PKCθ (protein kinase Cθ) which 
blocks IRS1 signaling by serine phosphorylation of IRS1. Eventually, insulin 
stimulated GLUT4 translocation is compromised. Adopted from Shulman et al 
[58]. 
DGAT1 and DGAT2 (Acyl-CoA: diacylglycerol acyltransferase) are ER 
resident enzymes synthesizing TAGs from DAGs by the addition of fatty acyl-
CoA moiety. Mice with DGAT overexpression (hence reduced quantity of 
DAGs) are protected from lipid induced insulin resistance even though they 
have increased triglyceride accumulation in liver [59]. Conversely, reduced 
expression of DGAT2 in adipose tissue and liver reverses diet induced hepatic 
insulin resistance by reducing lipogenesis. Similar effects of DGAT enzyme 
were also observed in muscle cells derived from mice and human skeletal 
muscle [60-62].  
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1.5.2 Inflammation  
Metabolic disorders are often a result of prolonged uncontrolled inflammation. 
Induction of inflammation is body’s defense mechanisms against external 
pathogens and important to maintain health. Inflammation induced due to 
metabolic intermediates is also termed as ‘meta-flammation’ [63]. Extensive 
research has brought forward mechanistic association between chronic low 
grade inflammation and metabolic diseases such as obesity and T2DM. Figure 
7 represents a pathway of progression from induction of inflammation due to 
metabolites and downstream impairment in insulin signaling in adipose tissue.  
Figure 7: Progression of inflammatory response in adipose tissue and 
inhibition of insulin signaling. 
Obesity and excess nutrients induce inflammation in all metabolically active 
tissues. In adipocytes, TLR4 receptors present in cell surface are activated by 
excess free fatty acids and induce inflammatory pathways inside the cell [64, 
65]. Presence of immune cells in adipose tissue is known for decades [66], but 
obesity induced increment in TNFα (secreted by macrophages) was observed in 
obese mice recently [19]. Being one of the earliest discovered inflammation 
induced cytokine, IL6 is well studied and is known to phosphorylate insulin 
receptor substrate (IRS) at serine residue and thus impair tyrosine 
phosphorylation in IRS proteins [67]. 
Chronic overload of nutrients in form of carbohydrates and lipids (expecially saturated free 
fatty acids)
Resident M1 macropahges and other immune cells in adipose tissue secrete 
proinflammatory cytokines (e.g TNFα, IL6 and IL1β) which in turn attract more immune 
cells. 
Cytokines together with excess nutrients inhibit insulin signalling either by alternate serine 
phosphorylation or ubiquitination of IRS proteins. 
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Unhealthy adipocytes are prone to attract macrophages. This process is clearly 
demonstrated in FAT-ATTAC mice, where apoptosis can be induced in adipose 
tissue by activation of caspase-8 and increased apoptosis leads to macrophage 
infiltration along with downregulation in adipokine secretion [68]. 
Phenotypically, macrophages are now categorized as either M1 or M2 and their 
ratio is crucial to maintain adipose tissue health. M2 macrophages (expressing 
CD206 or CD301 surface marker) are protective or anti-inflammatory, whereas 
M1 macrophages (expressing CD11c surface marker) are pro-inflammatory and 
secrete IL6, TNFα and IL1β cytokines. Obesity leads to increased infiltration of 
M1 macrophages in adipose tissue which leads to insulin resistance [69-71]. 
Figure 8 depicts changes in expression pattern of macrophages and adipokines 
from anti-inflammatory in the lean state to pro-inflammatory in obese state.  
Figure 8: Modulation of adipose tissue inflammation during weight gain or 
metabolic dysfunction. 
An imbalance between inflammation, metabolic control and vascular function 
occurs in obese individuals. Along with increasing inflammation, adipocytes 
secrete pro-inflammatory adipokines such as leptin, resistin and RBP4 in 
increasing amounts. Macrophage phenotype changes from M2 to M1, which 
further contributes to inflammation. Adopted from Ouchi, N. et al [72]. 
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Nevertheless, beneficial effects of inflammation in maintaining health cannot 
be negated. Local inhibition of inflammation in adipocytes results in systemic 
inflammation, ectopic lipid accumulation and glucose intolerance [73]. 
Likewise, inflammation and impaired insulin signaling is usually accompanied 
with anti-TNFα treatment against rheumatoid arthritis [74, 75]. Interestingly, 
upregulation of M2 type macrophages is also observed during cold induced 
browning of adipose tissue [76]. Thus, a delicate balance between beneficial 
and pathogenic inflammation exists and more research is needed to understand 
the switch between the two phenotypes. 
1.5.3 Unfolded protein response (UPR) 
Early studies observed induction of ER stress and apoptosis in MIN6 beta cells 
treated with nitric oxide (NO), a compound which has been implicated in 
cytokine induced beta cell dysregulation in type I diabetes [77]. Figure 9 
illustrates a typical ER stress response in a cell. ER stress induction have been 
linked to excess nutrients and obesity in different experimental models [78-80]. 
Figure 10 illustrates nutrient induced ER stress mechanisms. Chronic 
hyperglycemia (mainly through PERK pathway), free fatty acids and certain 
amino acids (via mTOR pathway) induce UPR as a counteractive mechanism 
which ultimately leads to ER stress, cytotoxicity and cell death if uncontrolled. 
In human subcutaneous adipose tissue, ER stress markers have a direct positive 
correlation to increasing BMI [81, 82] and elevated UPR proteins (calnexin and 
phospho-JNK1) and genes (XBP1s) are often observed in obese insulin resistant 
individuals [83]. UPR induction has been reported not only in nutrient excess, 
but in hyperinsulinemic conditions as well, which is a common prediabetic 
stage. Boden et al. observed UPR induction in 3T3-L1 adipocytes and human 
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subcutaneous adipose tissue from obese non-diabetic individuals after insulin 
treatment in vitro and during hyperinsulinemic clamps respectively [84]. Being 
an anabolic hormone, insulin upregulates protein synthesis and accumulation of 
misfolded proteins; eventually leading to UPR. Interestingly, there is also a 
decrease in ER stress markers in liver and adipose tissue from obese patients 
after they undergo marked weight loss [85].  
Figure 9: Canonical unfolded protein response pathway. 
UPR pathways are activated by stressful conditions such as depletion of Ca2+, 
oxidative stress, inflammatory stress etc. This may result in increased 
accumulation of unfolded and misfolded proteins. UPR is like a chain reaction 
with the initiators being PERK, ATF6 and IRE1a proteins. The main motive of 
this type of response is to alleviate the cellular stress. It does so by increasing 
ER chaperones, decreasing protein synthesis and by induction of ER associated 
protein degradation (ERAD). When all these measures are not able to help, the   
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cell undergoes autophagy and apoptosis. PERK leads to translational 
attenuation that reduces load on ER protein folding machinery. Activation of 
transcription factors ATF6 and IRE1a results in increased amount of ER 
chaperons and ERAD components. Activated IRE1a causes nonconventional 
splicing of XBP1 forming XBP1s which is important in eliciting the effect of 
IRE1a. In case of insufficient ERAD, cells proceed to apoptosis. All three, 
PERK, ATF6 and IRE1a pathways cause apoptosis via ATF4, XBP1s and ATF6 
respectively. They induce increased expression of pro-apoptotic factors such as 
CHOP. PERK and IRE1a also directly activates JNK, ASK1 and CHOP 
proteins which leads to apoptosis. Another important response is anti-oxidant 
response resulting from PERK pathway. PERK mediates this through the 
transcription factors NRF-2 and NFκB, resulting in increased expression of 
HO1, GST and IL6 respectively to combat oxidative stress. Figure developed in 
Pathway Builder, based on literature review.  
 
Figure 10: The unfolded protein response, nutrient sensing and 
inflammation. 
UPR is induced in response to ER stress inducers and can result in altered 
metabolic and inflammatory responses and thus metabolic disease. Adopted 
from Hotamisligil, G.S. et al [86]. 
Mice studies suggest that during initial stages of obesity, UPR is an adaptive 
response. For example, a heterozygous deletion of GRP78, an upstream 
controller of ER stress response leads to an adaptive activation of CHOP and 
XBP1s proteins, better adipogenesis, increased energy expenditure and in turn 
protection from diet induced hepatic steatosis and insulin resistance particularly 
 20 
 
in white adipose tissue [87]. Currently, the research community is persistently 
gaining deeper insights in contributions of ER stress pathway in the 
pathogenesis of metabolic syndrome. Table 1 summarizes involvement of some 
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in macrophages and also excess 
oxidized lipids induce ER stress in 





Type 2 Diabetes Obesity leads to ER stress which 







Type 2 Diabetes Free fatty acids like palmitic acid in 
beta cells leads to ER stress and 




Type I diabetes 
(Wolcott Rallison 
syndrome) 
PERK pathway is impaired in these 
individuals and leads to ER stress and 




Inflammation UPR caused increased synthesis of 
inflammatory cytokines such as IL6, 
IL8 and CRP. Inflammation further 
leads to complications such as 






ER stress causes impaired signaling. 
Homocysteine and high fat diet also 
cause ER Leptin resistance.  
[85] 
Table 1: ER stress proteins involved in various metabolism related disorders. 
1.6 Adipocyte models used for studying adipose tissue function 
Obesity research has advanced significantly during last few decades, primarily 
due to the availability of appropriate animal models, cell culture models and 
advanced protocols for culture and differentiation of adipocytes in vitro. Some 
of the commonly used adipocyte models are enlisted in table 2. Owing to its 
robust growth and proliferation potential, SGBS adipocytes is currently a 
widely used non-transformed primary human adipocyte model used for research 
[101]. Previous reports suggest that primary human subcutaneous adipocytes 
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and SGBS adipocytes have similar trends in differentiation and gene expression 
of PPARγ and FABP4 [102], and recently it was found to possess a transient 
brown adipocyte like phenotype [103] which has increased research interest in 
SGBS adipocyte biology. 
Cell line/model Origin Reference  
Adipocytes from rodent models 
3T3-L1 adipocytes Mouse 3T3-L1 fibroblasts [104, 105] 
3T3-F442A adipocytes Mouse 3T3-L1 fibroblasts [105] 
Ob17 adipocytes Epididymal fat pad of 
C57BL/6J ob/ob mouse  
[106] 
Adipocytes from human derived adipose depot 
Human or animal 
preadipocytes 
Mature adipocytes from 
adipose tissue depot from 




Syndrome or SGBS 
adipocytes 
3 month old infant suffering 
from SGBS 
[101] 
Table 2: Adipocyte models used for research. 
1.7 FIT2: lipid storage promoting GWAS identified T2DM candidate 
Adipose tissue expandability hypothesis emphasizes on healthy lipid storage 
inside lipid droplets in the form of TAGs. In East Asian population, meta-
analysis found SNP (rs6017317) in FIT2-R2HDML-HNF4α locus to be 
significantly associated with onset of T2DM (odds ratio =1.09 (1.07 – 1.12), P 
= 1.12E-11) [108]. FIT2 protein is an ER membrane associated lipid droplet 
protein actively involved in partitioning newly synthesized TAGs from ER to 
lipid droplets. Data from 3T3-L1 adipocytes and animal model indicate its role 
in maintaining adipose tissue function via TAG accumulation [48, 51]. Mice 
with adipose tissue specific FIT2 knockout are lipodystrophic and insulin 
intolerant accompanied by increased macrophage infiltration and inflammation. 
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Moreover, FIT2 overexpression in mice skeletal muscle (CFK2 mice) results in 
increased lipid droplets in muscle tissue, reduced body weight, fat mass and lean 
mass at 6 weeks of age along with increased oxygen consumption, glucose 
excursion rate, energy expenditure and complete protection from diet induced 
obesity [52]. These observations suggest a rather vital role of FIT2 mediated 
lipid storage in adipose tissue and make it an interesting target for obesity 
research.  
1.8 FTO: mitochondrial function prompting GWAS identified obesity 
candidate 
Response to “obesigenic” environment such as life style and diet varies in 
individual, often influenced by genetic components. Twin studies in 
monozygotic and dizygotic twins show greater inter-pair than an intra-pair 
alteration in weight loss, suggesting adiposity as a highly heritable trait with the 
estimated genetic contribution up to 40 – 70% of the difference in weight gain 
[109, 110]. Recognition of possible genetic influence on obesity has led to a 
search for causal genes which might assist us in containing obesity epidemic. 
Currently, 76 and 185 loci have been linked to T2DM and obesity respectively, 
with 17 overlapping loci among them (figure 11), FTO being the strongest 
association with obesity. SNPs in the first intron of FTO (Fat Mass and Obesity 
Associated) gene were strongly associated with obesity and T2DM [111, 112]. 
However, upon adjustment with BMI, association to T2DM was lost suggesting 
an indirect influence on T2DM, likely via obesity or increased BMI. Association 
of FTO SNPs with obesity has been validated across multiple ethnicities [113-
115] and the presence of a minor risk allele leads to increase in BMI by 0.39 
kg/m2 [116]. In mice, FTO deletion leads to reduced body weight and protection 
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from diet induced obesity [117]. The leanness of FTO-deficient mice is 
implicated to increased energy expenditure and systemic sympathetic 
activation, despite decreased spontaneous locomotor activity and relative 
hyperphagia. Overall, these observations suggest FTO SNPs to be valid targets 
to studying human obesity.  
Figure 11: GWAS candidates overlapping between obesity and T2DM. 
P value thresholds for association with BMI (y-axis) are P < 5×10−8 (red), 
5×10−8 ≤ P <10−4 (orange), 10−4 ≤ P < 0.01 (yellow), 0.01 ≤ P < 0.05 (green) 
and P ≥ 0.05 (blue). Red, orange and yellow associations are labeled with 









1.9 Aims and hypothesis of the study 
In the studies presented here, we have leveraged on current knowledge on 
adipose tissue expandability hypothesis [3], with the aim of furthering insights 
into novel adipose tissue related mechanisms leading to the development of 
insulin resistance or T2DM.  
In order to understand the biological role of specific GWAS genes of interest 
expressed in human adipose, we first sought to characterize human adipocyte 
cell models, to better understand the strengths and limitations of the SGBS 
human adipocyte cell line. SGBS adipocytes were derived from a child with an 
overgrowth syndrome [2, 5] and are widely used as a representative human 
adipocyte syndrome. Since isolation from SC adipose tissue depot from an 
infant, SGBS have been perceived and observed to have gene expression and 
adipogenic pattern similar to primary human adipocytes from adults. But 
recently SGBS were observed to retain a transient browning phenotype mid-
way during their course of differentiation [6]. However, transcriptome and 
functional differences between SGBS and primary human subcutaneous 
adipocytes emphasizing on their unique phenotype have not been described yet 
and we have addressed this question here. We hypothesized that while there are 
overlapping phenotypic similarities, there would be distinct metabolic 
signatures involving adipogenesis, lipid metabolism, browning and 
mitochondrial capacity between the two cell types, understanding which would 
assist in their appropriate usage in our studies or other studies in future. 
Following this, we used these adipocytes and investigated the role of two 
GWAS gene candidates expressed in adipose and associated with type 2 
diabetes and obesity; FIT2 and FTO. Both these proteins are involved in lipid 
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metabolism in adipocytes. FIT2 is an ER membrane associated lipid droplet 
protein, responsible for transferring newly synthesized TAGs into lipid droplets 
and a GWAS gene candidate for T2DM among East Asian population [7]. 
Adipose tissue specific FIT2 protein knockout mice show a lipodystrophic 
phenotype with smaller adipose tissue depots accompanied by peripheral insulin 
resistance [8]. The Role of FIT2 protein in human derived adipocytes or adipose 
tissue is not established yet, and we used subcutaneous adipocytes to study FIT2 
protein biology. We hypothesized that Partial deficiency of FIT2 protein would 
lead to reduced triglyceride storage, accumulation of free fatty acids and 
defective insulin signalling in the adipocytes. 
In contrast to lipid storage function of FIT2 protein, data from human adipocytes 
and animal models suggest a role of FTO protein in regulating energy 
expenditure through central and peripheral mechanisms [9-11]. Along with FTO 
protein knockdown, we tested the effects of a novel chemical inhibitor of 
dioxygenase activity of FTO protein in SGBS adipocytes [12]. We hypothesized 
that chemical inhibition of FTO protein would mimic increase in mitochondrial 
energy expenditure as observed after FTO protein knockdown in SGBS 
adipocytes [13] and thus may potentially be developed as an anti-obesity drug. 
Since FTO protein influences mitochondrial energy expenditure and SGBS 
adipocytes showed higher mitochondrial oxidative capacity in our initial 
experiments, SGBS were initially used for studies related to FTO protein. 
Next chapter focusses on studying transcriptomic signatures different amongst 
obese diabetics and obese non-diabetics. We aimed to identify adipose tissue 
components preventing the development of insulin resistance in obese non-
diabetics. Contributions of ECM components in obesity and inflammation 
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associated adipose tissue dysfunction has been suggested widely [14], but 
differences amongst obese diabetics and obese non-diabetics are not fully 
understood. We compared transcriptomes of subcutaneous and omental adipose 
tissue from obese diabetics and obese non-diabetics to address the question 
whether ECM components are involved in adipose tissue dysfunction in obese 
diabetics. 
1.9.1 Specific objectives were to: 
1. Evaluate the differences among SGBS and primary human adipocytes 
differentiated from stromal vascular fraction from subcutaneous 
adipose tissue. We sought to explore their 
a. Transcriptome differences using RNA sequencing. 
b. Adipogenic capacity using real-time qPCR. 
c. Mitochondrial function or energy expenditure using Seahorse 
mitochondrial flux analyzer. 
d. Brown and beige adipocyte markers using real-time qPCR and 
UCP1 protein expression by western blot.   
e. Triglyceride storage and glucose uptake.  
2. Characterize the role of FIT2 protein in regulating lipid storage and 
maintaining adipocyte health. We studied: 
a. mRNA and protein expression pattern in human adipose tissue 
from obese diabetics compared to obese non-diabetics. 
b. mRNA and protein expression pattern in subcutaneous and 
omental adipocytes derived from adipose tissue. 
c. Adipocyte phenotype in the context of triglyceride 
accumulation, inflammation, ER stress and insulin signaling 
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after siRNA mediated FIT2 protein knockdown and addition of 
palmitic acid to the mimic high fat challenge.  
3. Examine the effects of chemical inhibition of FTO demethylase activity 
in SGBS adipocytes when compared to SGBS with siRNA mediated 
FTO knockdown. We investigated the phenotype as: 
a. PGC1α and UCP1 gene expression pattern using real-time 
qPCR. 
b. Mitochondrial respiration capacity using Seahorse 
mitochondrial flux analyzer. 
c. AMPK pathway using western blot. 
4. Analyze transcriptome wide differences among subcutaneous and 
omental adipose tissue derived from obese diabetics compared to obese 
non-diabetics. We studied: 
a. The Number of differentially up and downregulated genes. 
b. Enriched biological pathways and cellular components (gene 
ontology) in omental compared to the subcutaneous depot. 
c. Enriched biological pathways and cellular components (gene 
ontology) in T2DM compared to NT2DM subjects. 
d. Positive and negative enrichment in extracellular matrix and 











Chapter 2:  













2.1 Procedure for RNA isolation 
Qiagen RNeasy plus kit was used for RNA isolation from both adipocytes or 
other adherent cells and adipose tissue.  
2.1.1 Protocol for RNA isolation from adipocytes and other adherent cells 
1. Cell-culture medium was aspirated completely and cells were lysed 
directly in the cell-culture vessel by adding 350 µl of buffer RLT. The 
lysate was homogenized with the help of a cell scrapper and collected in 
a microfuge tube. 
2. The tube was vortexed for about a minute to ensure no cellular clumps 
were remaining and the lysate was passed through QIAshredder 
homogenizer (spin at maximum rpm for 2 min) placed in 2 ml collection 
tube. 
3. Flow-through was added to gDNA (genomic DNA) removal columns 
and centrifuged at maximum rpm for one minute. 
4. One volume of 70% ethanol was added to the flow-through and mixed 
with a pipet or by vortexing. 
5. Finally, a maximum of 700 µl of lysate mixed with ethanol was added 
to RNeasy spin column placed in a 2 ml collection tube. Tube was 
centrifuged at 10,000 rpm for 30 sec and flow-through was discarded. 
Any remaining lysate from step 4 can be added to RNeasy spin column 
again with repeated centrifugation to collect all RNA in RNeasy spin 
column. 
6. 700 μl Buffer RW1 was added to the RNeasy spin column and 
centrifuged at 10,000 rpm for 15 sec to wash the spin column membrane. 
Flow-through was discarded.  
 30 
 
7. 500 μl Buffer RPE was added to the RNeasy spin column and 
centrifuged at 10,000 rpm for 15 sec and flow-through was discarded. 
The column was washed with RPE buffer again with centrifugation for 
2 min. Care was taken that no ethanol was carried over in column during 
washing and discarding processes. 
8. RNeasy spin column was transferred to a new 1.5 ml collection tube and 
30-50 µl of nuclease free water (depending on expected yield) was 
added directly onto column for RNA elution. The column was 
centrifuged at 10,000 rpm for 2 min to ensure complete elution. If lower 
yields were expected, the eluate was added to column and centrifugation 
step was repeated.  
9. The RNeasy spin column was discarded and RNA was quantified using 
NanoDrop spectrophotometer (Thermo Scientific) 
2.1.2 Protocol for RNA isolation from adipose tissue samples 
1. Frozen adipose tissue samples (about 250 mg) were used for 
homogenization using Qiagen TissueLyser LT. Samples were added 
directly into TissueLyser homogenization tubes with 500 µl TRIzol 
reagent (Thermo Scientific) and homogenized at 50 hertz for 10 min or 
until no tissue clumps were observed.  
2. Tubes were kept at room temperature for 5 min and 300 µl of chloroform 
was added to tubes and mixed by shaking for 15-20 sec. Tubes were 
incubated at room temperature for 5 min and centrifuged at 15,000 rpm 
for 20 min at 4°C. The clear upper layer containing RNA was transferred 
to new 1.5 ml microfuge tube and an equal volume of 70% ethanol was 
added and mixed by vortexing.  
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3. This mixture was processed downstream similar to cell culture RNA 
(step 5 onwards).  
2.2 Relative quantification of gene expression 
2.2.1 cDNA synthesis protocol 
Isolated RNA was converted to cDNA with the help of High-Capacity cDNA 
Reverse Transcription Kit (Thermo Scientific). 500-1000 ng of RNA was made 
to a final volume of 10 µl with nuclease free water and was added to 10 µl 
master mix prepared from individual components as 
Component Volume/Reaction (μl) per reaction 
10✕RT Buffer 2.0 
25✕dNTP Mix (100 mM) 0.8 
10✕RT Random Primers 2.0 
MultiScribe™ Reverse Transcriptase 1.0 
Nuclease-free water 4.2 
Total per Reaction 10 
Table 3: Preparation of master mix for cDNA synthesis. 
Final reaction mixtures were converted to cDNA using following cycling 
conditions 
 Step 1 Step 2 Step 3 Step 4 
Temperature (°C) 25 37 85 4 
Time 10 min 120 min 5 min ∞ 
Table 4: Cycling conditions for cDNA synthesis.  
2.2.2 Real-time qPCR protocol  
For qPCR, primers were designed using Primer Express 3.0 (Thermo Scientific) 
and QuantiFast SYBR Green PCR Kit (Qiagen) was used to prepare reaction 








2X QuantiFast SYBR Green 
PCR Master Mix 
5 μl 1X  
Forward Primer 0.1 µl 1 μM 
Reverse Primer 0.1 µl 1 μM 
Template cDNA 2 µl  15ng per reaction 
RNase-free water 2.8 µl   
Total reaction volume 10 µl  
Table 5: Preparation of master mix for qPCR reaction for gene expression. 
384 well plate was used in ViiA™ 7 Real-Time PCR System (Thermo 
Scientific) with below mentioned protocol. 
Step Time  Temperature 
PCR initial activation step 5 min 95ºC 
Two-step cycling 
Denaturation 10 sec 95ºC 
Combined annealing/ extension 30 sec 60ºC 
Number of cycles 40  
Table 6: Cycling conditions for qPCR reaction for gene expression. 
Threshold cycle (Ct) values were obtained and Δ ΔCt method was used to 
calculate relative expression using GAPDH as internal control throughout. 
2.2.3 Protocol for isolation of genomic DNA and relative quantification of 
mitochondrial DNA content 
Genomic DNA was isolated using traditional phenol: chloroform method.  
1. Cell culture medium was completely removed, the monolayer was 
washed with 1X ice cold PBS and 500 µl of DNA extraction buffer (0.1 
M NaCl, 10 mM Tris pH 8.0, 1 mM EDTA pH 8.0, 1% SDS) was added. 
With freshly added Proteinase K (0.2 µg/µl).  
2. Monolayers were scrapped and contents collected in microfuge tubes 
and incubated at 50°C overnight. One volume of Phenol Chloroform 
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Iso-amyl alcohol (PCI, Sigma) was added to the digested sample and 
tubes were shaken vigorously for 10-15 sec. 
3.  Tubes were centrifuged at 15,000 rpm for 10 min and the upper layer 
was carefully transferred to new microfuge tubes.  
4. 500 µl (or equal to DNA extraction buffer used) of chloroform was 
added and tubes were shaken vigorously for 10 min. Tubes were 
centrifuged at 15,000 rpm for 10 min and upper aqueous phase and 
transferred to new tube.  
5. 1/10th volume of sodium acetate (3 M, Sigma) and two volumes of 100% 
ethanol was added, vortexed and incubated overnight at -20°C.  
6. Tubes were centrifuged at 15,000 rpm for 10 min and supernatant was 
discarded. DNA pellet was usually visible at this stage. 
7. Pellet was washed with 70% ethanol and centrifuged at 15,000 rpm for 
10 min. Supernatant was carefully removed with help of a pipet and 
pellet was allowed to air dry for 10-15 min till pellet was translucent.  
8. The pellet was dissolved in 20-30 µl nuclease free water, quantified 
using NanoDrop spectrophotometer and stored at -20°C till further 
analysis.    
2.2.4 Relative quantification of mitochondrial DNA content 
Protocol was adopted from [119] and used with DNA extracted from 
adipocytes. 2 ng of total DNA was used for running qPCR with below 










TaqMan Universal PCR 
   
5 μl 1X  
Forward Primer 0.05 µl 500 nM 
Reverse Primer 0.05 µl 500 nM 
TaqMan probe 0.02 µl 200 nM 
Template cDNA 2 µl  2 ng per reaction 
RNase-free water 2.88 µl 
Total reaction volume 10 µl 
Table 7: Preparation of master mix for quantification of mitochondrial DNA 
content. 
Step Time  Temperature 
uracil-N-glycosylase (UNG) activation 2 min 50ºC 
PCR initial activation step 10 min 95ºC 
Two-step cycling 
Denaturation 15 s 95ºC 
Combined annealing/ extension 60 s 60ºC 
Number of cycles 40  
Table 8: Cycling conditions for quantification of mitochondrial DNA. 
2.3 Western blot protocol  
2.3.1 Preparation of protein lysate from adherent cells 
1. Adipocytes or other adherent cells were grown in 6 well plates and used 
for protein lysate preparation for protein studies.  
2. All plates were removed from incubator and immediately placed on ice. 
Cell culture medium was removed from wells and were thoroughly 
washed with ice cold PBS. 100 µl of RIPA buffer (Thermo Scientific) 
supplemented with protease and phosphatase inhibitor cocktail (Halt™ 
Protease and Phosphatase Inhibitor Cocktail, Thermo Scientific) was 
used to digest cell membrane and prepare cell lysate.  
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3. All contents of the well were pooled with help of a cell scrapper and 
transferred to a new microfuge tubes prechilled on ice. Lysates were 
incubated here for about 45 min with vortexing every ten min. 
4. Finally, the tubes were centrifuged at 15,000 rpm for 30 min at 4ºC and 
clear supernatants were collected in new microfuge tubes and quantified 
using Bradford protein assay.  
2.3.2 Preparation of protein lysates from adipose tissue 
1. Frozen adipose tissue samples (about 100 mg) were used for 
homogenization using Qiagen TissueLyser LT. Samples were added 
directly into TissueLyser homogenization tubes with 600 µl RIPA buffer 
(Thermo Scientific) supplemented with protease and phosphatase 
inhibitor cocktail (Halt™ Protease and Phosphatase Inhibitor Cocktail, 
Thermo Scientific) and homogenized at 50 hertz for 10 min or until no 
tissue clumps were observed.  
2. Homogenate was centrifuged at 15,000 rpm at 4ºC for 45 min. 
Typically, three layers are formed which includes debris at bottom, 
protein lysates in middle and deep yellow colored oily layer on the top. 
Red to beige colored middle layer containing protein lysate was 
carefully transferred to a new 1.5 ml microfuge tube and centrifuged at 
15,000 rpm at 4ºC for 15 min and subsequently transferred to new tubes 
to remove excess lipids.  
3. Lysates were then snap frozen-thawed for 5 times with help of liquid 





2.3.3 Protein quantification using Bradford protein assay 
Bradford protein assay was performed in 96 well plates. 
1. Standard curve was made using 10 concentrations of BSA (Bio-Rad, 2 
mg/ml) ranging from 0.05 mg/ml to 0.5 mg/ml in distilled water. Final 
volume was made to 10 µl for all. 
2. Cell culture protein lysates were then diluted either 10-20 times with 
distilled water depending on expected yield. Adipose tissue protein 
lysates were diluted 50-100 times with distilled water.  
3. 10 µl of each standard and unknown protein lysate was pipetted in 96 
well plate compatible with plate reader and 200 µl of diluted Bradford 
reagent was added to the wells. Bradford reagent was bought from Bio-
Rad as 4X concentrate and it was diluted to 1X, allowed to warm to 
room temperature and filter with 0.22 µm filter to remove any debris as 
it might interfere with optical density (OD). 
4. Plate was shaken carefully and incubated at room temperature for 5-10 
min (not more than 1 h) and read at 595nm in plate reader (VarioSkan 
from Thermo Scientific). OD obtained was used to draw standard graph 
and calculate concentration of protein lysates.    
2.3.4 Protocol for SDS Polyacrylamide Gel Electrophoresis (SDS-PAGE) 
2.3.4.1 Stock buffers and reagents 
1. 4X loading buffer (Laemmli buffer, Bio-Rad). 
2. 10X Tris-glycine SDS running buffer (Bio-Rad): To prepare 1L 1X 
running buffer: add 100 ml 10X running buffer to 900 ml distilled H2O. 
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3. 10X Tris-glycine transfer buffer (Bio-Rad): To prepare 1L 1X transfer 
buffer: add 100 ml 10X transfer buffer to 200 ml methanol + 700 ml 
distilled H2O. 
4. 10X Tris buffered saline (TBS) (Bio-Rad): To prepare 1L 1X TBS: add 
100 ml 10X TBS to 900 ml distilled H2O. 
5. Nonfat dry milk 
6. Bovine Serum Albumin (BSA, Sigma) 
7. Beta-mercaptoethanol (Bio-Rad) 
2.3.4.2 Working buffers and solutions 
1. Wash buffer: 1X TBST (1L of TBS + 1 ml Tween-20) 
2. Blocking buffer: 1X TBST with 5% w/v nonfat dry milk 
3. Primary antibody dilution buffer: 1X TBST with 5% BSA or 5% nonfat 
dry milk as indicated on primary antibody datasheet 
2.3.4.3 Other materials 
1. Prestained protein marker: Prism ultra-protein ladder (10-245 kDa) 
(Abcam) 
2. Blotting membrane and filter paper (Bio-Rad) 
3. Secondary antibody conjugated to HRP: anti-rabbit and anti-mouse 
(Bio-Rad) 
4. Detection reagent: Luminata crescendo western HRP substrate (Merck 
Millipore) 




1. 10% acrylamide gels were used for all proteins in our studies unless 
indicated.  
2. All protein samples were made to closest equal volumes with distilled 
water and one-third volume of 4X laemmli sample buffer (supplemented 
with beta-mercaptoethanol) was added, vortexed gently to mix and 
boiled in water bath for 5 min. 
3. Samples were loaded in the gel and run till the dye front migrates about 
2mm from the bottom of the gel. Gels were then transferred to PVDF 
membrane.  
2.3.4.5 Transfer 
1. PVDF membrane was immersed in methanol for 2-3 min and then 
transferred to ice cold transfer buffer along with filter papers and transfer 
sponges. Gel was arranged in the following order and a clean plastic tube 
was used to roll air bubbles out (crucial step). 
2. Setup was organized in the cassette and transfer was carried for 2 h at 







SDS-PAGE GEL  
PVDF MEMBRANE 





1. After transfer, membranes were blocked with 5% milk in TBST 
(blocking buffer) for 45 min and then washed with TBST for 45 min 
with three buffer changes.  
2. Membranes were either cut or incubated with primary antibody over-
night in 5% BSA or 5% milk as suggested by the protocol. They were 
then washed with TBST (15 min X 3 times) and incubated with 
respective secondary antibody in 5% milk in TBST for 2 h and washed 
again with TBST (15 min X 3 times).  
3. Blots were then incubated with HRP substrate for 5 min, excess 
substrate was drained and blots were packed in plastic sheets. 
4. X-ray films were exposed on the membrane and developed in dark room 
using x-ray film developer (Konica Minolta).   
2.4 Protocols for cell culture 
2.4.1 Isolation, culture and differentiation of adipocytes  
We have used two different adipocyte models in our study. (1) Human adipose 
tissue derived adipocytes and (2) Simpson-Golabi-Behmel syndrome (SGBS) 
adipocytes. Both are obtained as preadipocytes and differentiated to mature 
adipocytes using specific medium.   
2.4.1.1 Protocol for tissue digestion 
1. The tissue sample was immediately immersed in Hank’s Balanced Salt 
Solution (HBSS, Thermo Scientific) and transferred to lab. 
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2. Digestion medium (1 mg/ml collagenase in 2% BSA in DMEM) was 
prepared fresh and filtered. Tissue specimens were then transferred to 
digestion medium (10 ml digestion medium/gram tissue). 
3. Using scissors, tissue was cut into small pieces (as long as no specimens 
can be picked up by the scissors, the tissues are considered apt for 
digestion). 
4. Tubes were incubated at 37°C for one hour for collagenase digestion and 
then filtered through 100μm cell strainer. 
5. Filtrate was then Centrifuge at 400g for 1 minute. Two layers were 
obtained after this. Top lipid rich fraction containing mature adipocytes 
was used as ceiling culture if required. Infranatant was centrifuged at 
400g for 5min after which the pellet of stromal vascular fraction (SVF) 
was obtained (usually SVF contains ASC, fibroblasts, vascular 
endothelial cells and some immune cells). 
6. Pellet was resuspended in 10 ml HBSS and Centrifuged at 400g for 5 
min. The step was repeated 3 times with change to a new tube after 





7. Pellet was resuspended in 10 ml growth medium (DMEM high glucose, 
15% fetal bovine serum (FBS), 1% non-essential amino acids (NEAA), 
1% penicillin-streptomycin (pen-strep) and 5 ng/ml fibroblast growth 
Digested  
Tissue 
Figure 13: Isolation of ASCs from adipose tissue digest. 
Lipid rich layer 
transferred to new flask 
(ceiling culture) 
Infranatant centrifuged 
(400g for 5 minutes) 





factor) plated in bacterial dish and incubated in 37°C incubator for 1 h. 
This step allows monocytes and macrophages to attach to bacterial plate 
and gives purer ASC population.  
8. The supernatant was carefully transferred (red blood cells also float in 
the medium) to the new T75 flask with growth medium. At this stage, 
cells have small circular morphology which changes to fibroblastic once 
they become adherent and grow. Medium was replaced with new growth 
medium once most of the cells were adhering to the flask.  
9. Cells adhering as fibroblasts are typically adipocyte specific stem cells, 
which undergo differentiation to preadipocytes at confluence and can be 
differentiated to mature adipocytes.   
2.4.1.2 Differentiation of primary adipocytes derived from adipose tissue 
1. Differentiation medium (Preadipocyte basal medium 2, PBM-2) was 
purchased from Lonza and their recommended protocol was followed.  
2. Typically, Differentiation medium was reconstituted from individual 
components (Preadipocyte growth medium -2 bulletkit, PGM-2) and 
used within 2 weeks. Both PBM-2 and PGM-2 are proprietary of Lonza 
and concentration of individual components is unknown although it is 
acknowledged that final reconstituted medium contains FBS, L-
glutamine, GA-1000, human insulin, dexamethasone, 3-Isobutyl-1-
methylxanthine (IBMX) and indomethacin.  
2.4.2 SGBS cell culture and differentiation 
1. SGBS cells were grown and multiplied in their growth medium 
(DMEM-F12 (Thermo Scientific), 10% FBS and 1% pen-strep). 
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2. Once they were ready for differentiation, cells were incubated in 
differentiation medium for 4 days and then maintenance medium for 
another 4 to 6 days till they were fully mature or differentiated (as judged 





Rosiglitazone (Sigma) 2 µM 
Not added Dexamethasone 
 
25 nM 
IBMX 0.5 mM 
Cortisol 0.1 µM 0.1 µM 
Transferrin 0.01 mg/ml 0.01 mg/ml 
Triiodotryonin 0.2 nM 0.2 nM 
Human insulin 20 nM 20 nM 
Table 9: Differentiation and maintenance medium for SGBS adipocytes. 
2.4.3 Preparation of BSA: palmitic acid conjugate 
Fatty acids are not soluble in water and thus have to be conjugated to BSA for 
addition in cell culture. Protocol was adapted from [121] and final concentration 
of palmitic acid obtained was 10 mM.  
1. 20% fatty acid free BSA (Sigma) was prepared by adding 2 g of BSA to 
8 ml distilled water and made to 10 ml final volume once BSA is fully 
solubilized. Typically, overnight incubation results in maximum 
solubility. 
2. 56 mg sodium palmitate (Sigma) was added to 10 ml of 0.01 N NaOH 
(sodium hydroxide) and incubated at 70ºC water bath. Palmitic acid gets 
partially dissolved at this stage. Maintaining in water bath, 200 µL of 
1N NaOH was added to above solution which results in clear fully 
dissolved palmitic acid.  
3. Finally, 10 ml of solubilized palmitate was added to 8 ml of 20% BSA 
outside the water bath (BSA will precipitate if subjected to 70°C) which 
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gives a clear solution of palmitic acid conjugated to BSA. The solution 
was cooled down to room temperature and filtered using 0.22 µm filter, 
aliquoted and stored at -20ºC. Precipitation at room temperature would 
indicate improper conjugation of palmitic acid with BSA. Palmitic acid 
was used within 6 months. 
2.4.4 Treatment with palmitic acid and insulin stimulation in cell culture 
Free fatty acid challenge was performed in mature adipocytes (at day 8 or day 
9 of differentiation). Differentiation medium was replaced with respective 
growth medium for 24 h after which medium was changed to DMEM 
supplemented with 2% FBS and 1% pen-strep. Using lower percentage FBS 
medium is suggested as (1) conjugated palmitic acid also introduces protein in 
form of BSA (2) effect of palmitic acid is partially masked by presence of 10% 
FBS and (3) FBS also contains free fatty acids which might interfere with 
externally added palmitic acid. Cells were then treated with 500 µM palmitic 
acid for 24 h and subsequently medium was replaced with serum free DMEM 
for 2-3 h for serum starvation. 100nm insulin was added in respective wells for 
30 min before any further studies. 
2.4.5 Protocol for quantification of triglyceride accumulation 
Triglyceride accumulation was read fluorometrically after staining neutral lipids 
with Nile Red dye. Protocol was followed as recommended (AdipoRed Assay 
Reagent, Lonza). Assay was performed in 6 well cell culture plates.  
1. Medium in adipocyte culture was removed and cells were washed with 
PBS. Next, 2 ml of fresh PBS was added in wells followed by 140 µl of 
assay reagent. Plates were swirled and contents were mixed gently. 
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2. Volume in each well was made up to 5 ml with help of PBS and 
incubated in dark for 30 min at room temperature.  
3. Plate reader (Varioscan, Thermo Scientific) was set as excitation at 485 
nm and emission at 572 nm and plates were read. 
4. Results were reported as fluorescence units.  
2.5 Protocol for knock-down of proteins using siRNA 
 In our studies, we used siRNA against FIT2 and FTO in primary human 
adipocytes obtained from adipose tissue and SGBS. Protocol was adapted from 
datasheets and optimized to our cell culture conditions and adipocyte 
requirements. 
1. Adipocytes (primary human or SGBS) were seeded at about 60% 
confluence. At about 80% confluence, siRNA was introduced in them 
with the help of siTran 1.0 (OriGene, USA) transfection reagent. FIT2 
and FTO siRNA were purchased from Qiagen and OriGene respectively 
along with their scrambled negative control siRNAs. Transfection 
cocktail was optimized as 
Components Volume in µL per well  
Opti-MEM (Thermo Scientific) 120 
siRNA (5 µM stock) 2 
siTran reagent 4.5 
Final volume added per well 120 for 5 nm concentration siRNA 
Table 10: Preparation of transfection cocktail for introduction of siRNA. 
2. On the day of transfection, growth medium was replaced by serum free, 
pen-strep free DMEM and transfection cocktail was introduced for 6 h 
after which medium was replaced by growth medium. 
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3. Cells were allowed to grow for next 24 h till they reach 90-100 
confluence and then growth medium was replaced by differentiation 
medium. After 4 days, the transfection was repeated in serum free, pen-
strep free medium and finally replaced by differentiation medium.  
4. On day 6 or 7 of differentiation, cells were ready for further studies 
which included addition of FTO inhibitors or palmitic acid for respective 
studies. 
2.6 Protocol for radioactive glucose uptake assay 
Glucose uptake assay is an essential tool to study insulin sensitivity or insulin 
resistance at a functional level. We used mature adipocytes to study glucose 
uptake in various conditions. Each condition was tested as 2 biological 
replicates with each of them having 3 experimental and 2 technical replicates.  
Protocol for a 6 well plate is as follows 
1. Medium for cells was replaced with serum free DMEM supplemented 
with pen-strep and 0.2% BSA for 4-5 h to allow them to undergo a serum 
free stepdown.   
2. Next, cells were thoroughly washed twice with PBS and subsequently 
900 µl of PBS supplemented with 0.2% BSA was added to wells (1 ml 
for 6 well plate) for 30 min (glucose free stepdown).  
Component Stock 
concentration 
Volume (in µl) to be added 
per well 
Deoxyglucose 10 mM 10 
[3H]2-deoxyglucose 1 mCi (millicurie) 0.5 
PBS (with 0.2% 
 
10X 90 
Table 11: Preparation of start solution for glucose uptake assay. 
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3. Next, 100 µl of 10X start solution was added to all the wells. 
Composition of start solution iselaborated in table 11. 
4. Cells were allowed to uptake radioactive glucose for 20 min after which 
they were immediately placed on ice and maintained. 
5. Cells were washed twice with ice cold PBS and finally 500 µl of RIPA 
buffer was added to all the wells and contents were collected in 
prechilled microfuge tubes with the help of a scrapper. 
6. Tubes were incubated in ice for 30 min after which 200 µl of each of the 
lysate was added to 3.5 ml of Liquid Scintillation Cocktail 
(PerkinElmer) placed in 4 ml vials for measuring radioactivity. Each 
tube was prepared in technical duplicates at this stage. All the vials were 
capped tightly and mixed by inverting 4-5 times. Beta counts were 
measured as counts per minute using MicroBeta2 counter 
(PerkinElmer). 
2.7 Protocol for RNA sequencing 
RNA-SEQ was used to study transcriptome wide differences within following 
groups of interest. (1) Obese diabetics compared to obese non-diabetics 
(omental vs subcutaneous adipose tissue) and (2) SGBS compared to primary 
human subcutaneous adipocytes. Protocol used is as follows.  
1. Total RNA was extracted from either primary human adipocytes, SGBS 
or adipose tissue for respective experiments. Poly-A mRNA was then 
enriched with oligodT beads (Life Technologies) from approximately 
5µg of total RNA. 100 ng of poly-A mRNA recovered was used to 
construct multiplexed strand-specific RNA-seq libraries as per 
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manufacturer’s instruction (NEXTflexTM Rapid Directional RNA-SEQ 
Kit (dUTP-Based) v2).  
2. Individual library quality was assessed with an Agilent 2100 
Bioanalyzer and quantified with a QuBit 2.0 fluorometer before pooling 
for sequencing on a HiSeq 2000 (1x101 bp read). The pooled libraries 
were quantified using the KAPA quantification kit (KAPA Biosystems) 
prior to cluster formation. Fastq formatted reads were processed with 
Trimmomatic to remove adapter sequences and trim low quality bases 
(LEADING:3 TRAILING:3 SLIDINGWINDOW:4:15 MINLEN:36). 
Reads were aligned to the human genome (hg19) using Tophat version 
2 (settings--no-coverage-search--library-type=fr-firststrand). Feature 
read counts were generated using htseq-count (Python package HTSeq 
default union-counting mode, strand=reverse).  
3. Differential Expression analysis was performed using the edgeR 
package in both ‘classic’ and generalized linear model (glm) modes to 
contrast groups of interest. This generated a list of approximately 15,000 
genes.  
4. A false discovery rate (FDR) ≤ 0.05 and a fold change (FC) ≥ 1.5 were 
used to call significance in the input list of genes for further analysis.  
5. iPathwayGuide (Advaita bioinformatics), a web-based pathway analysis 
tool was used to identify the top biological pathways and biological 
processes different among groups (significance pegged at P ≤ 0.05, with 
Bonferroni correction) [122, 123]. iPathwayGuide uses two step 
approach to compute significantly different pathways; (1) over-
representation of differentially expressed genes and (2) the perturbation 
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of that pathway computed by propagating the measured expression 
changes across the pathway topology. This allows both upregulated and 
downregulated genes to be input together while computing enriched 
pathways and processes.  
6. We used DAVID [124, 125] for certain pathway analysis, especially for 
reporting enriched pathways in genes either upregulated or 
downregulated among groups.   
2.8 Protocol for measuring mitochondrial function of adipocytes 
XF Cell Mito Stress test kit (Seahorse Bioscience) was used to measure 
mitochondrial function in adipocytes in a 24 well plate format. Data were 
reported as pmoles of oxygen consumed per minute or oxygen consumption 
rate. Cellular respiration parameters calculated are basal respiration, ATP 
production, proton leak, maximal respiration and spare respiratory capacity. As 
suggested by the manufacturer, 5 replicates of control, treatment conditions and 
negative controls were used. Oligomycin inhibits ATP synthase (complex V) 
and the decrease in OCR following injection of oligomycin correlates to the 
mitochondrial respiration associated with cellular ATP production. Carbonyl 
cyanide-4 (trifluoromethoxy) phenylhydrazone (FCCP) is an uncoupling agent 
that collapses the proton gradient and disrupts the mitochondrial membrane 
potential. As a result, electron flow through the ETC is uninhibited and oxygen 
is maximally consumed by complex IV. The FCCP-stimulated OCR can then 
be used to calculate spare respiratory capacity, defined as the difference 
between maximal respiration and basal respiration. Spare respiratory capacity 
is a measure of the ability of the cell to respond to increased energy demand. 
The third injection is a mix of rotenone, a complex I inhibitor, and antimycin A, 
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a complex III inhibitor. This combination shuts down mitochondrial respiration 
and enables the calculation of non-mitochondrial respiration driven by 
processes outside the mitochondria. Detailed protocol can be found at 
manufacturer’s website.  
1. SGBS adipocyte were seeded (density of 40,000 cells per well) in a 
XFe24-well cell culture microplate and differentiated as per protocol 
mentioned before (2.4.2). 
2. On day 6 of differentiation, FTO inhibitor CA (50 µM and 100 µM) or 
DMSO (2 µl) were added in respective wells. DMSO served as a vehicle 
control for drug CA.  
3. XFe24 sensor cartridge was put to 24 h hydration in CO2 free incubator 
on day 7 by adding 1 ml of XF calibrant in each well of the utility plate 
and placing hydro-booster plate and sensor cartridge over it. All sensors 
must be submerged in calibrant fluid and cover lid should be placed in 
position.  
4. On day 8, XF test medium was prepared by adding glucose, sodium 
pyruvate and L-glutamine to XF basal medium as suggested by the 
manufacturer. Cells were then washed twice with XF test medium and 
finally 475 µl of XF test medium was added to all the wells. The plate 
was incubated in CO2 free incubator at 37°C for 1 h.  
5. During this incubation, sensor cartridges were removed from the 
incubator and it’s respective wells were filled up with XF test medium 
containing oligomycin (2 µM), FCCP (1 µM) and Rotenone+antimycin 
A (1 µM each).  
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6. Next, flux analyzer instrument (switched on from previous day to 
equilibrate at 37°C) was programmed for a particular experiment and 
run was finally executed by first calibrating it with sensor cartridge plate 
and finally replacing the utility plate with cell culture plate containing 
SGBS. 
7. Readings were obtained as pmole of oxygen consumed per minute in 
various conditions and Seahorse Bioscience tools were used to compute 
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Primary human adipocytes are essential cell model for metabolic research, 
particularly for mechanistic studies requiring knockdown, overexpression and 
editing of specific RNAs or proteins. But, adipocyte precursors or preadipocytes 
isolated from human adipose tissue are limited by the ability to grow and 
differentiate after few passages [101]. In 2001, investigators isolated 
preadipocytes from an infant derived adipose tissue [101] which could grow up 
to 50 passages while maintaining growth and differentiation capacity. SGBS 
adipocytes were derived from a 3 year old infant suffering from Simpson Golabi 
Behmel syndrome or SGBS. Since isolation, they have been widely distributed 
around the world and reported as a representative adipocyte model for primary 
human adipocytes. SGBS syndrome was first described in 1975 and is a rare X-
linked recessive disorder characterized by pre- and post-natal overgrowth 
(visceral and skeletal abnormalities). The majority of the SGBS patients are type 
1, triggered by deletions or point mutations in glypican 3 (GPC3) gene. A loss-
of-function mutation in GPC3 gene is thought to inhibit Hedgehog signaling 
[126-130]. Type 2 SGBS is a more severe variant due to mutations in oral-
facial-digital syndrome (OFD1) gene. As a result of these mutations, there is 
unregulated growth of many neonatal tissues, including mesenchyme and 
progenitors of adipose tissue. However, a GPC3 defect was not described in the 
formative paper [101] and the precise mutation in the SGBS adipocytes has not 
yet been characterized. 
Previous reports suggest that primary human subcutaneous adipocytes and 
SGBS adipocytes have similar trends in the expression of FABP4 and PPARγ 
mRNA as well as secretion of FABP4 during differentiation [102]. Another 
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study comparing SGBS adipocytes with primary human omental adipocytes 
derived from obese and non-obese individuals found similarity in morphology, 
induction of adipocyte-specific gene expression and GAPDH activity [131]. 
Although adult human adipose tissue and adipocytes have a minimal UCP1 
expression, SGBS adipocytes have been shown to possess nominal browning 
capacity in a study [132, 133]. Additionally, SGBS adipocytes were recently 
reported to display a rather versatile, inducible browning phenotype, with 
transient expression of UCP1 and PPARγ peaking at day 14 and declining by 
day 28 during differentiation [103]. But, inherent differences between metabolic 
profiles of SGBS adipocytes and primary human adipocytes remain 
inconclusive. Therefore, we hypothesized that while there are overlapping 
similarities; distinct metabolic and adipogenic signatures exist between SGBS 
and primary human adipocytes, understanding which will contribute to the 
knowledge and appropriate usage of relevant cell culture model in future 
metabolic research.  
3.2 Materials and methods 
3.2.1 Subject recruitment and cell culture 
All subjects recruited were patients at the National University Health System 
(NUHS, Singapore) undergoing bariatric surgery and had body mass index 
(BMI) ≥ 35 kg/m2. Nature, purpose and risks involved in the study were 
explained to subjects and written consent was obtained. Ethics approval was 
directed by the National Healthcare Group Domain Specific Review Board 
(reference number 2014/00396). Adipose tissue samples were obtained from the 
abdominal region during the surgery and primary human subcutaneous (SC) 
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preadipocytes (n=4 donors) were isolated by collagenase digestion. SGBS 
adipocytes were a kind donation from Dr. David Silver, DUKE-NUS, 
Singapore. Isolation, growth and differentiation of primary human adipocytes 
and SGBS adipocytes are discussed in section 2.4. 
3.2.2 RNAseq experiment and analysis 
Total RNA was extracted from SGBS (n=2) and SC control adipocytes (n=4) 
using Qiagen RNeasy plus mini kit (section 2.1.1). Protocol for RNA 
sequencing is described in section 2.7. Figure 14 represents work flow for RNA-
SEQ data analysis. We used two different methods for enrichment analysis of 
gene ontologies and KEGG biological pathways. “R” package was used to 
generate heatmap and clustering genes. GSEA (Gene Set Enrichment Analysis, 
Broad Institute) [134] and enrichment map creator (Cytoscape Plugin) [135] 
was used to analyze enriched gene ontologies and visualize interactions between 
them. Gene Set Enrichment Analysis (GSEA) uses a ranking system to 
distribute FPKM values across all the samples and classify ontologies into 
positively and negatively enriched ontologies. KEGG biological pathway 
enrichment analysis was done using iPathwayGuide [122, 136]. Impact analysis 
used by iPathwayGuide provides a systems biology approach to pathway 
analysis. It takes into consideration the role, type, position, function and 
interactions of genes in each pathway and measures the impact by propagating 
the signals through the pathway topology. The advantage of this approach is 




Figure 14: Work flow of RNA-SEQ data analysis for comparing SGBS versus 
SC control adipocytes. 
FPKM values were used either in “R” package or enrichment map creator to 
visualize positively and negatively enriched gene ontologies including 
biological processes (BP), cellular components (CC) and molecular functions 
(MF). For tabulation of KEGG biological pathways, fold changes (log FC ≥± 
0.5, FDR < 0.05) were analyzed in iPathwayGuide and pathways enriched with 
the highest impact were enlisted. Metabolic pathway genes obtained from 
iPathwayGuide were further distributed as up and downregulated genes, and 
DAVID bioinformatics was used to compute enriched KEGG biological 
pathways in both sets of genes.    
3.2.3 Real-time quantitative PCR and mitochondrial DNA content 
Total RNA was isolated using Qiagen RNeasy plus kit and quantified using 
NanoDrop spectrophotometer. cDNA was synthesized from 800 ng of total 
RNA using ABI high capacity cDNA synthesis kit (Thermo Scientific) 
according to protocol described in section 2.2.1. Quantitative PCR reactions 
were setup and run according to protocol suggested (section 2.2.2). Genes 
involved in different pathways such as adipogenesis (PPARγ, PPARα, CEBPα, 
FPKM data (n=2, SGBS and n=4, SC)
FPKM values (genes with 
FPKM < 1 excluded)
Clustering in heatmap 
using R (gene 
ontologies)
Development of enrichment map using 
GSEA and enrichment map builder in 
cytoscape 
(clustering gene ontologies together 
based on common genes) 
Fold change (FC) (SGBS 
vs SC)
iPathwayGuide to tabulate 








Gene lists fed into 
DAVID bioinformatics 
to compute enriched 




adiponectin and leptin), lipid metabolism (FABP4, DGAT1, FTO, and FIT2), 
inflammation (IL18, IL1β, NFKβ1, TLR4, and TNFα) and browning (UCP1, 
PRDM16, PGC1α, and DIO2) were probed. ABI primer express 3.0 was used 
to design primer sequences. Mitochondrial DNA content in SGBS and SC 
controls was quantified as described in section 2.2.4. 
3.2.4 Western blotting 
Cell lysates were prepared using RIPA buffer (Thermo Scientific) 
supplemented with protease and phosphatase inhibitors. 30 µg of total protein 
was separated using 10% acrylamide gel, transferred to PVDF membrane, 
blocked using 5% milk in TBS (with 0.1% Tween 20), and incubated overnight 
with UCP1 (Thermo Scientific) and GAPDH (Cell Signaling, MA, USA) 
antibodies at 4°C. Following this, blots were incubated with HRP-conjugated 
secondary antibody for 2 h and exposed using x-ray films. Detailed protocol in 
section 2.3.  
3.2.5 Mitochondrial respiration analysis 
Seahorse XFe24 Analyzer (Seahorse Biosciences, MA, USA) was used to 
measure mitochondrial respiration in adipocytes. Protocol described in section 
2.8 was followed.  
3.2.6 Lipid accumulation and radioactive glucose uptake assay 
Adipocytes were washed with sterile PBS and stained with AdipoRed (Lonza) 
according to the manufacturer’s protocol (section 2.4.5). After 30 min 
incubation, fluorescence was read at 485 nm excitation and emission at 572 nm. 
Protocol for insulin-stimulated glucose uptake assay was followed as described 




3.3.1 Fully differentiated SGBS and SC adipocytes display distinct 
transcriptomic profiles 
RNAseq analysis showed numerous differences in transcriptomes of SGBS and 
SC adipocytes. Red dots in volcano plot (figure 15) represent differentially 
expressed genes (inclusion was capped at FC ≥± 0.6, FDR ≤ 0.05). 1667 genes 
were upregulated and 2050 genes were downregulated in SGBS adipocytes 
when compared to SC controls. Disease association between SGBS adipocyte 
transcriptome and SGBS syndrome was established by GPC3 (FC = 0.181, FDR 
= 4.62E-06) and OFD1 (FC = 0.299, FDR = 0.00394) genes. 
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Figure 15: Global transcriptome profiling of SGBS and SC adipocytes 
(volcano plot). 
Volcano plots displaying number of differentially expressed genes in SGBS 
adipocytes compared to SC adipocytes. Red dots denote statistically significant 
genes. Genes with FDR < 0.05 and log (FC) > 0.60 were included. For the 
experiments involving SC adipocytes, experiments were performed in cells 
derived from 4 different donors (SC_1 to SC_4). For SGBS adipocytes, 
experiments were performed in duplicates (SGBS_1 and SGBS_2) from the 




Figure 16: Transcriptome profiling of top 1000 differentially expressed genes 
in SGBS adipocytes. 
Heat map clustering (unsupervised) top 1000 significantly upregulated (red) or 
downregulated (blue) genes in SGBS (n = 2) when compared to SC (n = 4) 
adipocytes. Enriched genes ontologies in up (lipid metabolism) or 
downregulated (membrane, extra-cellular matrix) set of genes in SGBS 
adipocytes are denoted on the right side of the figure.  For the experiments 
involving SC adipocytes, experiments were performed in cells derived from 4 
different donors (SC_1 to SC_4). For SGBS adipocytes, experiments were 
performed in duplicates (SGBS_1 and SGBS_2) from the same SGBS adipocyte. 
Heatmap (figure 16) was generated to cluster all six adipocyte samples and 
enriched biological processes (GO_BP) and cellular components (GO_CC) 
were analyzed in parallel. SGBS and SC adipocyte samples clustered distinctly 
from each other and all four SC adipocyte samples (except SC_025_1 or sample 





































































colored brackets) included genes upregulated in SGBS adipocytes and was 
significantly enriched in lipid metabolism (BP) and mitochondria (CC) 
ontologies. Cluster 2 (represented by blue colored brackets) included genes 
downregulated in SGBS and was significantly enriched in membrane (CC), 
extracellular matrix (CC) and cell adhesion (BP) ontologies.  
However, clustering did not allow analysis of positive and negative enrichment 
in gene ontologies or interactions between them. For detailed ontology analysis 
based on interactions, enrichment map of ontologies was built (figure 17). 
Positive and negative enrichment in ontologies were calculated based on the 
number of genes upregulated or downregulated in each ontology and denoted 
by red or blue colored nodes respectively. Gene ontology interactions 
(represented as green lines) were calculated based on the number of common 
genes between them, with thicker lines denoting more common genes. Final 
output illustrated significant interaction in ten ontology clusters or modules, five 
of which contained positively enriched ontologies and 5 contained negatively 
enriched ontologies (figure 17). Out of these, 6 clusters covered more than four 
individual ontologies, largest being cluster of mitochondria and oxidative 
respiration related ontologies suggesting that SGBS adipocytes were positively 
enriched in all these ontologies. Metabolism (especially lipid metabolism) 
related ontologies formed another cluster of positively enriched ontologies in 
SGBS adipocytes. Negatively enriched ontology clusters in SGBS adipocytes 
included (I) transcription and RNA metabolism (II) ECM components and (III) 













































Figure 17: Fully differentiated SGBS and SC adipocytes display distinct 
ontology clustering. 
FPKM values were analyzed in gene set enrichment analysis (GSEA) desktop 
version [137] and the output was exported in Cytoscape 3.3 (plugin: enrichment 
map creator) [135] to generate a map of positively and negatively enriched 
gene ontologies. The size of the node predicts the number of genes in particular 
ontology and green connecting line represents the number of common genes. 
Blue and red color denotes down and upregulated ontologies respectively 
(SGBS vs SC adipocytes). Cut off value for generating enrichment map was 
capped at conservative (P-value < 0.001, FDR < 0.05). Each cluster is 
magnified and shown below.  




3.3.2 Differentially enriched metabolic pathways in SGBS adipocytes 
compared to SC adipocytes 
iPathwayGuide was used to analyze significantly enriched KEGG biological 
pathways. More than 20 KEGG biological pathways were enriched in SGBS 
adipocytes when compared to SC adipocytes (table 12, P < 0.05 with Bonferroni 
correction). Deducing from results obtained in gene ontology analysis, 
noteworthy among these pathways were ECM-receptor interaction (figure 18), 
metabolic pathways, fatty acid metabolism (Figure 19), cytokine-cytokine 
receptor interaction and focal adhesion. Figure 18 and 19 illustrate upregulated 
(towards red color) and downregulated (towards blue color) genes in respective 
pathway map. Figure 20 represent up and downregulated genes in ECM-
receptor interaction pathway. 
Biological Pathways P-Value (Bonferroni corrected) 
ECM-receptor interaction 3.18E-06 
Metabolic pathways 3.07E-05 
Type I diabetes mellitus 0.000142 
Fatty acid metabolism 0.000178 
Cytokine-cytokine receptor interaction 0.000256 
Calcium signaling pathway 0.000443 
Autoimmune thyroid disease 0.001638 
PI3K-Akt signaling pathway 0.002073 
Neuroactive ligand-receptor interaction 0.003842 
Pathways in cancer 0.004007 
Hematopoietic cell lineage 0.004051 
Graft-versus-host disease 0.005511 
Cell adhesion molecules (CAMs) 0.005968 
Fatty acid degradation 0.006437 
Biosynthesis of unsaturated fatty acids 0.009968 
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Valine, leucine and isoleucine degradation 0.013166 
Focal adhesion 0.016408 
Allograft rejection 0.018391 
PPAR signaling pathway 0.029223 
Glycerolipid metabolism 0.044868 
Table 12: Top KEGG biological pathways significantly enriched in SGBS vs 
SC control adipocytes. 
Significance was pegged at P < 0.05. 
As seen in pathway map as well as bar graph, the majority of genes in ECM 
receptor interaction pathway were downregulated in SGBS (n = 26 of 31 genes, 
log (FC) ≥ 1 and FDR < 0.05). Genes in fatty acid metabolism pathway, 
especially coding for mitochondrial lipolysis enzymes and ER resident proteins 
catalyzing a reaction for fatty acid elongation from palmitic acid to C22 or C24 
free fatty acids were upregulated in SGBS adipocytes.  
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Figure 18: Representation of fold changes in ECM-receptor interaction 
pathway (SGBS vs SC adipocytes). 
Output was generated with the help of iPathwayGuide. Blue and red colors 
symbolize downregulated and upregulated genes respectively. Significance was 
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Figure 19: Representation of fold changes in fatty acid metabolism pathway 
(SGBS vs SC adipocytes). 
Output was generated in iPathwayGuide. Blue and red colors symbolize 
downregulated and upregulated genes respectively. Significance was pegged at 
P < 0.05. 










































































































Figure 20: Up and downregulated genes in ECM-receptor interaction 
pathway (SGBS vs SC adipocytes). 
Fold change was capped at (log FC ≥± 1 or FC ≥± 2) with FDR ≤ 0.05. 
3.3.2.1 Significantly up and downregulated metabolic pathways in SGBS 
adipocytes compared to SC adipocytes 
Metabolic pathway (P-value = 3.07E-05) genes from iPathwayGuide contained 
a total of 314 genes significantly up or downregulated genes in SGBS 
adipocytes. To obtain specific metabolism pathways enriched either in 
upregulated (n=220) or downregulated (n=94) genes, respective list of genes 
were input in DAVID bioinformatics tool and enriched KEGG pathways were 
computed (P < 0.05, Bonferroni corrected, table 13). Nineteen pathways were 
enriched in upregulated set of genes, including oxidative phosphorylation, fatty 
acid metabolism, glycerolipid metabolism, glycerophospholipid metabolism, 
TCA or citric acid cycle and pyruvate metabolism. Four pathways were 
enriched in downregulated set of genes including O-glycan biosynthesis, 
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sphingolipid metabolism, nicotinate and nicotinamide metabolism and drug 
metabolism. 
Biological Pathways P-Value (Bonferroni 
corrected) 
Upregulated genes in metabolic pathways 
Oxidative phosphorylation 1E-19 
Valine, leucine and isoleucine degradation 2E-19 
Parkinson's disease 7E-14 
Alzheimer's disease 1E-11 
Fatty acid metabolism 6E-11 
Huntington's disease 2E-10 
Glycerolipid metabolism 9E-08 
Butanoate metabolism 3E-07 
Propanoate metabolism 2E-06 
Citrate cycle (TCA cycle) 2E-05 
Terpenoid backbone biosynthesis 7E-05 
beta-Alanine metabolism 1E-04 
Glycerophospholipid metabolism 2E-04 
Glyoxylate and dicarboxylate metabolism 1E-03 
Pyruvate metabolism 2E-03 
Arginine and proline metabolism 4E-03 
Glycolysis / Gluconeogenesis 1E-02 
Limonene and pinene degradation 1E-02 
Fatty acid elongation in mitochondria 2E-02 
Downregulated genes in metabolic pathways 
O-Glycan biosynthesis 4E-04 
Sphingolipid metabolism 2E-02 
Nicotinate and nicotinamide metabolism 4E-02 
Drug metabolism 4E-02 
Table 13: Metabolic pathways significantly enriched in SGBS adipocytes 
compared to SC adipocytes. 
Significance was pegged at P < 0.05. 
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Overall, SGBS adipocyte transcriptome indicated downregulated ECM receptor 
interaction and upregulated fatty acid metabolism (especially mitochondrial 
lipolysis), pyruvate metabolism, TCA cycle and oxidative phosphorylation, 
most of which takes place in mitochondria. 
3.3.3 Adipogenic and metabolic gene profiling of SGBS and SC adipocytes 
To evaluate variances in gene expression profile during adipogenesis, eighteen 
genes-of-interest vital for differentiation, lipid metabolism, inflammation and 
browning in adipocytes were quantified at day 0, day 4, day 8 and day 12 of 
differentiation. SGBS and SC adipocytes were differentiated using respective 
protocols and gene expression in all samples was compared to day 0 in SC 
adipocytes. To rule out the possibility that the differences in characteristics seen 
between the two adipocyte types studied were due to differences in the media 
used to differentiate them, a series of experiments in which LONZA media was 
used to differentiate SGBS adipocytes were also performed. The results 
obtained for the SGBS adipocytes were similar, whether LONZA media or 
SGBS specific differentiation media was used (results not shown). 
Adipogenic markers (PPARγ, PPARα, CEBPα, FABP4, adiponectin and leptin) 
increased in both SGBS and SC adipocytes, but the magnitude was much higher 
in SGBS adipocytes (except PPARα) (figure 21A). Differences could be 
observed starting from day 4 of differentiation and continued until day 8 or 12. 
In mature state, fold change of adiponectin (~13 fold), CEBPα (FC = 171.05 ± 
83.503 in SC, FC = 1362 ± 740.98 in SGBS), PPARγ (FC = 15.98 ± 7.94 in SC, 
FC = 35.18 ± 6.22 in SGBS) and leptin (FC = 40.86 ± 22.56 in SC, FC = 470.63 
± 34.002 in SGBS) was greater in SGBS when compared to SC adipocytes, and 
indicated earlier and better adipogenesis in them. Baseline expression of 
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adiponectin was significantly higher (~20 fold) in SGBS starting from day 0. 
Along with adipogenesis, lipid metabolism genes DGAT1 (~4 fold) and FIT2 
(~3 fold) were higher in SGBS (figure 21B). 
Figure 21: SGBS adipocytes have distinct expression pattern of (A) 
adipogenic and (B) lipid storage and metabolism genes during adipogenesis 
Days of differentiation indicated as D0, D4, D8, and D12 respectively. Data 
represented as mean ± SEM obtained from three different donors for SC 
adipocytes (in duplicates) and three independent trials (in duplicates) for SGBS 
adipocytes. All data were normalized using SC control D0 samples. *P < 0.05, 














































1 0 0 0
2 0 0 0
4 0 0 0
6 0 0 0
8 0 0 0
1 0 0 0 0



































































































































































































































1 0 0 0
1 5 0 0
2 0 0 0
2 5 0 0














































































































5 0 0 0 0
1 0 0 0 0 0
1 5 0 0 0 0
2 0 0 0 0 0
1 .0×1 0 7
2 .0×1 0 7
3 .0×1 0 7







































































































































IL18 (~20 fold) and TLR4 (~10 fold) gene expression increased by day 12 of 
differentiation in SC adipocytes with minimal change in SGBS. On the contrary, 
IL1β expression increased (~40 fold) in SGBS adipocytes while minimally 
changing in SC adipocytes. TNFα and NFκB1 expression did not change 
significantly with differentiation in either SC or SGBS adipocytes (figure 22A). 
However, in mature state, expression of all inflammatory markers was 
significantly higher in SC adipocytes (except IL1β). 
PGC1α, PRDM16, DIO2, UCP1 gene expression was analyzed as markers of 
browning. PGC1α is an upstream master regulator of mitochondrial biogenesis 
[138, 139]. At day 0, baseline expression of PGC1α was significantly higher in 
SC adipocytes when compared to SGBS adipocytes and continued to be higher 
(~6 fold at day 12) in SC adipocytes. Similar results were seen for DIO2 gene 
expression. Unlike PGC1α and DIO2, UCP1 expression was ~1300 fold higher 
in mature SGBS adipocytes when compared to SC controls, although baseline 
expression of UCP1 seemed lower in SGBS adipocytes (figure 22B). PGC1α is 
a transcription coactivator for UCP1 gene expression, but we observed an 
opposing trend in their mRNA expressions in SC adipocytes. This suggested 
presence of either alternative UCP1 transcription factors in SGBS adipocytes or 





Figure 22: SGBS adipocytes have distinct expression pattern of (A) 
inflammatory and (B) browning genes during adipogenesis. 
Days of differentiation indicated as D0, D4, D8, and D12 respectively. Data 
represented as mean ± SEM obtained from three different donors for SC 
adipocytes (in duplicates) and three independent trials (in duplicates) for SGBS 
adipocytes. All data were normalized using SC control D0 samples.*P < 0.05, 
**P < 0.005, ***P < 0.0001. 
Gene expression data in mature adipocytes was used to validate RNAseq data 
and a strong correlation in log (FC) was observed (linear regression of r = 
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Figure 23: Gene expression data from RNAseq significantly correlated with 
qPCR data. 
Pearson’s correlation was used to determine significance among the groups. P 
< 0.05 was considered statistically significant.  
3.3.4 SGBS adipocytes have energy dissipating browning phenotype 
Ontology, KEGG pathway and UCP1 gene expression pattern in SGBS 
adipocytes suggest brown or beige adipocyte phenotype. To answer the question 
if they are brown or beige, we measured UCP1 protein expression, 
mitochondrial DNA content and respiration in SGBS and SC adipocytes. As 
beige adipocytes are induced from white adipocytes upon stimulation with 
PPAR agonist or T3, which are also active components of SGBS differentiation 
medium; UCP1 protein expression was evaluated before/after depletion of 
rosiglitazone (PPAR agonist) and T3 from differentiation medium of SGBS 
adipocytes. Consistent with gene expression, western blot in figure 24A 
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demonstrated significantly higher UCP1 protein expression in SGBS 
adipocytes; even after depletion of rosiglitazone or T3.  
Figure 24: SGBS and its browning phenotype. 
(A) UCP1 protein expression in differentiated SGBS and SC adipocytes at basal 
level and upon depletion of T3 and rosiglitazone (rosi) from differentiation 
medium. (B) Mitochondrial respiration measured as oxygen consumption rate 
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in SGBS and SC adipocytes (detailed protocol discussed in section 2.8 (C) 
Mitochondrial DNA content measured as a ratio of mitochondrial DNA 
(mtDNA) by nuclear DNA (nDNA). Data represented as mean ± SEM obtained 
from three different donors for SC adipocytes (in duplicates) and three 
independent trials for SGBS adipocytes.*P < 0.05, **P < 0.005. 
Mitochondrial respiration was measured using Seahorse mitochondrial flux 
analyzer and represented as oxygen consumption rate or OCR (pMoles/min/µg 
of protein). Figure 24B illustrates mitochondrial respiration profile and 
mitochondrial function. SGBS adipocytes (grey bars) exhibited significantly 
higher basal respiration (~2 fold), proton leak, maximal respiration (~4 fold) 
and spare respiratory capacity (~8 fold) when compared to SC adipocytes (P < 
0.05). Mitochondrial DNA content is an indirect representation a number of 
mitochondria and was ~3.5 fold higher in SGBS adipocytes (P = 0.0079) (figure 
24C). 
3.3.5 Lipid accumulation and glucose uptake in SGBS adipocytes 
compared to SC adipocytes 
Together with mitochondrial function, we measured lipid accumulation and 
glucose uptake as functional readouts in both adipocytes. In differentiated state, 
intracellular lipid droplet accumulation was significantly higher in SGBS 
adipocytes when compared to SC controls (P < 0.0001) (figure 25A). 
Furthermore, SGBS adipocytes possess higher insulin sensitivity as 




Figure 25: lipid accumulation and insulin-stimulated glucose uptake assay in 
SGBS vs SC adipocytes. 
Data represented as mean ± SEM obtained from three different donors for SC 
adipocytes (in duplicates) and three independent trials for SGBS adipocytes. 
**P < 0.005, ***P < 0.0001. 
3.3.6 Adipocyte lineage markers in SGBS and SC adipocytes 
Results indicated a robust heat producing phenotype in SGBS. To answer the 
question if lineage of SGBS differed from SC adipocytes, lineage specific 
markers (pooled from current literature) and their gene expression in SGBS 
were tabulated (table 14). Lineage markers were divided into 6 categories as 
brown (BAT), beige, white (WAT), brown and beige, white and beige as well 
as ubiquitous (found in all types of adipocytes). WAT (white) adipocyte 
markers ASC-1, NR1H3 and LPL; BAT and beige adipocyte marker PLIN5; 
and ubiquitous markers CITED1 and adiponectin (ADIPOQ) were upregulated 
in SGBS. WAT and beige marker PDGFRα and BAT plus beige markers 
MTUS1 and PGC1α were downregulated in SGBS. A common marker among 
beige and brown adipocytes (UCP1) was significantly higher in SGBS 
adipocytes when compared to SC controls. Overall, SGBS did not match to any 





Gene Name Lineage Fold Change FDR Reference 
EDNRB BAT -5.14 0.00532 Xue and Tseng et al 2015 
EBF2 BAT -4.68 0.00002 Rajakumari, Wu et al 2013 
PDK4 BAT 4.57 0.03001 Mottillo et al 2012 
PREX1 BAT 5.74 0.00005 Xue and Tseng et al 2015 
MYF5 BAT NA NA Seale, Bjork et al 2008 
ZIC1 BAT NA NA 
De Jong and Larsson et al 
2015  




































































NA NA Lidell et al 2013 
CD40 Beige -6.62 0.00237 Wu, Bostrom et al 2012 
EPSTI1 Beige -4.18 0.01117 
De Jong and Larsson et al 
2015  
SP100 Beige -2.44 0.00718 Wu, Bostrom et al 2012 
EAR2/NR2F6 Beige 1.85 0.00002 Wu, Bostrom et al 2012 
SHOX2 Beige 2.03 0.06347 Lidell 2013 
SLC27A1 Beige 4.48 0.00017 Wu, Bostrom et al 2012 
TBX1 Beige NA NA 
De Jong and Larsson et al 
2015 
TNFRSF9/CD137 Beige NA NA 
De Jong and Larsson et al 
2015  
TMEM26 Beige NA NA 
















De Jong and Larsson et al 
2015  
RBL1 WAT -2.29 0.04992 Scime, Grenier et al 2005 
Leptin WAT -0.71 0.52992 Ussar, Lee et al 2014 
NRIP1/RIP140 WAT 1.09 0.82716 
Hallberg, Morganstein et al 
2008 
RB1 WAT 1.34 0.37996 Hansen, Jorgensen et al 2004 
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TCF21 WAT 2.94 0.02604 
De Jong and Larsson et al 
2015  
LPL WAT 13.47 0.00055 Dani, Amri et al 1990 
NR1H3/LXRα WAT 16.32 0.00006 Wang, Zhang et al 2008 









De Jong and Larsson et al 
2015  
Table 14: Lineage specific markers in adipocytes and their expression in 
SGBS and SC control adipocytes. NA: Genes with FPKM < 1 and thus 
excluded from further analysis. P value < 0.05 and FDR < 0.05 were used as 
thresholds to select significant genes. 
3.4 Discussion 
Presence of a distinct transcriptome profiles, robust differentiation, increased 
oxidative respiration, brown adipocyte like phenotype, higher lipid 
accumulation and glucose uptake supported our hypothesis that there exists 
metabolic differences between SGBS adipocytes and primary human 
subcutaneous adipocytes derived from obese, non-diabetic subjects. 
RNA sequencing results showed differences in KEGG biological pathways and 
gene ontologies. Within these, a number of ECM-receptor interaction genes 
were differentially down (n=26) and upregulated (n=5) in SGBS when 
compared to SC controls. Additionally, GSEA output and enrichment map 
indicated ECM components to be negatively enriched in SGBS adipocytes. 
Functionally, ECM plays a critical role in maintaining the structural integrity of 
adipocytes and ECM-receptor interaction is associated with pro-inflammatory 
changes and dysregulation of adipocyte metabolism; also known to vary with 
the degree of obesity [140, 141]. Subject to individual protein function, ECM 
components seem to play a dual role in promoting or inhibiting adipose tissue 
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expandability. Several reports suggest that excessive ECM deposition in 
response to obesity-related inflammation reduces adipose tissue expandability 
which eventually results in adipose tissue dysfunction [15]. However, studies 
testing the effects of selective macromolecular crowding on adipogenesis and 
browning suggest beneficial effects. When differentiated with macromolecular 
crowding, bone marrow derived mesenchymal stem cells undergo improved 
adipogenesis in the presence of macromolecular crowding. In addition to better 
adipogenesis, deposition of ECM components such as collagen IV and perlecan 
(a heparan sulfate proteoglycan) were observed to be significantly higher [16]. 
Collagen IV cocoon formation around differentiating bone marrow derived 
mesenchymal stem cells also improved their UCP1 expression and thermogenic 
capacity [17]. In our dataset, transcripts of subcomponents of collagen IV were 
differentially expressed in SGBS adipocytes. Some subcomponents were 
upregulated: COL4A5 (log FC = 2.04), COL4A3 (log FC = 7.57), COL4A4 (log 
FC = 8.20), whereas other components were downregulated: COL4A1 (log FC 
= -2.00) and COL4A2 (log FC = -1.77). These observations remain to be 
verified at the protein expression level, but suggest that subcomponents of 
collagen IV may have differing activity in terms of whether they are more pro-
adipogenic (COL4A5, COL4A3 and COL4A4) or anti-adipogenic (COL4A1 
and COL4A2).In addition to ECM-receptor interaction, metabolic pathways in 
SGBS adipocytes differed from SC adipocytes with 220 genes significantly 
upregulated and 94 genes significantly downregulated in SGBS. Most of the 
upregulated genes annotated to oxidative phosphorylation pathway, which is 
active in brown adipocytes or beige adipocytes upon stimulation. In addition, 
oxidative respiration and fatty acid oxidation related ontologies were positively 
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enriched in SGBS. Transcriptome differences were recapitulated in the 
phenotype of SGBS adipocytes as mitochondrial content, respiration and UCP1 
gene as well as protein expression were significantly higher in SGBS 
adipocytes. Beige adipocytes differ from brown adipocytes in their ability to 
induce UCP1 expression upon stimulation with cold or PPARγ which is an 
active constituent of differentiation medium. SGBS adipocytes were able to 
maintain UCP1 protein expression even after depletion of PPARγ agonist. 
Together, these results were in line with transient brown phenotype in SGBS 
that has been reported recently [103]. 
SGBS gene expression profile was unable to fit any specific adipocyte lineage 
with upregulated and downregulated genes in all of categories although 
functionally they are similar to brown adipocytes. Resemblance of SGBS to 
previously documented neonatal white adipocytes is worth considering. Some 
of the previous reports suggest that neonatal white adipocytes have increased 
number of mitochondria and browning phenotype when compared to adipocytes 
derived from adult adipose tissue [142, 143] and function and composition of 
adipose tissue vary substantially between an early age and adulthood. During 
infant age, it displays more active thermogenic properties; for example the size, 
number and structure of its mitochondria are reminiscent to those of BAT [144]. 
Hence, it is essential to consider the infant origin of SGBS adipocytes (derived 
from the white adipose tissue of a 3-month-old baby) which could be a key 
contributing factor to the differences observed [101]. Infant or neonatal origin 
of SGBS is supported by certain genes. CYP19A1 (also known as aromatase) 
and ALDH1A1, which are expressed only in adult placental tissue are 
downregulated in SGBS adipocytes [145, 146]. In addition, ALDH3B2, known 
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to be minimally expressed in adult adipose tissue [147] is upregulated in SGBS 
adipocytes. However, studies also found CYP19A1 to be minimally expressed 
in fully differentiated, lipid-laden adipocytes [148, 149] and McInnes et al. 
reported similar gene expression of aromatase in SGBS and isolated primary 
human adipocytes [150]. Inconsistency in our data from previous reports needs 
further validation, but could be perhaps due to adipocyte differentiation 
protocol. In our study we limited differentiation of both cell types to 12 days in 
contrast to 21 days used in previous studies. Moreover, SGBS adipocytes were 
found to have transient brown phenotype around day 14 of differentiation which 
changes to white phenotype by day 28. It would be interesting for future studies 
to fully characterize infant WAT and establish genes differentially expressed in 
this tissue. It is important to note that reproducibility of this work might be 
affected by and limited to use of Lonza differentiation medium for primary 
human subcutaneous adipocytes. Lonza medium provided us with an added 
advantage of faster and better differentiation within 10 days when compared to 
homemade differentiation cocktails, which needs 21 days for differentiation. 
3.5 Conclusion 
Our work demonstrated numerous differences between SGBS and SC 
adipocytes during 12 days of differentiation. Given their high differentiation 
capacity and robust viability, SGBS cells remain as a valuable, preliminary, in 
vitro test model for studies relating to human adipocyte metabolism. However, 
due to the differences observed, we would caution against using SGBS as the 










Chapter 4:  
Partial deficiency of FIT2 protein 
impairs triglyceride storage and insulin 












Type II Diabetes have prevailed for centuries and due to rapid urbanization and 
life style modifications, documented cases have soared to nearly 387 million 
worldwide, with huge financial burden [3]. Historically, onset of diabetes has 
always been associated with the presence of obesity (defined as Body Mass 
Index > 30). With advancement in research, the role of different adipose tissue 
depots in regulating metabolic homeostasis has become increasingly 
appreciated. Excessive OM adipose tissue and ectopic lipids (fats stored in the 
liver, kidney, skeletal muscle, cardiac tissue etc.) are known to be more 
pathogenic compared to SC adipose tissue [22]. However, ectopic lipid 
deposition is largely implicated to lipid spillover from SC and OM adipose 
tissue depot due to their impaired lipid storage capacity. The ability of adipose 
tissue to expand and grow with minimal lipid spillover contributes towards 
better metabolic health. TAGs within lipid droplets is the most non-toxic form 
of lipids in adipose tissue and adipocytes [151, 152]. Excess quantities of free 
fatty acids, diacylglycerols and ceramides are potent toxic lipid species resulting 
in insulin resistance via activation of inflammation, ER stress and macrophage 
infiltration [57, 153, 154]. In this context, we studied a recently discovered lipid 
droplet protein; FIT2 (Fat Storage Inducing Transmembrane 2). The motivation 
for homing in on studying the FIT2 protein were two fold; (I) RNA-SEQ 
(discussed in detail in chapter 6) data comparing OM vs SC depot in NT2DM 
and T2DM subjects revealed that FIT2 protein was one of the lipid storage 
proteins expressed at significantly lower levels in OM depot from T2DM 
subjects only (figure 26) (II) FIT2 was recently identified as a GWAS candidate 
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Figure 26: Lipid storage genes in NT2DM and T2DM subjects. 
OM depot was compared to SC depot (OM vs SC). Most of the lipid storage 
genes were downregulated in OM adipose tissue, especially in T2DM subjects. 
FIT2 was significantly lower in OM depot only in T2DM subjects (FDR < 0.05). 
FIT2 is an evolutionarily conserved endoplasmic reticulum (ER) membrane 
resident protein which plays a role in the partitioning of newly synthesized 
triacylglycerol (TAG) molecules into lipid droplets [51]. FIT or FITM family 
of proteins includes FIT1 (292 amino-acids, murine) and FIT2 (262 amino 
acids, murine) isoforms. In humans, FIT1 is expressed primarily in skeletal 
muscle tissue whereas FIT2 protein is known to be expressed ubiquitously, 
being highest in adipose tissue (figure 27) [47, 48]. Both FIT1 and FIT2 proteins 
have six transmembrane domains with N and C terminus facing the cytosol 











Figure 27: Expression pattern of FIT1 and FIT2 protein. 
Analyzed by western blot in various tissues in mice. Figure adapted from 
Kadereit, B., et al [51]. Darker shade denotes higher protein expression and 
white boxes indicate zero expression. 
 
Figure 28: Schematic representation of FIT1 and FIT2 protein structure. 
FIT1 contains 292 amino acids and FIT2 protein contains 262 amino acids. 
FIT1 has 30 extra amino acids at the amino terminus or N-terminus. Adapted 
from Gross, D.A., et al [47]. 
Dr. Silver’s group showed that FIT2 protein expression increased with 
differentiation in 3T3-L1 adipocytes and its knockdown led to significant 

































perilipin protein expression [51]. Overexpression of FIT1 or FIT2 protein in 
HEK-293T cells increased lipid droplet formation without affecting TAG 
biosynthesis or lipolysis. However, differentiated adipocytes isolated from 
adipose tissue specific knockout mice (AF2KO mice) had similar TAG 
accumulation when compared to differentiated adipocytes from control mice, 
with significantly larger lipid droplets. These effects were more pronounced 
upon addition of oleic acid as a high fat challenge [155]. Mice with FIT2 
overexpression in skeletal muscle (CFK2 mice) exhibit increased lipid droplets 
in muscle tissue, reduced body weight, fat mass and lean mass at 6 weeks of 
age. They also display increased oxygen consumption, glucose excursion rate, 
energy expenditure and complete protection from diet induced obesity [52]. The 
beneficial effects of FIT2 overexpression in skeletal muscle in these animals 
were attributed to re-patterning of muscle tissue metabolism such that glucose 
is directed towards glycerol-3-phosphate instead of glycolysis. Adipose tissue 
specific FIT2 knockout mice were lipodystrophic in phenotype with increased 
macrophage infiltration on high fat diet [155]. In 2012, a GWAS study has 
identified FIT2 as potential loci (SNP rs6017317) associated with type 2 
diabetes in East Asians [108]. To date, the potential role of FIT2 protein in 
regulating human adipose tissue function has not been investigated. We 
hypothesized that lack of FIT2 protein in adipocytes would lead to its 
dysfunction through inflammation and ER stress pathways. Using siRNA 
mediated FIT2 knockdown in primary human adipocytes, we showed that FIT2 
protein was required for efficient TAG storage and its deficiency increased IL6 
and IL18 mRNA expression as well as IRE1α phosphorylation and reduced Akt 
phosphorylation in primary human adipocytes. 
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4.2 Materials and Methods 
4.2.1 Research design 
Subcutaneous (SC) and omental (OM) adipose tissue and primary human 
adipocytes were obtained from obese non-diabetic (NT2DM) and obese diabetic 
(T2DM) subjects undergoing bariatric surgery (Table 15). After explaining the 
nature, purpose, potential and risks of the study, informed consent was obtained 
from all the subjects. Tissue samples from obese subjects were divided into 
aliquots for RNA isolation, protein lysate preparation (approx. 250 mg each, 
snap frozen) and for cell culture. For cell culture, approximately 2 g of the tissue 
was immersed in HEPES buffer (Gibco, Life Technologies) until isolation of 
adipocytes (within 4-6 h of obtaining the tissue). Ethics approval was directed 
by the National Healthcare Group Domain Specific Review Board. 
















36±2.2 46.6±9.8 5.5±0.38 
Table 15: Characteristics of obese diabetic and obese non-diabetic subjects 
from whom adipose tissue was derived for FIT2 expression analysis. 
*P < 0.05 when compared to the non-diabetics 
4.2.2 Isolation and culture of adipocytes 
Primary human adipocytes were isolated from tissues obtained during bariatric 
surgery using methods adapted from [156] and standardized in our lab. Briefly, 
fat tissue was collagenase digested, filtered, centrifuged and stromal vascular 
fraction (SVF) was used for cell culture. SVF obtained was plated for 3-4 days 
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in growth medium (DMEM high glucose, 15% fetal bovine serum (FBS), 1% 
non-essential amino acids (NEAA), 1% penicillin-streptomycin (pen-strep) and 
5 ng/ml fibroblast growth factor) for cells to achieve fibroblastic morphology. 
At confluence, these cells were referred to as preadipocytes. They were either 
sub-cultured using growth medium or differentiated with help of Lonza 
differentiation medium for 10 days as recommended by the manufacturer 
(Lonza Walkersville, Inc.). A detailed protocol is described in section 2.4.1. 
4.2.3 Free fatty acid preparation and treatment 
Palmitic acid was prepared (section 2.4.3) as a 10 mM soluble conjugate with 
bovine serum albumin (fatty acid free, Sigma) as previously described [121] and 
stored at -20oC until use. For treatment with palmitic acid, medium in 
differentiated adipocytes was replaced with DMEM supplemented with 2% 
FBS and 1% pen-strep and required volume of conjugated palmitate was added 
for 24 h. Subsequently, adipocytes were serum starved for 2 h and insulin 
stimulated (100 nM) for 30 min before RNA or protein isolation.  
4.2.4 FIT2 protein knockdown 
For knockdown (section 2.5) using SiRNA (5 nM), preadipocytes at 70-80% 
confluence were transfected either with FIT2 specific (Cat No. SI02825417, 
Qiagen) or AllStars negative control SiRNA (Cat No.SI03650318) for 6 h in 
serum free and pen-strep free medium (DMEM, Gibco) using SiTRAN 1.0 
transfection reagent (Cat No.TT300002, Origene, Rockville, MD). Transfection 
medium was replaced by growth medium after 6 h till cells reached full 
confluence and differentiation was then initiated (considered as day 0). SiRNA 
transfection was repeated at day 4 of differentiation and replaced with 
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differentiation medium till day 8. Figure 29 summarizes the key time points in 
this protocol.  
Figure 29: Key time points within protocol for siRNA transfection in primary 
human adipocytes. 
4.2.5 TAG accumulation and lipid droplet size 
Triacylglycerol (TAG) accumulation was quantified using AdipoRed kit (Nile-
red dye, a neutral lipid stain) by protocol suggested (Lonza) (section 2.4.5). 
Lipid droplet size was measuring by ImageJ (National Institutes of Health) 
using confocal images from Olympus FluoView FV1000. Nile red (AdipoRed) 
and Hoechst (cell signaling) were used to fluorescently label and visualize lipid 
droplets and nucleus respectively.  
4.2.6 RNA isolation and Real time PCR 
Cellular and Tissue RNA was isolated with Qiagen RNeasy plus mini kit and 
Qiagen RNeasy lipid tissue mini kit respectively (section 2.1.1 and 2.1.2). High-
Capacity cDNA Reverse Transcription Kit (Life Technologies) was used to 
synthesize cDNA (approx. 300 – 500 ng RNA per sample). QuantiFast SYBR 
Green PCR Kit (Qiagen) was used to prepare reaction mixtures for quantitative 
PCR (qPCR) with concentrations suggested by manufacturer. Primers used are 
enlisted in table 20.    
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4.2.7 Protein isolation and western blot 
Frozen ATs (about 150 mg) were homogenized in 500 µL RIPA buffer 
[(supplemented with protease and phosphatase inhibitors (Cat No.78440)] using 
TissueLyser LT (Qiagen) and centrifuged at 15000 rpm for 40 min. Protein 
lysates (clear yellow to red layer fluid) were transferred to a new tube, snap 
frozen-thawed about 5 times in liquid nitrogen followed by centrifugation at 
15000 rpm for 25 min to remove any residual lipid and tissue remnants. Lysates 
were separated using 10% acrylamide gel, transferred to PVDF membrane, 
blocked with 5% milk (0.1% Tween 20) and incubated with respective 
antibodies (as instructed by the manufacturer). Following antibodies were used; 
FIT2 (kind donation from Dr. David Silver, DUKE-NUS, Singapore), BiP, 
IRE1α (ER Stress Antibody Sampler Kit #9956, Cell Signaling), p-IRE1α 
(PA1-16927, Thermo Scientific), IRS-1 (06-248, Merck Millipore), p-IRS1 
(Ser-307, sc-33956, Santa Cruz), p-IRS1 (Tyr-612, #09-432, Millipore), Akt 
1/2/3 (sc-8312, Santa Cruz), p-Akt 1/2/3 (sc-7985-R, Santa Cruz), GAPDH 
(#2118, Cell Signaling). Respective HRP-conjugated secondary antibodies 
were used to incubate membranes for 2 h and exposed using ECL substrate 
(WBKLS0500, Merck Millipore). GAPDH was used as a loading control in all 
experiments. Detailed protocols discussed in section 2.3. 
4.2.8 Insulin stimulated glucose uptake assay 
Differentiated adipocytes were first incubated in serum-free DMEM 
supplemented with 0.2% BSA for 6 h prior to the assay (serum starvation). 
Subsequently, they were washed with PBS to remove glucose completely and 
were incubated in PBS supplemented with 0.2% BSA for 30 min at 37°C 
(glucose starvation). Next, cells were insulin stimulated (100 nM) for 15 min 
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and the assay was initiated by the addition of [3H] 2-deoxyglucose (5 µCi/mL) 
and deoxyglucose (5 mM). At the end of 20 min incubation, plates were placed 
on ice immediately and washed thrice with ice cold PBS. Cells were then lysed 
using RIPA buffer and contents were collected and incubated in ice for another 
20 min. Finally, cell-associated radioactivity was determined using a liquid 
scintillation counter (Perkin Elmer). Detailed protocol discussed in section 2.6.  
4.2.9 Statistical analysis 
Statistical calculations were performed in GraphPad Prism version 6.00 for 
Windows (GraphPad Software, San Diego California USA) using non-
parametric one-way ANOVA with Holm-Sidak correction for multiple 
comparisons. Values were expressed as mean ± SEM and P < 0.05 was 
considered statistically significant. 
4.3 Results 
4.3.1 FIT2 protein expression in adipose tissue is higher in obese non-
diabetics when compared to obese diabetics 
FIT2 mRNA and protein expression was quantified in SC and OM depots from 
obese T2DM and obese NT2DM subjects. Analysis of the results from SC and 
OM depots from individual subjects were paired to account for baseline 
variation. As seen in figure 30A, compared to SC depot, mRNA expression of 
FIT2 was significantly lower in OM depot derived from NT2DM (FC = 0.452 
± 0.094 P < 0.05) and T2DM (FC = 0.430 ± 0.091, P < 0.05) subjects. Protein 
densitometry (n=8 for all) from western blot (representative blots shown) 
showed that FIT2 protein expression (figure 30B and 30C) was higher in 
NT2DM compared to T2DM, in both SC (38.8 ± 14.15 vs 20.37 ± 13.67, non-
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significant ) and OM (32.75 ± 10.13 vs 11.05 ± 7.06, P < 0.05) depots. 
Discordance between mRNA expression and protein expression data might be 
an outcome of regulation of translation level, but we have not explored these 
mechanisms. There are no known post transcriptional or post translational 
mechanisms regulating FIT2 protein expression.   
Figure 30: FIT2 protein expression in adipose tissue is higher in non-
diabetics when compared to diabetics. 
(A) FIT2 mRNA expression (qPCR) in SC and OM adipose tissue from obese 
subjects (NT2DM and T2DM, n=5 per group). SC and OM depots were paired 
for each subject. (B) and (C) FIT2 protein expression in OM and SC adipose 
tissue from obese non-diabetics and diabetics (n=8 per group). Data was 
analyzed using non-parametric one-way ANOVA, *P < 0.05. Data represented 
as mean ± SEM. 































































































































4.3.2 FIT2 protein expression is higher in omental adipocytes from non-
diabetics as compared to diabetics 
Next, we quantified and compared FIT2 mRNA and protein expression in SVF 
derived primary human adipocytes. FIT2 expression was evaluated in 
differentiating and mature SC and OM adipocytes. In general, OM adipocytes 
took a longer time to differentiate and mature during adipogenesis with poorer 
terminal differentiation capacity at the end of 10 days. Independent of their 
adipogenic potential; FIT2 mRNA and protein expression was differentiation 
dependent in both SC and OM adipocytes. As expected, mature OM adipocytes 
expressed lower FIT2 mRNA (FC = 0.565 ± 0.063, P < 0.05) when compared 
to SC adipocytes (figure 31A) (adipocytes from non-diabetics and diabetics 
were pooled together for studies comparing mRNA expression in different 
depots). Measured by densitometry (n=7, representative western blot shown), 
OM adipocytes from NT2DM subjects expressed higher FIT2 protein (39.10 ± 
5.5, P < 0.05) when compared to diabetics (22.43 ± 3.09) (figure 31B). Protein 
expression in SC adipocytes was similar between NT2DM and T2DM subjects. 
Due to poorer differentiation capacity and technical challenges with 
maintaining OM adipocytes, SC adipocytes were then used in all subsequent 
experiments. To verify if adipocytes increased TAG accumulation upon 
administration of free fatty acids and whether the TAG accumulation was 
influenced by FIT2 protein concentration, we quantified TAG accumulation 
before/after palmitic acid treatment in differentiated SC adipocytes. TAG 
accumulation at baseline, without palmitate treatment, did not correlate with 
FIT2 protein concentration (data not shown). However, TAG accumulation 
after 24 h palmitate treatment was directly proportional to FIT2 protein 
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concentration (quantified by western blots) present at baseline (R2 = 0.52, P < 
0.001) (figure 31C). These results support a vital role of FIT2 protein in TAG 
storage in adipocytes during conditions of high fat challenge or free fatty acid 
overload.  
Figure 31: FIT2 protein expression is higher in omental adipocytes from non-
diabetics as compared to diabetics. 
(A) FIT2 mRNA expression (qPCR) in SC and OM adipocytes from obese 
subjects (NT2DM and T2DM, n=6). (B) FIT2 protein expression in SC and OM 
adipocytes from obese non-diabetics and diabetics (n=7). (C) Correlation of 
TAG accumulation with FIT2 protein quantity in SC adipocytes from obese non-
diabetics and diabetics after palmitate treatment (500 µM, n=10). Data were 
analyzed using (A and B) non-parametric independent sample t-test and (C) 
Pearson's correlation, *P < 0.05. Data represented as mean ± SEM. 
4.3.3 TAG accumulation after FIT2 knockdown using siRNA 
Next, we sought to examine effects of FIT2 protein knockdown in SC 
adipocytes, particularly on TAG accumulation. Preadipocytes were transfected 
with 5 nM of FIT2 specific (FIT2 KD adipocytes) or scrambled siRNA 
(negative control) and differentiated into mature adipocytes. At Day 8, 
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approximately 50% knockdown was observed in FIT2 mRNA and protein levels 
(figure 32A). PPARγ and CEBPα mRNA expression did not differ with either 
siRNA, which indicated no effect on differentiation in these adipocytes (figure 
32B). Next, TAG accumulation was measured before and after palmitate 
treatment in control and FIT2 KD adipocytes. Lipid droplets were imaged after 
staining them with AdipoRed. As seen in figure 32C, upon addition of palmitate, 
TAG accumulation increased significantly in control adipocytes (OD = 2.66 ± 
0.298, P < 0.05) and failed to increase significantly in FIT2 KD (OD = 1.36 ± 
0.246) adipocytes. Apart from TAG accumulation, size of lipid droplets also 
determines their metabolic health and enzyme catabolic ability [157]. 
Previously, reports have observed increased lipid droplet size in adipocytes 
differentiated from adipose tissue specific FIT2 knockout mice [155] and 
smaller lipid droplet size after FIT2 knockdown in 3T3-L1 adipocytes [51]. We 
measured lipid droplet number and size (figure 32D) in images obtained after 
palmitate treatment in control (blue color) and FIT2 KD (red color) adipocytes 
using lipid droplet counter (ImageJ plugin) and observed no significant 
differences between the two groups.  It is worth bearing in mind that in these 
experiments, we achieved ~50% knockdown of FIT2 protein; a higher 
percentage of FIT2 knockdown in SC adipocytes would be ideal to better 
appreciate functional effects of FIT2 in adipocytes. Overall, our observations 
supported the hypothesis that the lack of FIT2 protein in adipocytes would 
partially reduce the TAG storage capacity in them. Subsequently, we evaluated 




Figure 32: TAG accumulation is reduced after siRNA mediated knockdown 
of FIT2 protein 
(A) mRNA expression (qPCR) and immunoblot of FIT2 in adipocytes 
transfected with FIT2 specific and scrambled (Scr) siRNA. (B) mRNA 
expression of differentiation markers PPARγ and CEBPα in adipocytes after 
FIT2 KD (n=3). (C) TAG accumulation upon palmitate treatment (500 µM) in 
control and FIT2 KD adipocytes with representative images (n=3). (D) 
Quantification of lipid droplet size (with representative images) in control and 
FIT2 KD adipocytes after palmitate treatment (500 µM, n=3). Data were 
analyzed using non-parametric one-way ANOVA with Holm-Sidak correction 
for multiple comparisons, *P < 0.05 compared to control adipocytes. Data 
represented as mean ± SEM. 
4.3.4 Effect of palmitic acid on inflammation and ER stress in FIT2 KD 
adipocyte 
We measured gene expression of various markers of inflammation and ER stress 
in SC adipocytes after FIT2 KD and palmitate treatment for 24 h. Figure 33 
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shows the relative expression levels of four inflammatory genes measured by 
qPCR. Pro-inflammatory markers IL18 (FC = 1.29 ± 0.118, P < 0.05) and IL6 
(FC = 2.37 ± 0.198, P < 0.05) were upregulated in control adipocytes after 
addition of palmitic acid which suggests inflammatory response to free fatty 
acid. However, in FIT2 knockdown adipocytes, IL18 (FC = 1.89 ± 0.054, P < 
0.05) and IL6 (FC = 1.35 ± 0.95, P < 0.05) were upregulated even in absence of 
palmitic acid which indicated low grade inflammation without external free 
fatty acid challenge. Upon addition of palmitic acid in FIT2 KD adipocytes, IL6 
(FC = 2.04 ± 0.113, P < 0.05) mRNA expression increased significantly. TLR4 




Figure 33: Effect of palmitic acid on inflammation related genes in FIT2 
knockdown adipocytes. 
(A) mRNA expression of IL18, IL1β, IL6 and TLR4 in control and FIT2 KD 
adipocytes (n=3). Data were analyzed using non-parametric one-way ANOVA 
with Holm-Sidak correction for multiple comparisons (Prism 6.0), *P < 0.05. 
Data represented as mean ± SEM. 
Figure 34A and 34B illustrates mRNA and protein expression of ER stress 
markers. In control adipocytes, mRNA expression of ER stress markers BiP (FC 
= 1.92 ± 0.039), XBP1s (FC = 2.51 ± 0.256), CHOP (FC = 1.70 ± 0.058), 











































































































































































































significantly after addition of palmitic acid. Conversely, compared to control 
adipocytes, palmitate induced upregulation of ER stress markers BiP (FC = 1.74 
± 0.018), XBP1s (FC = 1.61 ± 0.030), CHOP (FC = 1.10 ± 0.279), GADD34 
(FC = 1.04 ± 0.14) and PERK (FC = 1.17 ± 0.049) was alleviated in FIT2 KD 
adipocytes. While blotting for proteins (BiP, p-IRE1α, t-IRE1α, p-JNK, t-JNK 
and GAPDH), we included insulin stimulation (every alternate band in blots) as 
previous reports suggested insulin as an inducer of ER stress in subcutaneous 
adipose tissue in obese insulin resistant subjects [84]. BiP, t-IRE1α, p-JNK and 
t-JNK showed no change in protein expression. However, insulin stimulation 
increased p-IRE1α (6th well in blot) in FIT2 KD adipocytes without palmitate 
treatment and after addition of palmitic acid, p-IRE1α was upregulated with or 
without insulin in them. These results indicated activation of IRE1α arm of ER 





Figure 34: Effect of palmitic acid on ER stress related genes and proteins in 
FIT2 knockdown adipocytes. 
(A) mRNA expression of BiP, XBP1s, CHOP, IRE1α, GADD34 and PERK in 
controls and FIT2 KD adipocytes (n=3). (B) Representative immunoblot of ER 
stress markers in controls and FIT2 KD adipocytes (n=3). Data were analyzed 
using non-parametric one-way ANOVA with Holm-Sidak correction for 
multiple comparisons, *P < 0.05. Data represented as mean ± SEM. 
In addition to inflammation and ER stress, we quantified mRNA expression of 
GLUT4, PGC1α, leptin, adiponectin, FABP4, DGAT1 and PLIN2 in control 
and FIT2 KD adipocytes (figure 35). At basal level, expression of these genes 
were equivalent. But palmitate administration reduced mRNA expression of 
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PGC1α (FC = 0.601 ± 0.027 in control and FC = 0.700 ± 0.017 in FIT2 KD) 
and increased mRNA expression of leptin (FC = 1.29 ± 0.049 and FC = 1.31 ± 
0.025 in FIT2 KD). 
Figure 35: Effect of palmitic acid on adipogenesis related genes in FIT2 
knockdown adipocytes. 
Markers for various aspects of adipose tissue were chosen. Data was analyzed 
using non-parametric one-way ANOVA with Holm-Sidak correction for 
multiple comparisons, *P < 0.05. Data represented as mean ± SEM. 
4.3.5 Effect of palmitic acid on insulin signaling pathway proteins and 
glucose uptake in FIT2 knockdown adipocytes 
Insulin signaling pathway proteins are known to be altered in vitro in the 



























































































































































































































































































































































immunoblotted for p-Akt (Ser-473), t-Akt, p-IRS1 (Ser-312), p-IRS1 (Tyr-612), 
t-IRS1 and GAPDH in both control and FIT2 KD adipocytes (figure 36A). p-
Akt (Ser-473)/ t-Akt was measured by densitometry and represented in bar 
graph beneath western blots. The left-sided Y-axis denotes ratio from all bands 
separately (represented as bars in the graph) and right-sided Y-axis (red colored 
dots) denotes the ratio as insulin stimulated/no insulin for respective conditions. 
A decrease in pAkt (Ser-473)/ t-Akt ratio after insulin stimulation is 
representative of insulin resistance. In control adipocytes, phosphorylation of t-
Akt (represented as p-Akt (Ser-473)) increased after addition of palmitic acid 
whereas in FIT2 KD adipocytes, p-Akt (Ser-473) remained high with or without 
palmitic acid. As seen from red dots in graph, insulin stimulated p-Akt (Ser-
473)/ t-Akt ratio was lower in control adipocytes after addition of palmitate 
which indicated that they were insulin resistant. However, in FIT2 KD 
adipocytes, this ratio was significantly reduced with and without palmitate 
treatment indicating insulin resistance even in the absence of external free fatty 
acid challenge. Compared to control adipocytes, protein expression of t-IRS1, 
p-IRS1 (Ser-312) and p-IRS1 (Tyr-612) were lower in FIT2 KD adipocytes, 
which further dropped in the presence of palmitic acid. Near complete 
disappearance of IRS1 proteins was unexpected. The Probability of cytotoxicity 
due to knockdown or palmitate treatment cannot be excluded, but is unlikely 
since other ER stress and insulin signaling proteins did not follow similar 
expression pattern. Insulin stimulated glucose uptake is shown in figure 36B. 
Glucose uptake was measured as beta counts/minute and represented on the Y-
axis as a ratio of insulin stimulated/no insulin for respective condition. Palmitic 
acid administration lead to a non-significant reduction in glucose uptake in 
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control as well as FIT2 KD adipocytes. But glucose uptake was significantly 
reduced in FIT2 KD adipocytes (1.23 ± 0.062, P < 0.05) at basal state compared 
to control adipocytes (1.46 ± 0.037) at basal state.  
Figure 36: Effect of palmitic acid on insulin signaling pathway proteins and 
glucose uptake in FIT2 knockdown adipocytes. 
(A) Immunoblot of critical proteins involved in insulin signaling pathway [p-
Akt (Ser-473), t-Akt, p-IRS1 (Ser-312), p-IRS1 (Tyr-612) and t-IRS1]. Graph 
represents densitometry for p-Akt/Akt protein and Insulin/no insulin ratio of 
respective conditions is represented on right y-axis (red symbols and axis). (B) 
Glucose uptake in mature control and FIT2 KD adipocytes. Data were analyzed 
using non-parametric one-way ANOVA with Holm-Sidak correction for 
multiple comparisons, *P < 0.05. Data represented as mean ± SEM. 
4.4 Discussion 
For the first time, we characterized the role of FIT2 protein in human adipocytes 
and found that it was important for maintaining healthy adipocyte function. Our 
results indicated that (1) FIT2 mRNA expression was significantly higher in SC 
adipose tissue or adipocytes when compared to OM adipose tissue or 
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adipocytes, (2) FIT2 protein expression was significantly higher in SC and OM 
adipose tissue samples from NT2DM subjects when compared to T2DM 
subjects, (3) TAG accumulation after palmitate administration was reduced 
after FIT2 knockdown in SC adipocytes, (4) basal state mRNA expression of 
IL18 and IL6 were higher in FIT2 KD adipocytes along with upregulation of p-
IRE1α and (5) Ratio of p-Akt (Ser-473)/t-Akt (insulin stimulated/no insulin) 
was lower in FIT2 KD adipocytes when compared to control adipocytes. At this 
stage it would be difficult to conclude that individuals expressing lower FIT2 
protein will definitely have reduced lipid storage capacity. But this is supported 
by the fact that adipose tissue specific FIT2 knockout mice exhibit reduced 
adipose tissue volume, ectopic lipid deposition, impaired insulin tolerance and 
increased macrophage infiltration on high fat diet [155].  
Previous studies have highlighted the importance of adipose tissue function and 
appropriate regulation of adipose inflammation in preserving metabolic health 
[158, 159]. A recent study in humans showed increased visceral adipose tissue  
(and not subcutaneous adipose tissue) as a crucial predictor for progression of 
obese non-diabetics to obese diabetics [160]. In particular, IL6 originating from 
the visceral adipose tissue is thought to be a potential mechanistic link between 
visceral obesity and systemic inflammation in individuals with abdominal 
obesity [161] and increased IL6 mRNA expression is also observed in EWAT 
from adipose tissue specific FIT2 knockout mice on high fat diet [155]. In our 
study, pro-inflammatory markers IL6 and IL18 were significantly higher at 
basal state in FIT2 KD adipocytes when compared to control adipocytes. 
However, only negligible upregulation was observed in IL18 and IL6 mRNA 
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expression in FIT2 KD adipocytes after palmitate administration which could 
be due to higher mRNA expression at basal state. 
ER stress and UPR mechanisms are known pathogenic pathways especially in 
metabolically active tissues such as adipose tissue, liver and pancreas [93, 162]. 
Studies have found upregulated expression of calnexin and p-JNK 1 proteins as 
well as XBP-1s mRNA in obese individuals [83]. Increased UPR in adipose 
tissue among obese individuals has also been associated with increased insulin 
concentration and its protein synthetic or anabolic signal in adipose tissue [84]. 
Insulin induced UPR was observed in FIT2 KD adipocytes as IRE1α 
phosphorylation was higher upon insulin stimulation. On palmitate challenge, 
p-IRE1α upregulation was observed even without insulin stimulation in FIT2 
KD adipocytes. BiP, XBP1s, CHOP and GADD34 mRNA expression increased 
significantly and more markedly upon palmitate challenge in control adipocytes 
when compared to FIT2 KD adipocytes which suggest two possibilities; either 
FIT2 KD adipocytes have defective UPR sensing mechanisms or they induce 
and propagate UPR pathways earlier. The Second mechanism seems more 
plausible since we observed an upregulation of protein expression of p-IRE1α 
in FIT2 KD adipocytes.  
Insulin signaling pathways involve numerous proteins and we blotted for 
established markers of insulin resistance after free fatty acid challenge [163-
165]. Decreased ratio of p-Akt (Ser-473)/t-Akt before and after insulin 
stimulation is a direct representation of insulin resistance and was reduced at 
basal and palmitate challenged states in FIT2 KD adipocyte indicating insulin 
resistance. Overall, partial absence of FIT2 protein was detrimental to the 
optimal function of mature human adipocytes as demonstrated by upregulation 
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of pro-inflammatory markers at basal level, increased phosphorylation of IRE1α 
on free fatty acid challenge and reduced glucose uptake. 
4.5 Conclusion 
Involvement of lipid droplet formation proteins in the pathogenesis of metabolic 
disorders is a relatively new field of research. Our results demonstrated probable 
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Genome Wide Association Studies (GWAS) has been an important approach 
for identification of gene locus or loci responsible for pathogenesis of 
multigenic disorders such as Type II diabetes [166]. In 2007, SNPs in first intron 
of Fat Mass and Obesity (FTO) associated gene was found to be strongly linked 
to early onset obesity in children and adults of European ancestry [111, 112]. 
Subsequently, more SNPs in first two introns and second exon of FTO gene 
were also found to be strongly linked with an increased risk of obesity in both 
children and adults [167, 168]. To date, FTO locus has showed largest effect 
size on BMI and obesity risk and is most widely replicated in more than 22 
different ethnic populations including Chinese, Malay and Asian-Indian 
populations in Singapore [169-172]. FTO protein is a member of AlkB related 
non-haem iron and 2-oxoglutarate-dependent oxygenase superfamily. It was 
initially identified as single stranded DNA and RNA demethylase or 
dioxygenase (particularly N6-methyladenosine) [173], and later established to 
be a transcriptional coactivator of CEBP proteins active in promoting 
adipogenesis [174]. A second link between FTO and adipogenesis was 
confirmed by Merkestein, M et al [175]. They showed that FTO leads to 
alternative splicing of RUNX1T1 mRNA due to demethylation at N6-
methyladenosine, which in turn induce mitotic clonal expansion of mice derived 
pre-adipocytes. 
FTO is ubiquitously expressed across multiple tissues, but is most highly 
expressed in brain, especially the hypothalamus, a region which controls food 
intake [176]. Human studies suggest that the association between SNPs in FTO 
and BMI are predominantly driven by increased energy intake and not energy 
 113 
 
expenditure [177-179]. For instance, individuals homozygous for the obesity-
risk allele present with greater ad libitum food intake [180], particularly 
consumption of dietary fat [181] along with increased appetite and reduced 
satiety [182]. Within the arcuate nucleus of the hypothalamus, prolonged 
exposure to high fat diet increased FTO expression, whereas 48 h fasting 
reduced FTO expression, [176]. Conversely, alteration of FTO level in the 
arcuate nucleus also influenced food intake [183]. The presence of FTO SNP 
(rs1421085 T-to-C) in primary human adipocytes transformed them from an 
energy expending adipocyte phenotype to a more lipid storing white adipocyte 
phenotype and correction of this particular SNP reversed them to energy 
expending phenotype. Detailed studies showed that FTO SNP induced 
expression IRX3 and IRX5 genes, which in turn drive adipocyte towards white 
lipid storing phenotype [184].  
Recently, several animal studies have shown the effect of FTO on body weight 
regulation and energy expenditure through peripheral actions of FTO [117, 
185]. FTO null mice exhibit a significant reduction in adipose tissue and a 
decreased propensity towards weight gain on a high-fat diet (HFD), compared 
with their wild-type littermates. The lean phenotype in these mice developed as 
a consequence of increased energy expenditure and systemic sympathetic 
activation, despite decreased physical activity and hyperphagia [117]. Detailed 
molecular mechanisms by which FTO dioxygenase inhibition regulates energy 
metabolism in human adipocytes remains to be elucidated. The aim of this 
research was to characterize the function of FTO in human SGBS adipocyte 
metabolism using two approaches (I) gene silencing or knockdown and (II) 
using a novel pharmacologic inhibitor (CA) of FTO catalytic activity. SGBS 
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adipocytes was a preferred model over SC adipocytes in this instance since our 
previous results suggest that the SGBS is a human preadipocyte model that has 
capacity for displaying the bioenergetics characteristics of brown/beige 
adipocytes.  
5.2 Materials and methods 
5.2.1 Cell culture and differentiation and drug treatment of SGBS 
adipocytes 
SGBS adipocytes were cultured and differentiated as discussed previously in 
section 2.4.2. For drug treatment, adipocytes were differentiated for 6 days 
either in 6-well plates (for RNA and protein expression) or XFe24-well cell 
culture microplate (for measuring mitochondrial respiration). Subsequently, 
drug CA was added at 50 µM and 100 µM concentration and incubated for 48 
h for all experiments.   
5.2.2 Protein knockdown using FTO specific siRNA 
SGBS adipocytes were transfected with FTO specific or scrambled siRNA at 5 
nM concentration (protocol section 2.5). 
5.2.3 Preparation of protein lysates and western blotting 
Cell monolayers were washed with cold phosphate buffered saline and lysates 
were collected in 80 µL RIPA buffer (Thermo Scientific) using a cell scrapper. 
Detailed protocol of lysate preparation and immunoblotting can be found in 
section 2.5.  
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5.2.4 RNA isolation and mRNA expression analysis 
RNA was isolated using Qiagen RNeasy plus kits (section 2.1). cDNA was 
synthesized and used for expression analysis (section 2.2).  
5.2.5 Measurement of mitochondrial respiration 
Oxygen consumption rate (OCR) was measured in mature SGBS adipocytes. 
Cells were drug treated for 48 h before performing this experiment (section 2.8). 
OCR reading was used to compute mitochondrial function parameters.     
5.3 Results 
5.3.1 FTO knockdown and inhibition increased mRNA expression of 
PGC1α and UCP1 in SGBS adipocytes 
SGBS and 3T3-L1 adipocytes were transfected with 5 nM of either species 
specific siRNA against FTO (siRNA_1 and siRNA_2) or scrambled siRNA 
(negative control). Transfection was performed at preadipocyte stage and 
maintained throughout differentiation. Drug CA (50 µM and 100 µM) and 
DMSO vehicle control (equivalent to 100 µM CA volume) were added to 
partially mature adipocytes at day 6 of differentiation for 48 h. As seen in figure 
37A, FTO mRNA and protein was successfully reduced to approximately 50% 
with two different siRNA transfections, while there was no change with the 
addition of drug CA, scrambled siRNA and DMSO vehicle control. 
Differentiation marker, PPARγ mRNA expression remain unchanged either 
with siRNA transfection or drug treatment (figure 37B). PGC1α and UCP1 gene 
expression increased significantly after FTO knockdown using siRNA_1 (FC = 
1.93 ± 0.12 in PGC1α, FC = 3.02 ± 0.105 in UCP1) and siRNA_2 (FC = 3.26 ± 
0.23 in PGC1α, FC = 3.58 ± 0.523 in UCP1) as well as chemical inhibition using 
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drug CA at 50 µM (FC = 1.83 ± 0.186 in PGCα, 1.42 ± 0.24 in UCP1) and 100 
µM (FC = 2.53 ± 0.142 in PGCα, 3.12 ± 0.257 in UCP1) concentration (Figure 
37C and 37D).  
Figure 37: Effect of FTO knockdown and drug inhibition on browning genes 
in SGBS and 3T3-L1 adipocytes. 
(A) FTO mRNA and protein (B), (C), (D) and (E) mRNA expression of PPARγ, 
PGC1α, UCP1 and IRX3 respectively. (F) PGC1α mRNA expression in 3T3-L1 
adipocytes. Fold change as normalized using GAPDH in SGBS and beta actin 
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as mean ± SEM. Significance was calculated using Two-Way Anova (with 
Dunnett’s correction for multiple comparisons). 
IRX3 mRNA expression remained unchanged in all experimental conditions 
(figure 37E). Similar to SGBS, FTO knockdown (FC = 2.24 ± 0.22, P < 0.05) 
and inhibition (100 µM CA, FC = 1.87 ± 0.13, P < 0.05) increased mRNA 
expression of PGC1α in differentiated 3T3-L1 adipocytes as well (figure 37F). 
Expression of all genes remain unchanged in scrambled siRNA transfected and 
DMSO vehicle control treated wells. 
5.3.2 FTO inhibition using drug CA potentiated spare respiratory capacity 
and maximal respiration rate 
To determine whether upregulation in PGG1α and UCP1 was functionally 
relevant, Seahorse mitochondrial flux analyzer was used to measure 
mitochondrial respiration in SGBS adipocytes treated with 50 µM or 100 µM 
CA or DMSO vehicle control for 48 h. Seahorse flux analyzer uses oligomycin, 
FCCP and a combination of antimycin A + rotenone sequentially to evaluate 
mitochondrial activity. FCCP (Carbonyl cyanide 4-(trifluoromethoxy) 
phenylhydrazone) is an uncoupler of oxidative phosphorylation and allows 
mitochondria to function at maximal efficiency and oxygen consumption at any 
stage is representative of mitochondrial activity. Figure 38A and 38B shows 
mitochondrial respiration as line graph and mitochondrial function parameters 
as bar graph respectively. Addition of CA did not alter basal respiration 
(measured before addition of oligomycin), ATP production and proton leak 
(measured after adding oligomycin). But, compared to control SGBS adipocytes 
(OCR = 77.8 ± 10.3), maximal respiration rate increased significantly with 50 
µM (OCR = 126.7 ± 10.9, P < 0.05) and 100 µM (OCR = 97.5 ± 7.2, P < 0.05) 
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drug CA. Spare respiratory capacity (maximal respiration – basal respiration) 
also improved significantly at 50 µM CA (OCR = 80.6 ± 11.4 compared to 40.7 
± 14.7 in controls, P < 0.05). Surprisingly, maximal and spare respiratory 
capacity increased maximally at 50 µM CA, which suggested an optimum 
working range of the drug. All the readouts were equivalent in control and 
DMSO treated SGBS adipocytes. These results confirmed that chemical 
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Figure 38: Effects of FTO drug inhibition on mitochondrial respiration and 
function in SGBS adipocytes. 
(A) OCR as measured in Seahorse mitochondrial flux analyzer. (B) 
Mitochondrial function parameters computed from OCR measurements. *P < 
0.05 when compared with control adipocytes. Data represented as mean ± SEM. 
Significance was calculated using Two-Way Anova (with Dunnett’s correction 
for multiple comparisons). 
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5.3.3 FTO knockdown and inhibition increased AMPKα phosphorylation 
We evaluated t-AMPKα and p-AMPKα protein in SGBS adipocytes with FTO 
knockdown, CA treatment (50 µM, 48 h) or both in presence/ absence of insulin. 
Compared to control adipocytes (figure 39), p-AMPKα increased after FTO 
protein knockdown and addition of 50 µM CA for 48 h. Combination of 
knockdown and CA also elevated p-AMPKα similar to drug only well. p-
AMPKα levels reduced after insulin treatment in all conditions. FTO 
knockdown and inhibition resulted in increased AMPK phosphorylation which 
might potentially have increased mitochondrial respiration and PGC1α mRNA 
expression seen previously, although further research is required to confirm this. 
 
Figure 39: Effect of FTO knockdown and drug inhibition on AMPKα 
phosphorylation in SGBS adipocytes. 
Knockdown was maintained throughout 8 days of differentiation and drug 
treatment was performed for 48 h starting from day 6.  
5.4 Discussion 
Single nucleotide polymorphisms (SNPs) in Fat Mass and Obesity Associated 
gene locus have been the strongest candidate for obesity phenotype across 
various ethnicities around the world. Studies have identified pathways through 
which FTO gene locus influences expression or function of FTO, IRX3 and 
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RPGRIP1L gene expression or protein activity [117, 184, 186-189]. Upon 
advances in understanding the molecular regulation of energy expenditure, 
activating energy expending pathways such as oxidative respiration to improve 
metabolic health of adipocytes and other cell types is being commonly targeted 
as a potential therapeutic modality to treat obesity. In our study, we tested an 
inhibitor (drug CA) specific towards dioxygenase or demethylase activity of 
FTO and evaluated its effect on mitochondrial function in SGBS adipocytes.  
In all cell types in humans, mitochondrial biogenesis and adaptive 
thermogenesis are regulated primarily by upstream transcriptional coactivator 
PGC1α in conjunction with NRF1 (nuclear respiratory factor 1) which is 
strongly activated by cAMP and cytokine pathways [190]. In adipocytes 
particularly, PGC1α leads to formation of metabolically active brown 
(constitutive UCP1 expression) or beige adipocytes (inducible UCP1 
expression) possessing inherent capacity for increased mitochondrial 
respiration, production of heat and free fatty acid oxidation [191-193]. In our 
data, FTO inhibition and knockdown increased PGC1α and UCP1 expression 
which indicated a brown or beige phenotype. Studies suggest that IRX3 and 
RPGRIP1L are main drivers for activation of energy expending pathways due 
to presence of obesity associated SNP in FTO gene and not the FTO protein 
itself. However, the involvement of IRX3 can be excluded in our study since 
drug inhibition acts directly on FTO protein and no change was observed in 
IRX3 mRNA expression with either FTO knockdown or drug inhibition. In 
addition to elevated PGC1α, maximal respiratory capacity and spare respiratory 
capacity were significantly increased at 50 µM drug CA; suggesting an 
important role for RNA demethylase activity of FTO in forming metabolically 
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active adipocytes. RNA with N6 methyl-adenosine is shown to be a substrate of 
FTO [173, 194] and studies show that FTO overexpression enhances 
adipogenesis in mice derived pre-adipocytes via alternative splicing of pro-
adipogenic gene RUNX1T1 [175]. AMPK pathway is actively involved in 
regulation of mitochondrial function at both transcriptional and post-
translational levels [195] and it also influences coactivator function of PGC1α 
with help of SIRT1. FTO knockdown and inhibition increased phosphorylation 
of AMPKα which might may explain the increased mitochondrial function but 
needs further validation. Though, recently, IOX3, an inhibitor of HIF prolyl 
hydroxylases (also known to inhibit FTO) was found to increase FTO protein 
expression, AMPKα phosphorylation and mitochondrial respiration in C2C12 
cells [196], drug treatment in our study did not influence FTO mRNA or protein 
expression. These differences in results could be due to (I) cellular model used 
(C2C12 myotubes used previously versus SGBS adipocytes used in our study) 
and (II) broad specificity of IOX3 unlike CA which is highly specific for FTO 
protein. Altogether, we confirmed the involvement of FTO protein in 
influencing PGC1α expression and successfully tested the ability of an FTO 
inhibitor to increase mitochondrial respiration.  
5.5 Conclusion 
Our results show that inhibiting demethylase activity of FTO by drug CA led to 
increased UCP1 and PGC1α mRNA expression along with elevated 
mitochondrial respiration in SGBS adipocytes; a phenotype similar to FTO 
protein knockdown. Collectively, these findings support plausible utility of 
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White adipose tissue (WAT) distribution in different depots (SC or OM) and 
anatomical regions (central vs peripheral) of the body is an important 
determinant of metabolic homeostasis [197]. Even in lean individuals, a higher 
proportion of central to peripheral adipose tissue mass can increase the risk of 
insulin resistance in them [198]. Adipocytes within different depots are distinct 
in their metabolic capacity, adipokine secretion and proliferation pattern which 
eventually affects their lipid storage capacity and inflammation process [29, 
199, 200]. The OM depot in particular is more susceptible to macrophage 
infiltration when compared to SC depot. The differences in macrophage 
infiltration within the adipose tissue depots are further exaggerated by the 
presence of central obesity, which itself is strongly linked with elevated 
inflammation, macrophage infiltration and adverse metabolic outcomes [201-
203].  
Genome and transcriptome analysis between the adipose from different depots 
under different metabolic disease status can be informative to delineate the 
complex networks of genes and signaling pathways that may contribute to 
dysregulation of metabolic homeostasis. Significant variation has been 
described in more than 500 genes between human mesenteric, SC and OM 
depots as well as preadipocytes, most of them being developmental regulators 
[204, 205]. The role of ECM and its components in adipose tissue expandability 
and insulin resistance has been characterized recently [41]. Structural proteins 
like collagens, adherent proteins such as fibronectins, laminins and integrins are 
vital ECM components for adipose tissue remodeling, but in excess certain 
collagens and integrins have known detrimental effects [41, 206, 207]. 
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During the development of obesity, an aberrant increase in interstitial fibrosis 
in adipose tissue impairs adipose tissue flexibility and reduces its plasticity and 
leads to adipocyte dysfunction [45]. On a high fat diet, fibrosis events precede 
inflammation and begins shortly after high fat diet challenge [44]. Additionally, 
the macrophages also contribute to fibrosis by producing soluble factors like 
TGFβ1 and PDGF and direct activation of fibroblasts [208]. Analogous to 
weight gain, ECM alters along with weight loss as well. Comparing 
transcriptomes of adipose tissue from obese subjects before and after 
undergoing bariatric surgery suggested increased interstitial fibrosis in WAT of 
obese [209]. Specifically, increased ECM constituents and members of integrin 
family play an important role in mediating interactions between inflammation 
and alteration of metabolism in WAT [209]. Accumulated ECM components 
signal via integrin receptors and contribute to pathogenic environment. In 3T3-
L1 adipocytes, accumulation of ECM during differentiation leads to 
metabolically unfavorable environment via impaired insulin signaling and 
increased secretion of MCP1 and NFκB [210].  
Our objective was to address differences in transcriptomic signatures in adipose 
tissue from obese diabetics compared to obese non-diabetics with a particular 
focus on KEGG biological pathways and gene ontologies related to ECM 
constituents, integrins and fibrosis and evaluate transcripts involved in 





6.2 Materials and methods 
6.2.1 Characteristics of subject 
 NT2DM (n=8) T2DM (n=8) 
Age (years) 46.6 ± 9.8 43.5 ± 11.3 
BMI (kg/m2) 36 ± 2.2 40.7 ± 9.8 
HBA1C (mmol/L) 5.5 ± 0.38 8.88 ± 1.19 * 
Ethnicity (Chinese=2, Malay=4, Indian=2) 
(Chinese=3, 
Malay=4, Indian=1) 
Tissue types SC and OM SC and OM 
Table 16: Characteristics of obese diabetic and obese non-diabetic subjects 
from which adipose tissue was derived for RNA sequencing analysis. 
Frozen subcutaneous and omental adipose tissue were used for RNA isolation. 
*P < 0.05, significance calculated using non-parametric Independent sample t-
test. 
SC and OM adipose tissue samples were selected from age and BMI matched 
obese non-diabetic (n=8) and obese diabetic (n=8) subjects of South Asian 
ethnicity. Subjects on medication that can affect adipose tissue function and/or 
metabolic homeostasis (such as corticosteroids and thiazolidinediones) were 
excluded. Glycated hemoglobin or HBA1C was used to define presence of 
diabetes and was significantly higher in the diabetic subjects when compared to 
non-diabetic subjects (table 16). 
6.2.2 Tissue RNA isolation 
Approximately 250 mg of frozen tissue was used to extract total RNA using 
Qiagen RNeasy lipid tissue mini kit. Protocol was followed as discussed in 
section 2.1.2.  
 127 
 
6.2.3 RNA sequencing and data analysis 
Detailed RNA-SEQ experimental protocol is written in section 2.7. RNA 
sample from omental adipose tissue from one diabetic subject was of poor 
quality and hence excluded from analysis resulting in n=7 or this group. We 
analyzed both disease specific (T2DM vs NT2DM) and depot specific (OM vs 
SC) differences (figure 40). In the depot specific analysis, we paired expression 
in OM and SC depots from each subject in order to eliminate baseline intra-
individual variation. This method involved normalization of each gene in OM 
depot to a respective gene in SC depot for an individual subject and then 
grouping them into T2DM and NT2DM. Due to pairing of data for depot 
specific analysis, FPKM values for SC depot for all genes was normalized to 
one and hence not used for depot specific transcriptome analysis. FPKM values 
were used for disease specific enrichment analysis into pathways and 
ontologies. The following groups were finally used for analysis: 
1. OM vs SC depot (NT2DM, paired data). 
2. OM vs SC depot (T2DM, paired data). 
3. T2DM vs NT2DM (SC depot). 
4. T2DM vs NT2DM (OM depot). 
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Figure 40: Workflow for RNA-SEQ data analysis for comparing adipose 
tissue depots. 
Disease specific and depot specific differences in gene ontologies and KEGG 
biological pathways were analyzed using iPathwayGuide or GSEA in 
conjunction with enrichment map creator.  
6.3 Results 
6.3.1 Depot specific and disease specific differences in transcriptomes 
6.3.1.1 Sample – to – sample distance  
Data obtained from RNA sequencing was used to visualize sample – to – sample 
distance by means of Euclidean distance heatmap (figure 41) and principle 
Adipose tissue RNA
1. obese non-diabetics (SC 
and OM)
2. Obese diabetics (SC and 
OM)
Disease specific (T2DM vs 
NT2DM) comparison
1. FPKM used in GSEA and 
Cytoscape 3.3 - enriched 
cellular components and 
KEGG biological pathways
Depot specific (OM vs SC) 
comparison
1. Pairing OM and SC data.
2. Fold change (FC) fed in ipathwayGuide -
KEGG pathway enrichment
3. Up and downregulated genes used in DAVID 
Bioinformatics and Cytoscape 3.3 - cellular 
component enrichment
RNA sequencing after 




component analysis (PCA) (figure 42) using R package. In the heatmap, all 
subject characteristics (SC/OM and NT2DM/T2DM) are denoted on X and Y 
axis and compared to every other sample. Each square represents a comparison 
between two intersecting samples and the darker shades of blue denote 
increasing similarity between the two samples. As seen in the heatmap, SC and 
OM samples clustered distinctly, suggesting considerable variance between 
them, whereas NT2DM and T2DM samples were distributed randomly, 
suggesting less variation between these comparator groups.  
Figure 41: Euclidean distance (sample – to – sample distance) heatmap of all 
tissue RNA-SEQ data.  
Tissue samples are individually arranged on X and Y axis with each sample 
being compared to the other. Darker shades of blue denote decreased distance 
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or increased similarity between the compared samples. As seen, all SC samples 
clustered together and distinctly from OM samples. This suggests considerable 
transcriptome variation among the SC and OM tissue samples.  
In principle component analysis, samples were distributed in two directions or 
principle components (PC1 and PC2) and results indicated that different adipose 
depots (OM or SC) resulted in 61% (principle component 1/PC1) variance 
among the samples. Disease state (being T2DM or NT2DM) resulted in 10% 




Figure 42: Principle component analysis of RNA-SEQ data. 
Each sample from RNA-SEQ is represented as a circle, orange: OM 
(non_T2DM or NT2DM), green: OM (T2DM), blue: SC (non_T2DM or 
NT2DM), purple: SC (T2DM). Samples were distributed into two components 
(PC1 and PC2) to identify differences among them. 
6.3.1.2 Up and downregulated genes 
About 15000 genes were finally read and annotated in the RNA-SEQ results. 
Figure 43 shows Venn diagram and bar graph for the number of differentially 
expressed genes (DEGs) in OM depot compared to SC depot. 3063 and 1944 
 132 
 
(FC ≥± 1.5, FDR < 0.05) genes were differentially up or downregulated in OM 
depot from T2DM and NT2DM respectively. Of these, 1850 genes were 
upregulated and 1213 genes were downregulated in T2DM whereas 1149 genes 
upregulated and 795 genes downregulated in NT2DM. As shown in the Venn 
diagram, 1547 DEGs in OM depot were common between NT2DM and T2DM 
group while 398 genes were exclusive to T2DM. 
Figure 43: Illustration of the number of differentially expressed genes by 
depot specific comparisons. 
Numbers in Venn diagram on the left represents number of DEGs in T2DM or 
NT2DM or common in both. Bar graph on the right denotes number of up and 
downregulated genes either in T2DM or NT2DM subjects. Inclusion: log FC ≥ 
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Figure 44: Illustration of the number of differentially expressed genes by 
disease specific comparisons. 
Numbers in Venn diagram on the left represents number DEGs in OM or SC 
depot or common in both depots. Bar graph on the right denotes the number of 
up and downregulated genes either in OM or SC depots. Inclusion: log FC ≥± 
0.6 and FDR < 0.05. 
Compared to the respective depots from NT2DM, 199 genes (n = 100 
downregulated, n = 99 upregulated) were differentially expressed in SC depot 
from T2DM and 295 genes (n = 235 downregulated and n = 60 upregulated) 
were differentially expressed in the OM depot from T2DM (figure 44). 
6.3.2 Enriched KEGG biological pathways in OM depot compared to SC 
depot 
We identified KEGG pathways significantly enriched in OM depot when 
compared to SC depot and looked for any notable differences between NT2DM 
and T2DM subjects. Fold changes (log FC ≥± 0.6, FDR < 0.05) obtained from 
paired data were analyzed via iPathwayGuide to identify significantly enriched 
KEGG biological pathways based on overrepresentation and impact analysis 
[122]. Compared to SC depot, 6 pathways were significantly enriched in OM 
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significantly enriched in OM depot of T2DM (table 17). Pathways exclusive to 
T2DM are highlighted in red text and common pathways between both groups 
are highlighted in blue text.  
 P Value 
(Bonferroni




) (OM vs. 
SC 
NT2DM) 
Protein digestion and absorption 9.26E-07 7.58E-08 
Basal cell carcinoma 0.000219 0.233382 
Arrhythmogenic right ventricular 
cardiomyopathy (ARVC) 
0.000653 0.04904 
Cytokine-cytokine receptor interaction 0.001519 0.085594 
ECM-receptor interaction 0.00156 0.002171 
Cell adhesion molecules (CAMs) 0.001938 0.020796 
PI3K-Akt signaling pathway 0.002497 0.076626 
Hippo signaling pathway 0.002605 0.051186 
Complement and coagulation cascades 0.003442 1 
Neuroactive ligand-receptor interaction 0.004274 0.063844 
Pathways in cancer 0.011087 1 
Retinol metabolism 0.017137 0.016105 
Focal adhesion 0.018516 0.006296 
Steroid hormone biosynthesis 0.025695 0.184109 
Melanogenesis 0.037103 1 
Hypertrophic cardiomyopathy (HCM) 0.041311 1 
Dilated cardiomyopathy 0.041905 1 
Proteoglycans in cancer 0.049116 0.77726 
Table 17: Significantly enriched biological pathways in NT2DM and T2DM 
subjects (OM vs SC). 
Output was generated in iPathwayGuide. Significance was pegged at P ≤ 0.05 
with Bonferroni correction to minimize false positive results. 
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6.3.2.1 PI3K-Akt signaling pathway 
Cytokine-cytokine receptor interaction and PI3K-Akt signaling pathways were 
exclusively enriched in OM depot from T2DM. In the PI3K-Akt signaling 
pathway, 91 genes were differentially expressed (43 upregulated and 48 
downregulated). The top 10 most up and downregulated genes in T2DM are 
shown in the bar graph (figure 45) and pathway map with up (pink to red colored 
rectangles) and downregulated genes (blue colored rectangles) illustrated in 
figure 46. As seen in pathway map, PI3K-Akt signaling pathway is influenced 
by growth factors (GF), cytokines, extra cellular matrix (ECM) components, 
chemokines, hormones and neurotransmitters. As shown in green boxes, 
thirteen of the top 20 DEGs in PI3K-Akt signaling pathway were upstream 
genes such as growth factors (FGF1, NGF, FGF9, ANGPT4), extracellular 
matrix components (TNC, COL5A3, VWF, TNN, SPP1, LAMB3, COL4A5, 
ITGB8) and cytokines (CSF3). Among the intermediates in PI3K-Akt signaling 
pathway, PPP2R2C (Protein Phosphatase 2, Regulatory Subunit B, Gamma, log 
FC = 2.06) and PPP2R2B (Protein Phosphatase 2, Regulatory Subunit B, Beta, 
log FC = 1.38) were significantly upregulated in OM depot (when compared to 
SC depot). Differential expressions of upstream genes indicated a potential link 
between ECM and PI3K-Akt signaling pathway in our data.  
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Figure 45: Top 10 up and downregulated genes in PI3K-Akt signaling 
pathway in T2DM subjects (OM vs SC). 










VWF, TNN, SPP1, 
LAMB3, 
COL4A5, ITGB8 CSF3 
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Figure 46: Representation of fold change of genes in PI3K-Akt signaling 
pathway in T2DM subjects. 
Fold changes in genes are represented by colors (upregulation – towards red 
and downregulation – towards blue).Green text boxes represent genes in GF 
(growth factor), cytokine and ECM within PI3K-Akt signaling pathway. 
6.3.2.2 ECM receptor interaction pathway 
ECM receptor interaction, cell adhesion molecules (CAMs) and focal adhesion 
were enriched in OM depot (compared to SC depot) from both NT2DM and 
T2DM. Figure 47 shows DEGs in ECM receptor interaction pathway in both 
groups. Collagens COL24A1 (log FC = -1.24), COL11A1 (log FC = -2.82), 
COL6A2 (log FC = -0.78), COL6A1 (log FC = -0.80), COL5A1 (log FC = -
0.75), COL4A4 (log FC = -1.17) were downregulated and COL6A6 (log FC = 
0.96) was upregulated in OM depot (compared to SC depot) from NT2DM only. 
COL5A3 (log FC = -1.23 in NT2DM and log FC = -1.54 inT2DM) and 
COL4A5 (log FC = 1.73 in NT2DM and log FC = 2.12 in T2DM) were 
differentially expressed in OM depot (compared to SC depot) from both 
NT2DM and T2DM.  
Integrins ITGA11 (log FC = -1.38), ITGA10 (log FC = -0.62), ITGB5 (log FC 
= -0.64), ITGB1 (log FC = -0.95), ITGA1 (log FC = -1.02) were downregulated 
and ITGA3 (log FC = 1.21) as well as ITGA2 (log FC = 0.79) were upregulated 
in OM depot (compared to SC depot) from T2DM only. ITGB8 was upregulated 
in both T2DM (log FC = 5.28) and NT2DM (log FC = 3.99). Additional DEGs 
in ECM receptor interaction pathway were THBS4 (log FC = -0.84 in T2DM), 
VWF (log FC = -1.57 in T2DM) and TNN (log FC = -1.13 in NT2DM and log 
FC = -2.08, T2DM). Next, we analyzed enriched cellular components to study 
ECM components in detail.  
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Figure 47: ECM receptor interaction pathway genes in NT2DM and T2DM 
subjects. 
Log (FC) for all the genes were plotted (Log FC ≥± 0.6 and FDR < 0.05). Genes 
below the cut off values in either NT2DM or T2DM are indicated as empty bar 
spaces.  
6.3.3 Enriched cellular components in OM depot compared to SC depot 
The cellular component ontology describes locations, at the levels of subcellular 
structures and macromolecular complexes. Table 18 illustrates enriched cellular 
components (GO_CC) in OM depot compared to SC depot in NT2DM and 








(OM vs. SC 
NT2DM) 
Extracellular space 1.00E-24 3.38E-20 
Extracellular region 1.00E-24 1.00E-24 
Membrane part 1.00E-24 1.32E-19 
Integral component of membrane 1.00E-24 2.20E-20 
Plasma membrane part 1.00E-24 3.23E-21 
Integral component of plasma membrane 1.00E-24 1.03E-15 
Intrinsic component of plasma membrane 1.00E-24 1.76E-16 
Extracellular matrix 1.00E-24 1.00E-24 
Intrinsic component of membrane 1.00E-24 1.10E-22 
Plasma membrane 1.00E-24 1.00E-24 
Cell periphery 1.00E-24 1.00E-24 
Membrane 7.60E-23 0.000044774 
Proteinaceous extracellular matrix 1.50E-21 3.20E-23 
Cell surface 9.74E-15 3.1562E-06 
Plasma membrane region 1.15E-13 1.25E-07 
Extracellular region part 9.74E-13 3.23E-14 
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Cell-cell junction 4.87E-11 0.00020552 
Cell projection 1.15E-10 0.0044774 
Neuron part 2.39E-10 1.69E-07 
Cell junction 3.63E-10 0.0071932 
Anchored component of membrane 1.15E-08 0.00063124 
Membrane region 2.66E-08 0.02569 
Apical plasma membrane 2.66E-08 0.000001835 
Apical part of cell 4.69E-08 2.20E-07 
Ion channel complex 1.06E-07 0.0019084 
Receptor complex 1.59E-07 0.44774 
Extracellular matrix part 5.40E-07 3.82E-09 
Synapse 6.37E-07 0.12478 
Collagen trimer 0.000001062 0.000016148 
Transmembrane transporter complex 0.000001062 0.0041838 
Transporter complex 0.000005133 0.010276 
External side of plasma membrane 6.6375E-06 1 
Somatodendritic compartment 0.000008496 0.00023488 
Neuron projection 0.000036285 0.00016882 
Cation channel complex 0.00004956 0.06239 
Golgi lumen 0.000071685 8.81E-07 
Basolateral plasma membrane 0.00007611 0.0027892 
Neuronal cell body 0.00011505 0.000008808 
Cell projection part 0.0001239 0.16148 
Cell body 0.000177 0.000013212 
Membrane raft 0.00018585 1 
Axon 0.0002655 0.0034498 
Basement membrane 0.0003894 0.00019084 
Intermediate filament 0.0025665 0.0013946 
Axon part 0.0057525 0.0027158 
Keratin filament 0.0076995 0.027158 
Sodium channel complex 0.0076995 1 
Anchored component of plasma membrane 0.01416 1 
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Side of membrane 0.020355 1 
Synaptic membrane 0.025665 1 
Junctional sarcoplasmic reticulum membrane 0.02832 1 
Cornified envelope 0.02832 0.019084 
Myelin sheath 0.02832 1 
Sarcolemma 0.029205 0.016882 
Postsynaptic membrane 0.03186 1 
Main axon 0.03363 1 
Secretory granule 0.04071 1 
Table 18: Enriched GO_CC in OM depot compared to SC depot in both 
NT2DM and T2DM subjects. 
Output was generated in iPathwayGuide. Significance was pegged at P ≤ 0.05 
with Bonferroni correction to minimize false positive results. 
Both positively and negatively enriched cellular components (OM vs SC) from 
NT2DM and T2DM were used to build enrichment maps using Cytoscape 3.3 
(enrichment map creator plugin). Only interacting clusters are shown here 
(interaction defined by FDR < 0.05). As seen in blue discontinuous circles, 
upregulated genes formed two ontology clusters or modules and downregulated 
genes formed one ontology cluster or module in both NT2DM (figure 48 and 
50) and T2DM (figure 49 and 51). Significant interactions were observed within 
clusters or modules and contained membrane proteins and ECM or extracellular 
matrix components related ontologies, with a different set of genes in NT2DM 






































Figure 48: Positively enriched cellular components in NT2DM (OM vs SC). 
Upregulated genes were analyzed using DAVID bioinformatics and the 
“functional annotation chart” output was exported in Cytoscape 3.3 (plugin: 
enrichment map creator) [135] to generate a map of enriched GO_CC. Size of 
the node predicts the number of genes in particular ontology with green 
connecting line representing the number of common genes. Cut off value for 


































































Figure 49: Negatively enriched cellular components in NT2DM (OM vs SC). 
Downregulated genes were analyzed using DAVID bioinformatics and the 
“functional annotation chart” output was exported in Cytoscape 3.3 (plugin: 
enrichment map creator) [135] to generate a map of enriched GO_CC. Size of 
the node predicts the number of genes in particular ontology with green 
connecting line representing number of common genes. Cut off value for 
































































































































Figure 50: Positively enriched cellular components in T2DM (OM vs SC). 
Upregulated genes were analyzed using DAVID bioinformatics and the 
“functional annotation chart” output was exported in Cytoscape 3.3 (plugin: 
enrichment map creator) [135] to generate a map of enriched GO_CC. Size of 
the node predicts the number of genes in particular ontology with green 
connecting line representing number of common genes. Cut off value for 


























































































Figure 51: Negatively enriched cellular components in T2DM (OM vs SC). 
Downregulated genes were analyzed using DAVID bioinformatics and the 
“functional annotation chart” output was exported in Cytoscape 3.3 (plugin: 
enrichment map creator) [135] to generate a map of enriched GO_CC. Size of 
the node predicts the number of genes in particular ontology with green 
connecting line representing number of common genes. Cut off value for 
generating enrichment map was capped at conservative (P-value < 0.001, FDR 
< 0.05). 
Gene symbols written in red or green text in each figure denote ECM genes 
exclusive to that group. Compared to SC depot, 2 genes (LTBP4, VEGF) were 
upregulated and 7 genes (FMOD, COL3A1, VIT, MMP2, CD44, GRIA3, 
ADAMTS2) were downregulated in OM depot from NT2DM exclusively. On 
the other hand, 20 genes (OMD, ENTPD2, EMID1, ADAMTS17, COL9A2, 
COL8A1, LAMC2, BMP7, ADAMTS3, ARGN, BMP4, EMILIN3, WNT9A, 
COL17A1, PRSS12, TGFB2, WNT4, WNT3, TGFB3, WNT5B) were 
upregulated and 12 genes (HSPG2, NID, COL16A1, MMRN2, VWF, 
COL12A1, FREM1, VWA1, COL24A1, TNC, COL4A2, COL4A1) were 
downregulated in OM tissue from T2DM exclusively. 
6.3.4 Enriched KEGG pathways in T2DM compared to NT2DM 
To evaluate disease specific differences in KEGG pathways, we used FPKM 
values and Gene Set Enrichment Analysis (GSEA) which empowered us to 
visualize positively and negatively enriched ontologies based on enrichment 
score (ES). ES score obtained from GSEA reflects the degree to which a gene 
set is overrepresented at the top or bottom of a ranked list of genes. A positive 
ES indicates gene set enrichment at the top of the ranked list and a negative ES 
indicates gene set enrichment at the bottom of the ranked list. Bar graphs show 
the percentage of gene coverage (GC) in particular cellular component (ratio of 
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genes in database/ total number of genes in the ontology) and blue and red color 
signify negative and positive enrichment in respective ontologies (figure 52). 
Total 160 gene sets or KEGG pathways were analyzed. Compared to SC depot 
in NT2DM, 25 gene sets (P < 0.05) were upregulated and 19 gene sets (P < 
0.05) were downregulated in SC depot from T2DM (table 21). Compared to 
OM depot from NT2DM, 3 gene sets (P < 0.05) were upregulated and 19 gene 
sets (P < 0.05) were downregulated in OM depot from T2DM subjects (table 
22). Pathways with significant interactions are shown here and detailed list is 
tabulated in the appendix. Three metabolic pathways including butanoate 
metabolism (FDR = 0.041), propanoate metabolism (FDR = 0.012) as well as 
valine, leucine and isoleucine degradation (FDR = 0.01) were negatively 
enriched in SC depot (shown in blue bars) from T2DM subjects compared to 
SC depot from NT2DM subjects. Gene coverage was highest in butanoate 
metabolism (54%) followed by propanoate metabolism (52%) and valine, 




Figure 52: KEGG pathway enrichment and their interaction map illustrating 
transcriptomic signatures in T2DM compared to NT2DM subjects. 
FPKM values were analyzed in gene set enrichment analysis (GSEA) desktop 
version [165] and the output was exported in Cytoscape 3.3 (plugin: enrichment 
map creator) [163] to generate a map of positively and negatively enriched 
gene ontologies. Inner node represents enrichment in SC depot (left cluster) and 
OM depot (right cluster). The size of the node predicts the number of genes in 
particular ontology with green connecting line representing number of common 
genes or interaction. Blue and red color denote significant negative and positive 
enrichment respectively. Cut off value for generating enrichment map was 
capped at permissive (P-value < 0.05, FDR < 0.25). 
In addition to these, cytokine-cytokine receptor interaction (FDR = 0.016) and 
chemokine signaling (FDR = 0.038) (not present in interaction maps) pathways 
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were positively enriched in SC depot from T2DM subjects compared to SC 
depot from NT2DM subjects. In OM depot, allograft rejection (FDR = 0.006), 
type 1 diabetes mellitus (FDR = 0.008), autoimmune thyroid disease (FDR = 
0.02), graft versus host disease (0.006) and antigen processing and presentation 
(FDR = 0.03) were negatively enriched.6.3.5 Enriched cellular components in 
T2DM compared to NT2DM 
GSEA and Cytoscape 3.3 were used to identify enriched ontologies and build 
interaction maps using FPKM values as an input (figure 53). Common cellular 
components were present in both datasets and hence enrichment maps have been 
combined for easier visualization. Inner node denotes enrichment in SC depot 
(T2DM vs NT2DM) and outer border denotes enrichment in OM depot (T2DM 
vs NT2DM), with red color representing significant positive enrichment and 
white color representing non-significant enrichment. Bar graph depicts the 
percentage of gene coverage (GC) in particular cellular component (ratio of 
genes in database/ total number of genes in the ontology). 
Total 138 gene sets or GO_CC were analyzed. Compared to SC depot from 
NT2DM, 19 gene sets (P < 0.05) were upregulated and 1 gene set (P < 0.05) 
was downregulated (table 23) in SC depot from T2DM. Compared to OM depot 
from NT2DM, 17 gene sets (P < 0.05) were upregulated (P < 0.05) (table 24) in 
OM depot from T2DM. No gene sets were significantly downregulated in OM 




Figure 53: GO cellular component enrichment and their interaction map 
illustrating transcriptomic signatures in T2DM compared to NT2DM 
subjects. 
FPKM values were input into gene set enrichment analysis (GSEA) desktop 
version [165] and the output was exported in Cytoscape 3.3 (plugin: enrichment 
map creator) [163] to generate a map of positively and negatively enriched 
gene ontologies. Inner node represents enrichment in SC depot and outer 
border in node represents enrichment in OM depot. Size of the node predicts 
the number of genes in the particular ontology with green connecting line 
representing the number of common genes or interaction. Blue and red color 
denote significant negative and positive enrichment respectively. Cut off value 
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for generating enrichment map was capped at permissive (P-value < 0.05, FDR 
< 0.25). 
Pathways with significant interactions are shown here. ECM components 
including extracellular region (GC = 27% in SC depot and 28% in OM depot), 
extracellular matrix (GC = 30%) and proteinaceous extracellular matrix (GC = 
29%) formed a cluster, with later 2 ontologies being significantly positively 
enriched only in OM depot (T2DM vs NT2DM). Next, we analyzed the ECM 
and fibrosis components respectively in details. 
6.3.5.1 ECM and fibrosis components  
Heatmap (figure 54) represents ranked FPKM values of ECM genes in OM 
depot from T2DM and NT2DM subjects and enrichment plot shows density of 
overrepresented genes in up or downregulated genes. ECM comprised of 67 
genes in total and the top 20 genes in heatmap contributed the most towards 
positive enrichment (ES score = 0.354). As seen from the figure, upregulated 
genes included collagens (COL16A1, COL6A3, COL4A2, COL5A2, COL5A3 
and COL15A1), laminins (LAMC1 and LAMB2), metallopeptidases 










































































Figure 54: Heat map and enrichment plots of ECM genes in OM depot 
(T2DM vs NT2DM). 
Each black vertical line in enrichment plot denotes one gene and color bar 
represents gene rank within list of genes. Output was generated in GSEA and 
significance was capped at P < 0.05. 
Fibrosis is deposition of excess connective tissue including extracellular matrix 
proteins such as collagens. We analyzed list of 59 genes responsible for fibrosis 
in T2DM compared to NT2DM subjects in both SC and OM depots (figure 55). 
Fibrosis genes were positively enriched (ES = 0.324) in OM depot from T2DM 
(compared to NT2DM) whereas enrichment was non–significant in SC depot 
indicating increased fibrosis in OM from T2DM subjects. 16 genes (AGT, 
COL16A1, COL6A3, 
ADAMTS5, LAMC1, FBLN2, 
ECM2, THBS4, DGCR6, MGP, 
SOD1, COMP, POSTN, LAMB2, 
ADAMTS9, COL5A2, LTBP2, 




TIMP4, ITGB1, EDN1, ITGA1, BCL2, LOX, THBS2, ITGB5, SMAD3, 
ITGAV, LTBP1, JUN, THBS1, PDGFA, TGFBR2) contributed significantly 
towards positive enrichment. Altogether, ECM and fibrosis genes were 
positively enriched in T2DM, especially in OM depot indicating the role of 
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Figure 55: Enrichment analysis of fibrosis genes in T2DM compared to 
NT2DM (SC and OM depots). 
Each black vertical line in enrichment plot denotes one gene and color bar 
represents gene rank within list of genes. Output was generated by analyzing 
genes of interest using GSEA and significance was capped at P < 0.05.  
6.4 Discussion 
Adipose tissue function and expandability is an important determinant of 
metabolic homeostasis [211] and failure to remodel ECM during obesity results 
in adipose dysfunction and onset of T2DM [37]. Although, several secretory 
and functional variances among OM and SC depot are now understood, 
transcriptomic differences between adipose from obese non-diabetics 
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(metabolically healthy obese) and obese diabetics have not been explored 
previously. In the present study, we performed detailed KEGG pathway and 
GO_cellular component enrichment as well as interaction analysis of transcripts 
between (I) OM depot compared to SC depot in both T2DM and NT2DM 
subjects and (II) T2DM compared to NT2DM in both SC and OM depots. This 
strategy enabled us to elaborate on both the depot specific and the disease 
specific differences occurring in obese diabetics compared to obese non-
diabetics.  
Sample-to-sample distance calculation and principle component analysis 
showed that OM and SC depot have very distinct transcriptome signatures, 
whereas there is less variation between T2DM and NT2DM samples. This is 
also confirmed by number of differentially expressed genes (DEGs) in OM 
depot compared to SC depot in both T2DM (n = 3063) and NT2DM (n = 1944) 
subjects in contrast to DEGs in T2DM compared to NT2DM subjects in SC (n 
= 199) and OM (n = 295) depot. Raw data was paired subject-wise (OM 
normalized to SC in each subject) when comparing OM with SC depot in order 
to reduce baseline biological variation and hence, the functional annotation of 
DEGs to KEGG biological pathways and gene ontologies was performed using 
fold change in this case. The Ranked FPKM was used for comparing unpaired 
data sets between T2DM and NT2DM subjects with the help of gene set 





KEGG pathways and cellular components of interest in OM compared to 
SC depot 
Cytokine-cytokine receptor interaction (P = 0.0015) and PI3K-Akt signaling 
pathway were exclusively enriched in the omental depot from T2DM subjects 
(P = 0.002). PI3K-Akt signaling pathway was of an interest owing to its direct 
link to insulin signaling pathway, growth stimuli, activation of transcription, 
translation, proliferation, growth and survival. The majority of DEGs (total 
DEGs = 91) were positioned upstream in this pathway and contained genes 
common with the ECM-receptor interaction pathway (COL5A3, COL4A5, 
LAMB3, ITGB8, TNC, VWF, TNN and SPP1, figure 46). Compared to SC 
depot, COL5A3 was downregulated in the OM depot in both T2DM (log FC = 
-1.54) and NT2DM (log FC = -1.23) subjects. COL5A3 deficient mice exhibit 
lipodystrophy like phenotype with reduced dermal fat, resistance to diet induced 
weight gain, glucose intolerance and insulin resistance [212]. Hence 
downregulation of COL5A3 in OM depot compared to SC depot may indicate 
a pathogenic role of COL5A3 in the OM depot specifically. Several other 
members of collagen family including COL9A2, COL8A1 and COL17A1 were 
upregulated in OM depot whereas COL16A1, COL12A1, COL24A1 and 
COL4A2 were downregulated in OM depot exclusively in T2DM subjects but 
their functions are not fully understood yet. VEGF is an angiogenesis promoter 
[37] and compared to SC, was upregulated in OM depot from NT2DM only. 
Angiogenesis is a vital process to maintain growing adipose tissue in a non-
hypoxic environment and multiple studies have linked impaired angiogenesis 




Apart from several collagens, detailed analysis of GO_CC revealed 
upregulation in Wnt signaling genes; WNT5B, WNT11, WNT9A, WNT3 and 
WNT4 in OM depot exclusively in T2DM subjects (figure 50). Wnt signaling 
glycoproteins are part of the canonical pathway which signals growth, 
proliferation, cell fate specification and cell migration. Among the members of 
Wnt signaling pathway, TCF7L2 and WNT5B mutations have been previously 
implicated to increased T2DM (χ2 = 15.6, P = 00008; odds ratio = 1.74; 95% 
confidence interval = 1.32–2.29) susceptibility in humans. WNT5B 
overexpression improves adipogenesis and also plays a role in the pathogenesis 
of T2DM through regulation of adipocyte function through adipokine 
production [215-218]. WNT4 promotes adipogenesis and WNT3A inhibits 
adipogenesis in 3T3-L1 adipocytes [219, 220]. Due to opposing effects of Wnt 
members, our results remain inconclusive, but dysregulated expression in 
numerous members of this pathway supported the role of Wnt signaling 
pathway in the pathogenesis of insulin resistance, partly because of OM depot 
related pathogenic mechanisms.  
KEGG pathways and cellular components of interest in T2DM compared 
to NT2DM subjects 
In the SC depot, three metabolic pathways including butanoate metabolism, 
propanoate metabolism as well as valine, leucine and iso-leucine (branched 
chain amino acids or BCAA) degradation were negatively enriched and showed 
significant interactions. Increased BCAA are associated with obesity, insulin 
resistance and T2DM [221, 222] and casual mechanisms involves activation of 
mTORC pathway and uncoupling of IRS1 from insulin receptor, thus inhibiting 
insulin signaling pathway. Reduced transcripts of BCAA in our dataset might 
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indicate a propensity towards increased cellular BCAA, but needs further 
quantitative validation. The role of butanoate and propanote metabolism in 
adipose tissue associated pathogenesis of insulin resistance is not well studied 
yet. Mice supplemented with butanoate or butyric acid exhibit increased PGC1α 
and UCP1 gene expression in brown adipose tissue and skeletal muscle and are 
protected from diet induced obesity and insulin resistance [223]. Compared to 
NT2DM subjects, insulin signaling pathway was negatively enriched (ES = -
0.30, P = 0.40) in SC depot from T2DM. PPP1R3C, PRKAR2B, IRS2, PHK2 
and PRKAG2 genes contributed to negative enrichment. IRS2 is an upstream 
signaling molecule in insulin signaling pathway and its disruption in mice is 
known to result in hepatic as well as skeletal muscle insulin resistance and onset 
of type 2 diabetes [224]. 
Amid ECM genes (T2DM compared to NT2DM); structural proteins such as 
collagens (COL16A1, COL6A3, COL5A2, COL4A2 and COL5A3), laminins 
(LAMC1 and LAMB2) and fibulins (FBLN2 and FBLN5) were upregulated in 
OM depot and contributed to core enrichment in ECM in this subject group. 
Among fibrosis genes; integrins (ITGAV, ITGB1, ITGB5 and ITGA1), 
glycoproteins (THBS1 and THBS2) and enzymes (LOX and TIMP4) were 
upregulated in OM depot (T2DM compared to NT2DM subjects). Previously, 
Collagen I, III and VI were observed to be particularly abundant in SC and OM 
depot from obese individuals when compared to lean individuals [225]. Our 
results suggest that these are differentially expressed amongst the diabetics and 
non-diabetics at same BMI. Collagen VI is one of the highly enriched collagen 
in adipose tissue and upon its deletion in adipose tissue results in uninhibited 
expansion capacity in conjunction with improved energy homeostasis; both in 
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HFD and ob/ob background. A recent study linked expression of collagen VI, 
alpha 3 (COL6A3) to paracrine effects of leptin secreted from adipose tissue 
[226]; where leptin resulted in the dose dependent decrease in gene expression 
of COL6A3.  
Pathogenic contribution of ECM and fibrosis components in obese diabetics is 
partially understood, and our analysis showed upregulation of transcripts 
annotated to ECM and fibrosis components in OM depot from T2DM compared 
to OM depot from NT2DM subjects, which highlights their importance in 
healthy adipose tissue expandability in obese non-diabetics compared to obese 
diabetics. However, it is important to consider possible discordance between 
expression at transcript level and protein level and selected genes might need 
further validation.  
6.5 Conclusion 
RNA sequencing showed that there are more distinguishing features between 
the OM and SC adipose depots than there are between adipose from T2DM vs 
NT2DM, even when variability due to inter individual differences are accounted 
for. RNA sequencing analyses interestingly revealed that pathways involved in 
ECM and fibrosis to be different in OM depot between T2DM and NT2DM 
subjects, supporting the concept that healthy adipose expansion in obesity is 
required for maintenance of metabolic homeostasis. 
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7. Summary and future work  
Adipose tissue health is determined by its ability to expand and (I) store excess 
nutrients inside lipid droplets without spill over to visceral organs such as liver, 
skeletal muscle and heart (II) maintain adipokine secretion and inflammation 
(III) balance lipogenesis and lipolysis according to fed or fasting state and (IV) 
remodel ECM and angiogenesis [58, 199]. We studied three aspects of adipose 
tissue biology which included lipid storage via FIT2 protein, mitochondrial 
function via FTO protein and the relevance of extracellular matrix components.  
Re-evaluating the use of SGBS adipocytes as a representative model of 
human adipocytes, by comparison with primary human subcutaneous 
adipocytes 
Transcriptome and functional analysis suggested that SGBS adipocytes retained 
a UCP1 expressing brown adipocyte like phenotype when compared to stromal 
vascular fraction derived primary human adipocytes. Moreover, results obtained 
from RNA sequencing indicated positive enrichment of transcripts belonging to 
mitochondria and oxidative phosphorylation gene ontologies. This is further 
validated and confirmed by elevated UCP1 mRNA and protein expression as 
well as significantly increased mitochondrial spare respiratory capacity and 
maximal respiratory capacity in them. SGBS adipocytes also have elevated 
radioactive glucose uptake and lipid accumulation. Overall, even with existing 
differences, SGBS are a valid and robust model for preliminary studies in 
adipocyte metabolism. But, it is still unclear if phenotypic variances are due to 
neonatal origin or mutations in SGBS adipocytes and needs further studies.  
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Partial deficiency of FIT2 protein impairs triglyceride storage and insulin 
signaling in human adipocytes 
Deficiency of lipid storage protein FIT2 leads to dysfunctional primary human 
adipocytes at basal and free fatty acid challenged state. FIT2 protein expression 
was higher in SC and OM adipose tissue depot from non-diabetics compared 
respective depots from diabetics. We used palmitic acid, one of the most 
abundant and pathogenic saturated free fatty acid to induce insulin resistance in 
adipocytes derived from the stromal vascular fraction of adipose tissue. In SC 
adipocytes, palmitate induced lipid accumulation was directly proportional to 
FIT2 protein expression. Its Knockdown resulted in reduced TAG 
accumulation, significantly increased IL6 and IL18 mRNA expression as well 
as palmitate induced IRE1α phosphorylation. Akt phosphorylation at Ser-473 
amino acid was observed to be lower in FIT2 knockdown adipocytes along with 
decreased radioactive glucose uptake.  
Next, we aim to: 
• Investigate effect of oleic acid in FIT2 deficient SC adipocytes. Oleic 
acid is a relatively low toxicity monounsaturated free fatty acid [165]. 
This experiment will enable us to mimic the free fatty acid milieu more 
accurately.  
FTO protein knockdown or chemical inhibition of FTO can increase 
energy expenditure in human adipocytes 
FTO protein knockdown and drug inhibition resulted in increased PGC1α and 
UCP1 mRNA expression. In addition, FTO inhibition by drug CA at 50µM 
concentration increased mitochondrial spare respiratory capacity and maximal 
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respiration capacity in SGBS adipocytes. Also, FTO knockdown or drug 
inhibition or a combination of both augmented AMPKα phosphorylation 
indicating possible role of AMPK pathway in FTO induced mitochondrial 
function. AMPK pathway contributes to adipose health through suppression of 
inflammation and regulation of adipogenesis as well as carbohydrate and lipid 
metabolism pathways [227]. In recent years, AMPK pathway proteins have 
become lucrative drug targets to combat insulin resistance and type 2 diabetes 
[228] and we validated an FTO inhibitor with potential for further elaborate 
studies and therapeutic use. 
Next we aim to:  
• Examine the role of AMPK pathway in FTO mediated upregulation 
of mitochondrial function. Normally, AMPK pathway is activated by 
cAMP in response to stimuli such as glucose deprivation or lack of ATP. 
In conjunction with drug CA, we aim to use cAMP inhibitors in SGBS 
adipocytes to study FTO biology in more detail.  
In future, we also hope to relate our work to studies in animal models that 
establish causality. It will be of tremendous clinical interest to determine if the 
FTO inhibitor could bring about similar beneficial metabolic effects in animal 
models. It would also be interesting to map out the mRNAs targeted by FTO 
demethylase activity in order to give rise to the obesity phenotypes and better 





Transcriptomic analysis reveals a role for extracellular matrix and fibrosis 
pathways in maintaining healthy human adipose tissue function in obese 
non-diabetics 
Transcriptome analysis by RNA sequencing displayed significant enrichment 
in numerous KEGG biological pathways and gene ontologies in OM depot 
compared to SC depot in both diabetics and non-diabetics. PI3K-Akt signaling 
pathway was enriched in OM depot compared to SC depot in T2DM subjects. 
Extracellular matrix and fibrosis components were positively enriched in OM 
depot from diabetics when compared to OM depot from non-diabetics. 
Increased fibrosis and extracellular matrix are known to be detrimental to 
adipose tissue expandability [45]. Hence, our data suggest that increased ECM 
and fibrosis could potentially contribute to adipose tissue dysfunction and 
pathogenesis of type 2 diabetes in obese individuals. 
Future directions:  
• Currently, our analysis is limited to gene expression obtained from RNA 
sequencing. Our next step would be to validate differences in expression 
of selected genes at the protein level. 
• Novel genes identified from this study can be functionally validated and 
characterized in human derived cell lines to better understand processes 
driving insulin sensitivity in the metabolically healthy obese. In 
particular, genes contributing significantly to positive enrichment in 
ECM and fibrosis components in T2DM subjects can be investigated 
further either by inhibiting over-accumulation of ECM or fibrosis 
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9. Appendix  
I. List of SYBR green primers used for real-time qPCR. 
Gene Primer sequence (5’ – 3’) 







































































































Table 19: List of SYBR green primers for Real-time qPCR.  
2. List of primers and probes used for quantification of mitochondrial DNA 
content. 











5’ – FAM 












5’ – FAM 
3’ - TAMRA 







3. Table of KEGG biological pathways enriched in SC depot from diabetics 
compared to SC depot from non-diabetics. 







KEGG_RIBOSOME 83 0.721 0 
KEGG_SPLICEOSOME 124 0.498 0 
KEGG_PROTEASOME 40 0.603 0 
KEGG_LEISHMANIA_INFECTION 61 0.518 0 
KEGG_ANTIGEN_PROCESSING_AND_PRESE
NTATION 
54 0.514 0 
KEGG_SYSTEMIC_LUPUS_ERYTHEMATOSU
S 
68 0.487 0 
KEGG_NOD_LIKE_RECEPTOR_SIGNALING_
PATHWAY 
55 0.496 0 
KEGG_PRIMARY_IMMUNODEFICIENCY 24 0.595 0 
KEGG_CYTOKINE_CYTOKINE_RECEPTOR_I
NTERACTION 
152 0.384 0 
KEGG_HEMATOPOIETIC_CELL_LINEAGE 63 0.439 0 
KEGG_BUTANOATE_METABOLISM 24 -0.616 0 
KEGG_PROPANOATE_METABOLISM 29 -0.641 0 
KEGG_CHEMOKINE_SIGNALING_PATHWAY 147 0.358 0.002 
KEGG_NATURAL_KILLER_CELL_MEDIATE
D_CYTOTOXICITY 
91 0.405 0.002 
KEGG_VALINE_LEUCINE_AND_ISOLEUCIN
E_DEGRADATION 
42 -0.574 0.002 
KEGG_TGF_BETA_SIGNALING_PATHWAY 68 -0.451 0.002 
KEGG_ALZHEIMERS_DISEASE 134 -0.329 0.004 
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KEGG_LYSOSOME 112 0.352 0.006 
KEGG_DRUG_METABOLISM_OTHER_ENZY
MES 
22 0.562 0.006 
KEGG_CITRATE_CYCLE_TCA_CYCLE 28 -0.54 0.007 
KEGG_PYRUVATE_METABOLISM 33 -0.507 0.007 
KEGG_TOLL_LIKE_RECEPTOR_SIGNALING_
PATHWAY 
83 0.366 0.011 
KEGG_INOSITOL_PHOSPHATE_METABOLIS
M 
49 -0.45 0.013 
KEGG_VASCULAR_SMOOTH_MUSCLE_CON
TRACTION 
83 -0.378 0.015 
KEGG_CYTOSOLIC_DNA_SENSING_PATHW
AY 
40 0.446 0.016 
KEGG_GRAFT_VERSUS_HOST_DISEASE 26 0.472 0.018 
KEGG_COMPLEMENT_AND_COAGULATION
_CASCADES 
41 0.428 0.018 
KEGG_B_CELL_RECEPTOR_SIGNALING_PA
THWAY 
69 0.375 0.019 
KEGG_OXIDATIVE_PHOSPHORYLATION 104 -0.339 0.019 
KEGG_OLFACTORY_TRANSDUCTION 21 0.537 0.02 
KEGG_AMYOTROPHIC_LATERAL_SCLEROS
IS_ALS 
37 0.422 0.022 
KEGG_VASOPRESSIN_REGULATED_WATER
_REABSORPTION 
39 -0.439 0.022 
KEGG_FATTY_ACID_METABOLISM 36 -0.474 0.023 
KEGG_PATHOGENIC_ESCHERICHIA_COLI_I
NFECTION 
45 0.404 0.027 
KEGG_PARKINSONS_DISEASE 101 -0.345 0.028 
KEGG_INTESTINAL_IMMUNE_NETWORK_F
OR_IGA_PRODUCTION 





65 -0.394 0.033 
KEGG_ALANINE_ASPARTATE_AND_GLUTA
MATE_METABOLISM 
26 -0.467 0.035 
KEGG_GLYCINE_SERINE_AND_THREONINE
_METABOLISM 
22 -0.485 0.038 
KEGG_INSULIN_SIGNALING_PATHWAY 119 -0.303 0.04 
KEGG_FC_GAMMA_R_MEDIATED_PHAGOC
YTOSIS 
91 0.321 0.04 
KEGG_PPAR_SIGNALING_PATHWAY 50 -0.389 0.041 
KEGG_RNA_POLYMERASE 29 0.43 0.044 
KEGG_PROXIMAL_TUBULE_BICARBONATE
_RECLAMATION 
15 -0.553 0.048 
Table 21: KEGG biological pathways enriched in SC depot from diabetics 
when comparted to SC depot form non-diabetics. 
FPKM values were fed in gene set enrichment analysis (GSEA) desktop version 
[165] and positively and negatively enriched KEGG pathways (as denoted by 









4. Table of KEGG biological pathways enriched in OM depot from 
diabetics compared to OM depot from non-diabetics. 








TION 54 -0.524 0 
KEGG_GRAFT_VERSUS_HOST_DISEASE 26 -0.657 0 
KEGG_ALLOGRAFT_REJECTION 25 -0.674 0 
KEGG_TYPE_I_DIABETES_MELLITUS 28 -0.675 0 
KEGG_BASAL_CELL_CARCINOMA 32 -0.605 0.002 
KEGG_ASTHMA 16 -0.645 0.002 
KEGG_PROTEIN_EXPORT 23 0.511 0.003 
KEGG_RNA_POLYMERASE 29 0.533 0.003 
KEGG_AUTOIMMUNE_THYROID_DISEASE 26 -0.6 0.005 
KEGG_AXON_GUIDANCE 101 -0.387 0.007 
KEGG_OXIDATIVE_PHOSPHORYLATION 104 -0.386 0.008 
KEGG_CELL_ADHESION_MOLECULES_CAMS 95 -0.385 0.01 
KEGG_PROTEASOME 40 0.398 0.014 
KEGG_LYSOSOME 112 -0.356 0.015 
KEGG_APOPTOSIS 78 -0.38 0.029 
KEGG_PARKINSONS_DISEASE 101 -0.353 0.033 
KEGG_ENDOMETRIAL_CANCER 47 -0.415 0.036 
KEGG_ENDOCYTOSIS 161 -0.31 0.037 
KEGG_VIRAL_MYOCARDITIS 55 -0.406 0.038 
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KEGG_ALZHEIMERS_DISEASE 134 -0.314 0.043 
KEGG_HEDGEHOG_SIGNALING_PATHWAY 29 -0.458 0.045 
KEGG_CARDIAC_MUSCLE_CONTRACTION 43 -0.422 0.046 
KEGG_FC_EPSILON_RI_SIGNALING_PATHWAY 64 -0.379 0.05 
Table 22: KEGG biological pathways enriched in OM depot from diabetics 
when comparted to OM depot form non-diabetics. 
FPKM values were fed in gene set enrichment analysis (GSEA) desktop version 
[165] and positively and negatively enriched KEGG pathways (as denoted by 














5. Table of GO_cellular components enriched in SC depot from diabetics 
compared to SC depot from non-diabetics. 







NUCLEOLUS 116 0.506 0 
RIBONUCLEOPROTEIN_COMPLEX 136 0.491 0 
RIBOSOME 37 0.534 0 
NUCLEAR_LUMEN 350 0.317 0 
MEMBRANE_ENCLOSED_LUMEN 414 0.295 0 
ORGANELLE_LUMEN 414 0.295 0 
VACUOLE 56 0.409 0.002 
EXTRACELLULAR_REGION 248 0.298 0.004 
NUCLEOLAR_PART 17 0.613 0.004 
PROTEASOME_COMPLEX 23 0.536 0.004 
SPLICEOSOME 51 0.44 0.006 
GOLGI_APPARATUS_PART 90 -0.372 0.013 
LYSOSOME 48 0.411 0.015 
LYTIC_VACUOLE 48 0.411 0.02 
SMALL_NUCLEAR_RIBONUCLEOPROTEIN_COM
PLEX 22 0.534 0.021 
RNA_POLYMERASE_COMPLEX 16 0.528 0.025 
DNA_DIRECTED_RNA_POLYMERASE_COMPLEX 16 0.528 0.026 
ORGANELLAR_RIBOSOME 22 0.484 0.027 
MITOCHONDRIAL_RIBOSOME 22 0.484 0.027 
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EXTRACELLULAR_SPACE 127 0.297 0.035 
NUCLEAR_DNA_DIRECTED_RNA_POLYMERASE
_COMPLEX 16 0.528 0.05 
Table 23: GO_cellular components enriched in SC depot from diabetics when 
comparted to SC depot form non-diabetics. 
FPKM values were fed in gene set enrichment analysis (GSEA) desktop version 
[165] and positively and negatively enriched KEGG pathways (as denoted by 















6. Table of GO_cellular components enriched in OM depot from diabetics 
compared to OM depot from non-diabetics. 







PROTEASOME_COMPLEX 23 0.611 0 
MITOCHONDRIAL_LUMEN 44 0.466 0 
MITOCHONDRIAL_MATRIX 44 0.466 0 
NUCLEOLUS 116 0.382 0 
MITOCHONDRIAL_PART 135 0.314 0 
RIBONUCLEOPROTEIN_COMPLEX 136 0.307 0 
EXTRACELLULAR_REGION_PART 189 0.252 0 
MEMBRANE_ENCLOSED_LUMEN 414 0.223 0 
ORGANELLE_LUMEN 414 0.223 0 
NUCLEOLAR_PART 17 0.654 0.003 
MITOCHONDRION 318 0.223 0.011 
MITOCHONDRIAL_RIBOSOME 22 0.489 0.011 
EXTRACELLULAR_MATRIX 67 0.355 0.012 
PROTEINACEOUS_EXTRACELLULAR_MATRIX 66 0.342 0.016 
ORGANELLAR_RIBOSOME 22 0.489 0.017 
RNA_POLYMERASE_COMPLEX 16 0.488 0.037 
EXTRACELLULAR_REGION 248 0.219 0.045 
RIBONUCLEOPROTEIN_COMPLEX 136 0.491 0 
RIBOSOME 37 0.534 0 
 194 
 
NUCLEAR_LUMEN 350 0.317 0 
MEMBRANE_ENCLOSED_LUMEN 414 0.295 0 
ORGANELLE_LUMEN 414 0.295 0 
VACUOLE 56 0.409 0.002 
EXTRACELLULAR_REGION 248 0.298 0.004 
NUCLEOLAR_PART 17 0.613 0.004 
PROTEASOME_COMPLEX 23 0.536 0.004 
SPLICEOSOME 51 0.44 0.006 
GOLGI_APPARATUS_PART 90 -0.372 0.013 
LYSOSOME 48 0.411 0.015 
LYTIC_VACUOLE 48 0.411 0.02 
SMALL_NUCLEAR_RIBONUCLEOPROTEIN_CO
MPLEX 22 0.534 0.021 
RNA_POLYMERASE_COMPLEX 16 0.528 0.025 
DNA_DIRECTED_RNA_POLYMERASE_COMPL
EX 16 0.528 0.026 
ORGANELLAR_RIBOSOME 22 0.484 0.027 
MITOCHONDRIAL_RIBOSOME 22 0.484 0.027 
EXTRACELLULAR_SPACE 127 0.297 0.035 
NUCLEAR_DNA_DIRECTED_RNA_POLYMERA
SE_COMPLEX 16 0.528 0.05 
Table 24: GO_cellular components enriched in OM depot from diabetics 
when comparted to OM depot form non-diabetics. 
FPKM values were fed in gene set enrichment analysis (GSEA) desktop version 
[165] and positively and negatively enriched KEGG pathways (as denoted by 
























Examiner 1:  
1. Figures (e.g. Fig 6, 8, 9, 10), if cited from literature, should include the 
statement such as “adopted from [reference and #]” 
• Amendments have been made to figure legends for figure 6, 8 
and 10. The signal transduction pathway in figure 9 was built in 
Pathway Builder Tool 
(http://www.proteinlounge.com/PathwayBuilder.aspx) based on 
literature review and this has been indicated as well. 
• Figure 6: Mechanism of lipid induced insulin resistance. 
Elevated DAGs and free fatty acids activate PKCθ (protein 
kinase Cθ) which blocks IRS1 signaling by serine 
phosphorylation of IRS1. Eventually, insulin stimulated GLUT4 
translocation is compromised. Adopted from Shulman et al [58]. 
• Figure 8: Modulation of adipose tissue inflammation during 
weight gain or metabolic dysfunction. 
An imbalance between inflammation, metabolic control and 
vascular function occurs in obese individuals. Along with 
increasing inflammation, adipocytes secrete pro-inflammatory 
adipokines such as leptin, resistin and RBP4 in increasing 
amounts. Macrophage phenotype changes from M2 to M1, 
which further contributes to inflammation. Adopted from Ouchi, 
N. et al [72]. 
 
 
• Figure 10: The unfolded protein response, nutrient sensing 
and inflammation. 
UPR is induced in response to ER stress inducers and can result 
in altered metabolic and inflammatory responses and thus 
metabolic disease. Adopted from Hotamisligil, G.S. et al [86]. 
2. p51, SGBS line was reported in 2001, not 2011 
• Corrected in the thesis.  
• Revised text 
In 2001, investigators isolated preadipocytes from an infant 
derived adipose tissue [2] which could grow up to 50 passages 
while maintaining growth and differentiation capacity. SGBS 
adipocytes were derived from a 3 year old infant suffering from 
Simpson Golabi Behmel syndrome or SGBS. Since isolation, 
they have been widely distributed around the world and reported 
as a representative adipocyte model for primary human 
adipocytes. 
3. What does ‘NA’ mean in Table 14? Simply did not examine? 
• NA (not applicable) refers to all the genes with FPKM < 1 and 
thus were not included in our analysis. Have updated the figure 
legend accordingly. 
• Revised Legend: 
Table 14: Lineage specific markers in adipocytes and their 
expression in SGBS and SC control adipocytes. NA: Genes with 
FPKM < 1 and thus excluded from further analysis. P value < 
0.05 and FDR < 0.05 were used as thresholds to select significant 
genes. 
4. What is the future plan for the project #4 (Transcriptome analysis of fat 
depots)? 
• A description of future plans have since been added in the thesis 
as well.  
• Currently, our analysis is limited to gene expression obtained 
from RNA sequencing. Our next step would be to validate 
differences in expression of selected genes at the protein level.  
• Novel genes identified from this study can be functionally 
validated and characterized in human derived cell lines to better 
understand processes driving insulin sensitivity in the 
metabolically healthy obese. In particular, genes contributing 
significantly to positive enrichment in ECM and fibrosis 
components in T2DM subjects can be investigated further either 
by inhibiting over-accumulation of ECM or fibrosis components 







Examiner 2:  
1. The abstract is weak: it merely recites results, but does not state the 
background, the research question, and the final outcome of the work; 
this needs to be completely rewritten, this is not an abstract for a 
publication, this is the essence of your PhD work! 
• Revised abstract 
Adipose tissue (AT) functions as an active endocrine organ and 
an energy reserve compartment for storing lipids. It’s now well 
accepted that adipose tissue expandability, remodelling and 
effective storage of excess lipids in the form of triglycerides 
(TAGs) play an important role in maintaining metabolic 
homeostasis. To understand healthy AT expansion and function, 
we used human derived in-vitro adipocyte models to interrogate 
pathways of interest, as well as Next Generation Sequencing 
methods. We first sought to validate and functionally 
characterize two GWAS candidate genes involved in lipid 
metabolism and expressed in adipose; FIT2 (Fat Storage 
Inducing Transmembrane Protein 2) and FTO (Fat Mass and 
Obesity Associated). The FIT2 gene is associated with type 2 
diabetes in the East Asian population and plays a role in 
transporting TAGs from ER to lipid droplets. On the other hand, 
FTO is an obesity associated gene in multiple ethnicities and 
regulates mitochondrial energy expenditure through central and 
peripheral mechanisms. Our observations suggest that improved 
TAG storage via FIT2 protein as well as improved mitochondrial 
oxidative capacity via FTO protein can promote insulin 
sensitivity in primary human adipocytes. Next, using RNA 
sequencing data from AT, we observed positive enrichment in 
the extracellular matrix (ECM) and fibrosis components in 
omental AT depots from T2DM when compared to NT2DM 
subjects. Excessive ECM and fibrosis components have been 
shown to inhibit obesity associated adipose tissue expansion and 
inflammation in the obese, but the differences identified in the 
OM depot among obese T2DM and obese NT2DM subjects are 
novel. Overall, our work contributes insights into the molecular 
and transcriptomic determinants of adipocyte and adipose tissue 
function as well as their potential role in health and disease. 
2. A hypothesis is needed, along with a clear research question. The 
expandability hypothesis is mentioned, it is a general hypothesis (who 
put if forth the first time?), but what is the candidate’s own hypothesis 
and what are the specific aims of this work, and what was the strategy 
behind this. Where relevant, each chapter discussing data sets should 
reiterate what the specific aim was. Chapter 1.9 does at least some work 
here. 
• The adipose tissue expandability hypothesis was put forth for the 
first time by Dr. Tony Vidal-Puig [3] and this is described in the 
introduction section 1.4, as outlined below. 
 
 
• Adipose tissue expandability hypothesis: 
“The adipose tissue expandability hypothesis states that the 
capacity of an individual to expand their fat mass to store lipid 
is a more important determinant of obesity-associated metabolic 
problems than the absolute amount of AT an individual 
possesses” [3, 4]. In a situation where an individual fails to 
maintain AT functions due to impaired expansion, usually due 
to excessive obesity, ectopic lipids begin to accumulate in tissues 
such as liver, heart and skeletal muscle which accelerates 
development of metabolic syndrome. 
• Updated the hypothesis (section 1.9) 
Revised aims and hypothesis of the study 
In the studies presented here, we have leveraged on current 
knowledge on adipose tissue expandability hypothesis [3], with 
the aim of furthering insights into novel adipose tissue related 
mechanisms leading to the development of insulin resistance or 
T2DM. 
We first sought to characterize human adipocyte cell models, to 
better understand the strengths and limitations of the SGBS 
human adipocyte cell line. SGBS adipocytes were derived from 
a child with an overgrowth syndrome [2, 5] and are widely used 
as a representative human adipocyte model. More recently 
SGBS adipocytes were observed to also exhibit a transient 
browning phenotype mid-way during their course of 
differentiation [6]. To date, any potential transcriptomic and 
functional phenotypic differences between SGBS and primary 
human subcutaneous adipocytes have not been examined. We 
hypothesized that while there are overlapping characteristics, 
there may be distinct metabolic signatures involving 
adipogenesis, lipid metabolism, browning and mitochondrial 
capacity between the two cell types. A better understanding of 
these similarities and differences would assist in their 
appropriate usage in our studies or other studies in the future. 
Following this, we leveraged on the use of these adipocytes as 
human derived in vitro models and investigated the role of two 
GWAS gene candidates that are associated with type 2 diabetes 
and expressed in adipose; namely FIT2 and FTO. Both these 
proteins are known to be involved in lipid metabolism pathways 
in adipocytes but its role and function in human adipose have yet 
to be validated and the mechanistic links to the development of 
type 2 diabetes are incompletely understood. 
FIT2 is an ER membrane associated lipid droplet protein, 
responsible for transferring newly synthesized TAGs into lipid 
droplets and a GWAS gene candidate for T2DMin the East Asian 
population [7]. Adipose tissue specific FIT2 protein knockout 
mice show a lipodystrophic phenotype with smaller adipose 
tissue depots accompanied by peripheral insulin resistance [8]. 
The potential role of FIT2 protein in human derived adipocytes 
or adipose tissue has not been established. We hypothesized that 
even partial deficiency of FIT2 protein would lead to reduced 
triglyceride storage, accumulation of free fatty acids and 
defective insulin signalling in the adipocytes. Here, we used 
primary human adipocytes to test this hypothesis. 
In contrast to the lipid storage function of FIT2 protein, data 
from human adipocytes and animal models suggest a role of FTO 
protein in regulating energy expenditure through central and 
peripheral mechanisms [9-11]. Along with FTO protein 
knockdown, we tested the effects of a novel chemical inhibitor 
of dioxygenase activity of FTO protein in SGBS adipocytes [12]. 
We hypothesized that chemical inhibition of FTO protein would 
mimic increase in mitochondrial energy expenditure as observed 
after FTO protein knockdown in SGBS adipocytes [13] and thus 
may potentially be developed as an anti-obesity drug. Since FTO 
protein influences mitochondrial energy expenditure and SGBS 
adipocytes showed higher mitochondrial oxidative capacity in 
our initial experiments, SGBS were initially used for studies 
related to FTO protein. 
The fourth chapter focusses on studying transcriptomic 
signatures that may differ between obese diabetics and obese 
non-diabetics. Insulin resistance is associated with obesity and 
Type 2 Diabetes, and comparing obese diabetics vs obese non-
diabetics would enable us to tease out which signals are unique 
to diabetes. We were interested to examine whether FIT2 and/or 
FTO expression may differ between these two groups we also 
aimed to identify other adipose tissue related pathways that may 
be relevant to the development of insulin resistance and type 2 
diabetes. Specifically, contributions of extracellular matrix 
(ECM) components in obesity and inflammation associated 
adipose tissue dysfunction have been suggested widely [14], but 
potential differences amongst obese diabetics and obese non-
diabetics have not been systematically examined.. We compared 
transcriptomes of subcutaneous and omental adipose tissue from 
obese diabetics and obese non-diabetics to address the question 
whether ECM components are involved in adipose tissue 
dysfunction in obese diabetics. 
3. The rationale for using SGBS cells is not clear. Genetic databases do 
not reveal a connection of mutations in the SBGS locus, or specifically 
in glypican 3, an extracellular matrix component. The candidate needs 
to build a case using literature and then extract a research quest(ion) 
from it that guided him through the thesis work. References are cited 
copiously, but the candidate’s own thinking on what is driving his work 
remains obscure. 
• The possibility of a mutation (not characterized yet) in GPC3 or 
OFD1 driving the phenotype in SGBS cannot be excluded and 
remains a limitation of using SGBS adipocytes. 
• SGBS and stromal vascular fraction (SVF) derived pre-
adipocytes are the most commonly used primary human 
adipocyte cell model. Despite both being primary adipocytes in 
origin, SGBS adipocytes can grow up to a passage number 30 
with better differentiation capacity when compared to SVF 
derived adipocytes from adults. These properties give SGBS 
adipocytes a significant advantage over SC adipocytes especially 
in experiments involving sub-culturing multiple times. 
However, our preliminary data showed that SGBS adipocytes 
differentiate into brown or beige adipocytes with a higher 
number of active mitochondria and UCP1 protein expression 
when compared to SC adipocytes, and thus we initiated studies 
for characterizing them in detail. SGBS adipocytes were 
especially useful in preliminary studies on FTO protein due to 
its role in regulating mitochondrial energy expenditure. Overall, 
both SGBS and SC adipocytes have its advantages and 
drawbacks, and our argument is that understanding their 
characteristics in greater depth allows for more appropriate 
choice of the adipocyte model to be used. 
4. If the extracellular matrix is seen as important in terms of adipogenesis, 
the candidate might want to refer to and cite Ang et al 2014 in Tissue 
Engineering, highlighting differentiation of MSCs into adipocytes which 
is improved under improved matrix deposition. 
• Have updated this in the discussion of SGBS chapter in section 
3.4.  
• Discussion added 
Subject to individual protein function, ECM components seem 
to play a dual role in promoting or inhibiting adipose tissue 
expandability. Several reports suggest that excessive ECM 
deposition in response to obesity-related inflammation reduces 
adipose tissue expandability which eventually results in adipose 
tissue dysfunction [15]. However, studies testing the effects of 
selective macromolecular crowding on adipogenesis and 
browning suggest beneficial effects. When differentiated with 
macromolecular crowding, bone marrow derived mesenchymal 
stem cells undergo improved adipogenesis in the presence of 
macromolecular crowding. In addition to better adipogenesis, 
deposition of ECM components such as collagen IV and 
perlecan (a heparan sulfate proteoglycan) were observed to be 
significantly higher [16]. Collagen IV cocoon formation around 
differentiating bone marrow derived mesenchymal stem cells 
also improved their UCP1 expression and thermogenic capacity 
[17]. In our dataset, transcripts of subcomponents of collagen IV 
were differentially expressed in SGBS adipocytes. Some 
subcomponents were upregulated: COL4A5 (log FC = 2.04), 
COL4A3 (log FC = 7.57), COL4A4 (log FC = 8.20), whereas 
other components were downregulated: COL4A1 (log FC = -
2.00) and COL4A2 (log FC = -1.77). These observations remain 
to be verified at the protein expression level, but suggest that 
subcomponents of collagen IV may have differing activity in 
terms of whether they are more pro-adipogenic (COL4A5, 
COL4A3 and COL4A4) or  anti-adipogenic (COL4A1 and 
COL4A2). 
 
5. 1.4 mentioning the lipodystrophy syndrome actually makes a point on 
free TAGs as in the lipotoxicity hypothesis by Vidal-Puig. It is not clear 
what you wish to tell the reader in this paragraph that bears the heading 
“Adipose tissue expandability hypothesis”. It’s not clear what case you 
are building here. At the end, isn’t the expandability hypothesis 
intertwined with lipotoxicity? Do you wish to demonstrate expandability 
and what can be done to promote it? The motivation is not always clear. 
• AT Expandability hypothesis is closely intertwined with 
lipotoxicity. Three contrasting examples have been stated here 
to demonstrate the importance of healthy AT expansion. 
Lipodystrophy syndrome exemplifies a group of lean patients 
who have insulin resistance due to inability to store lipids in the 
AT. In contrast, metabolically healthy obese subjects represent a 
condition where individuals have excess AT, which is able to 
expand and maintain metabolic homeostasis and insulin 
sensitivity. They were used to support the overall AT 
expandability hypothesis which is the basis of all our studies.  
6. I am not sure whether it is acceptable in scientific work to use an 
adipocyte different ion medium provided by a manufacturer, which 
ingredients are not fully disclosed. How can people reproduce your 
work with non-LONZA medium, or will your work forever be specific for 
Lonza medium-cultivated cells. At least this should be stressed in the 
results and discussion section that the universality of your data is strictly 
limited to this culture medium. Why was it not possible, as many other 
labs to make your own differentiation medium? FBS is variable enough 
as an additive, so at least the concentration of components of the other 
ingredients should be clear. 
• Primary human adipocytes can be differentiated with either in-
house reconstituted adipogenic medium or commercially 
available (such as Lonza) adipogenic medium. In our experience, 
Lonza medium induces better and faster adipogenesis in SC 
adipocytes within 10 days without any need for replacing fresh 
differentiation medium. Maturation of these subcutaneous 
adipocytes takes approximately 21 days while using in-house 
formulated differentiation medium. 
• During initial validation experiments in our study, SGBS 
adipocytes were differentiated with both Lonza and SGBS 
differentiation medium. Phenotype and gene expression pattern 
was similar in SGBS adipocytes differentiated with either 
adipogenic medium. However, SC adipocytes did not 
differentiate well when subjected to SGBS differentiation 
medium due to the absence of FBS in it. Thus, we eventually 
used their respective ‘optimal’ differentiation medium for both 
cells types due to following reasons: 
o To standardize differentiation timeline to 10 - 12 days in 
both adipocyte models. (For near complete 
differentiation, Lonza differentiation medium in SC 
adipocytes and SGBS differentiation medium for SGBS 
adipocytes). 
o To mimic most widely used and published differentiation 
conditions for SGBS adipocytes since we were trying to 
characterize both the adipocyte models using the most 
commonly used protocols [18].  
• Results of this study will be best replicated when primary 
adipocytes are differentiated using Lonza differentiation 
medium and SGBS adipocytes will be differentiated using 
recommended in-house or Lonza differentiation medium.  
7. It is stated the SGSB went brown while SVF went white after 
differentiation. However, you added rosiglitazone and T3 to SGBS and 
not to SVF so of course they did not go white, what happened if you gave 
the rosiglitazone, and T3-containing protocol to SVF, while exposing 
SGBS to LONZA medium? Was there underlying knowledge and 
rationale why you gave SGBS only the brown and the primary 
adipocytes only the white treatment? So it is no wonder you get different 
gene expressions. So what was the goal, to find a difference between 
human brown and white expression or of different cell sources. You 
could have used a white and a brown protocol on the same cell type and 
seen the gene expression differences. At the moment this thesis compares 
a normal and a mutated subcutaneous cell source not in one protocol 
but with two different differentiation protocols. Thus the comparison 
appears to make little sense. The observed differences could merely be 
caused by the different differentiation media. For example the intrinsic 
brown potential in SGBS, might have been visible already in a white 
differentiation setting? Please explain. 
• Motives to use their respective differentiation medium have been 
discussed in the previous section.  
• Rosiglitazone and T3 (triiodothyronine) are known inducers of 
browning in-vitro. Thus, in addition to complete adipogenic 
medium, we also differentiated SGBS adipocytes in medium 
depleted with either T3 or rosiglitazone individually or in 
combination. UCP1 protein expression remained similar in all 
the above mentioned conditions. These results are discussed in 
section 3.3.4. This suggests that browning potential observed in 
SGBS adipocytes is an inherent capacity, which might be due to 
either (1) underlying mutation in GPC3 or OFD1 gene (not 
characterized yet) or (2) the fact that they originate from the 
subcutaneous white AT of a 3 month old infant.  White AT from 
infants is known to be metabolically very active with a greater 
number of mitochondria [5]. 
• Irrespective of certain limitations, SGBS serves as a valid 
adipocyte model especially when one needs to evaluate and 
compare phenotype in both white and brown adipocytes. 
8. RNA-seq and PCR validation correlation, UCP-1 and inflammation 
markers do not seem to correlate that much, what role did leptin as 
maturation marker play here; it seems to be missing from Fig 23. 
• Leptin was not significantly different between SGBS and SC 
adipocytes in RNA-seq data (P > 0.05) and thus not included in 
this analysis.  
• Fold changes (SGBS vs SC control adipocytes) in the expression 
of UCP-1 and inflammation genes were marginally higher when 
analysed with qPCR when compared to RNA sequencing data. 
Due to these differences in expression pattern, a shift in 
Pearson’s co-relation coefficient may arise.  
9. Not clear how brown and white are defined in your study. UCP-1 for 
brown is clear; however, what was your criterion for white – simply 
absence of UCP-1? What role did you assign to leptin in your 
differentiation system, a white or maturation marker? 
• Presence of UCP-1 protein was used as a definitive marker of 
browning in all our studies. White adipocytes were defined by; 
(1) absence of UCP-1 protein expression and (2) decreased 
mitochondrial number and mitochondrial respiration in them. 
• Lipid storage capacity was not used as a marker for white or 
brown adipocytes.   
• Leptin was used as a marker of maturation in adipocytes.  
10. Genes up and down. As long as you do not know the protein expression 
levels you will not knowhow significant these data are. The ECM genes 
for example show some discordance between mRNA and protein levels. 
It is conceivable that after ample deposition of a certain collagen for 
example, like type IV, mRNA levels will drop in response to that as in a 
negative feed-back loop. In this case, an mRNA analysis would suggest 
“reduced expression” while in reality a lot of the protein is around (see 
Ang et al 2014 on collagen IV). 
• Strength of RNA sequencing is limited to analysis of transcript 
expression. It allows visualization of the whole transcriptome 
and pathway interactions within the transcriptome. As suggested 
by the examiner, discordance between mRNA and protein 
expression is expected and we have updated this as a limitation 
of our study in the discussion of the chapter (section 6.4).  
• Revised text: 
Pathogenic contribution of ECM and fibrosis components in 
obese and in diabetics is being understood progressively. Our 
analysis showed upregulation of transcripts annotated to ECM 
and fibrosis components in OM depot from T2DM compared to 
OM depot from NT2DM subjects. However, it is important to 
consider possible discordance between expression at transcript 
level and protein level and selected genes will need further 
validation. 
11. Define “healthy adipocyte function” 
• In our understanding, healthy adipocyte function can be defined 
as a state where adipocytes are able to maintain their 
physiological functions such as lipid storage, lipid utilization, 
adipokine secretion and expandability even in the presence of 
stress inducers such as excess nutrients. Overloading of 
adipocytes with excess free fatty acids, glucose and certain 
amino acids is known to disrupt its functions and the insulin 
signalling pathway and lead to dysfunctional adipocytes.  
 
12. Numbering of chapters skips jumps from 6 to 8 and omits. 
• Corrected in thesis. 
13. Figure 5: ECM, laminins do not form fibers, I would prefer the term 
supramolecular assemblies to macromolecules, as these assemblies are 
made from macromolecules. 
• Corrected in the thesis.  
 
Figure 1: Basic components of ECM. ECM composition is tissue specific and 
varies with obesity and age in AT. Macromolecules including fibrous proteins 
and proteoglycans support internal cellular components and enzymes such as 
MMPs which are usually involved in degeneration of ECM, particularly 
important for a process like bone resorption, migration and tissue remodeling.  
14. P 6 spell out TAG here, it’s the first you use the abbreviation. 





(heparan sulfate, chondroitin sulfate 
and keratan sulfate)
Fibrous proteins
(Collagens, elastins and fibronectins)
Enzymes
Serine proteases, threonine proteases and matrix 
metalloproteins (MMPs)
15. Resolution of images (At least in my copy of the thesis) is often 
substandard. When lifted from pdf documents enlarge at least to 400% 
before you snapshot them and paste them. Figures 15, 17-19, 41, 46 -55 
etc are in the softcopy not legible at all, and a lot of other figures look 
pixelated and annoy the reader. 
• Have changed the figures with higher resolution images or have 
added magnified images of individual sub-components for easier 
reading. 
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Figure 2: Global transcriptome profiling of SGBS and SC adipocytes 
(volcano plot). Volcano plots displaying number of differentially expressed 
genes in SGBS adipocytes compared to SC adipocytes. Red dots denote 
statistically significant genes. Genes with FDR < 0.05 and log (FC) > 0.60 were 
included. For the experiments involving SC adipocytes, experiments were 
performed in cells derived from 4 different donors (SC_1 to SC_4). For SGBS 
adipocytes, experiments were performed in duplicates (SGBS_1 and SGBS_2) 
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Figure 17: Fully differentiated SGBS and SC adipocytes display distinct 
ontology clustering. FPKM values were analyzed in gene set enrichment 
analysis (GSEA) desktop version [6] and the output was exported in Cytoscape 
3.3 (plugin: enrichment map creator) [7] to generate a map of positively and 
negatively enriched gene ontologies. Size of the node predicts the number of 
genes in particular ontology and green connecting line represents number of 
common genes. Blue and red color denotes down and upregulated ontologies 
respectively (SGBS vs SC adipocytes). Cut off value for generating 
KappaB-Kinase signaling regulation 
Remaining smaller clusters 
enrichment map was capped at conservative (P-value < 0.001, FDR < 0.05). 
Each cluster is magnified and shown separately.  
 
Figure 18: Representation of fold changes in ECM-receptor interaction 
pathway (SGBS vs SC adipocytes). Output was generated with help of 
iPathwayGuide. Blue and red colors symbolize downregulated and upregulated 
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Figure 19: Representation of fold changes in fatty acid metabolism 
pathway (SGBS vs SC adipocytes). Output was generated in iPathwayGuide. 
Blue and red colors symbolize downregulated and upregulated genes 


















 Figure 3: Euclidean distance (sample – to – sample distance) heatmap of all 
tissue RNA-SEQ data. Tissue samples are individually arranged on X and Y 
axis with each sample being compared to the other. Darker shades of blue 
denote decreased distance or increased similarity between the compared 
samples. As seen, all SC samples clustered together and distinctly from OM 
samples. This suggests considerable transcriptome variation among the SC and 










COL4A5, ITGB8 CSF3 
Figure 4: Representation of fold change of genes in PI3K-Akt signaling 
pathway in T2DM subjects. Fold changes in genes are represented by colors 
(upregulation – towards red and downregulation – towards blue).Green text 
boxes represent genes in GF (growth factor), cytokine and ECM within PI3K-
Akt signaling pathway. 
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Figure 5: ECM receptor interaction pathway genes in NT2DM and T2DM 
subjects. Log (FC) for all the genes were plotted (Log FC ≥± 0.6 and FDR < 
0.05). Genes below the cut off values in either NT2DM or T2DM are indicated 
































Figure 6: Positively enriched cellular components in NT2DM (OM vs SC). 
Upregulated genes were analyzed using DAVID bioinformatics and the 
“functional annotation chart” output was exported in Cytoscape 3.3 (plugin: 
enrichment map creator) [7] to generate a map of enriched GO_CC. Size of the 
node predicts the number of genes in particular ontology with green connecting 
line representing number of common genes. Cut off value for generating 




























































Figure 7: Negatively enriched cellular components in NT2DM (OM vs SC). 
Downregulated genes were analyzed using DAVID bioinformatics and the 
“functional annotation chart” output was exported in Cytoscape 3.3 (plugin: 
enrichment map creator) [7] to generate a map of enriched GO_CC. Size of the 
node predicts the number of genes in particular ontology with green connecting 
line representing number of common genes. Cut off value for generating 




























































































































Figure 8: Positively enriched cellular components in T2DM (OM vs SC). 
Upregulated genes were analyzed using DAVID bioinformatics and the 
“functional annotation chart” output was exported in Cytoscape 3.3 (plugin: 
enrichment map creator) [7] to generate a map of enriched GO_CC. Size of the 
node predicts the number of genes in particular ontology with green connecting 
line representing number of common genes. Cut off value for generating 




















































































Figure 9: Negatively enriched cellular components in T2DM (OM vs SC). 
Downregulated genes were analyzed using DAVID bioinformatics and the 
“functional annotation chart” output was exported in Cytoscape 3.3 (plugin: 
enrichment map creator) [7] to generate a map of enriched GO_CC. Size of the 
node predicts the number of genes in particular ontology with green connecting 
line representing number of common genes. Cut off value for generating 
enrichment map was capped at conservative (P-value < 0.001, FDR < 0.05). 
Figure 10: KEGG pathway enrichment and their interaction map illustrating 
transcriptomic signatures in T2DM compared to NT2DM subjects. FPKM values 
were analyzed in gene set enrichment analysis (GSEA) desktop version [165] and the 
output was exported in Cytoscape 3.3 (plugin: enrichment map creator) [163] to generate 
a map of positively and negatively enriched gene ontologies. Inner node represents 
enrichment in SC depot (left cluster) and OM depot (right cluster). Size of the node 
predicts the number of genes in particular ontology with green connecting line 
representing number of common genes or interaction. Blue and red color denotes 
significant negative and positive enrichment respectively. Cut off value for generating 
enrichment map was capped at permissive (P-value < 0.05, FDR < 0.25). 
 
Figure 11: GO cellular component enrichment and their interaction map 
illustrating transcriptomic signatures in T2DM compared to NT2DM 
subjects. FPKM values were input into gene set enrichment analysis (GSEA) 
desktop version [165] and the output was exported in Cytoscape 3.3 (plugin: 
enrichment map creator) [163] to generate a map of positively and negatively 
enriched gene ontologies. Inner node represents enrichment in SC depot and 
outer border in node represents enrichment in OM depot. Size of the node 
predicts the number of genes in particular ontology with green connecting line 
representing number of common genes or interaction. Blue and red color 
denotes significant negative and positive enrichment respectively. Cut off value 







































































 Figure 12: Heat map and enrichment plots of ECM genes in OM depot 
(T2DM vs NT2DM). Each black vertical line in enrichment plot denotes one 
gene and color bar represents gene rank within list of genes. Output was 
generated in GSEA and significance was capped at P < 0.05. 
COL16A1, COL6A3, ADAMTS5, 
LAMC1, FBLN2, ECM2, THBS4, 
DGCR6, MGP, SOD1, COMP, 
POSTN, LAMB2, ADAMTS9, 
COL5A2, LTBP2, FBLN5, DMD, 
COL15A1  LUM 
 
  
AGT, TIMP4, ITGB1, EDN1, ITGA1, 
BCL2, LOX, THBS2, ITGB5, SMAD3, 
ITGAV, LTBP1, JUN, THBS1, PDGFA, 
TGFBR2 
 
Figure 13: Enrichment analysis of fibrosis genes in T2DM compared to 
NT2DM (SC and OM depots). Each black vertical line in enrichment plot 
denotes one gene and color bar represents gene rank within list of genes. Output 
was generated by analyzing genes of interest using GSEA and significance was 




16. Table 2: mouse cells should be shown as a group separate from human 
cells, and not in mixed order. The point is that that much knowledge in 
human cells does not exist; most of the work in adipocyte biology is 
mouse-heavy. 
• Order of cells revised. 
• New table 
Cell line/model Origin Reference  
Adipocytes from rodent models 












Adipocytes from human derived adipose depot 
Human or animal 
preadipocytes 
Mature adipocytes 
from adipose tissue 
depot from humans or 





or SGBS adipocytes 
3 month old infant 
suffering from SGBS 
[2] 
Table 1: Adipocyte models used for research. 
17. 3.2.4 “GAPDH (Cell Signalling)” in Western Blotting is not used for 
cell signalling but as a housekeeping protein analogously to a 
housekeeping gene  
• Cell signalling is the name of the company where antibody was 
bought from. Have correct it to GAPDH (Cell Signalling, MA, 





1. Page 6. It is remarkable that the main function of adipose tissue, storage 
of fuel is not included. 
• Have updated the introduction section in the thesis accordingly.  
• Revised part: 
Conventionally, AT was considered as merely a storage organ 
for excess nutrients in the form of lipid droplets which could be 
utilized during periods of fasting/starvation via lipolysis. Over 
the years, more complex functions of fat (mentioned below) 
were slowly understood. Figure 4 summarizes known functions 
of AT. AT functions include: 
1. Endocrine function: secretion of hormones such as leptin 
[12, 13] and adiponectin [14] which regulate food intake and 
fuel utilization. 
2. Regulation of angiogenesis to support adipocyte growth 
within the tissue [15]. 
3. Regulation of inflammation and macrophage infiltration 
[16]. 
4. Metabolic functions including lipogenesis, lipid storage and 
lipolysis. 
In healthy individuals, the degree of lipid storage or 
breakdown is controlled primarily by insulin and glucagon 
hormones. During the fed state, insulin promotes the storage 
of dietary lipids in AT. After being absorbed, free fatty acids 
are converted to TAGs (triacylglycerol/triglycerides) in the 
liver and transported to the AT after being packaged inside 
lipoproteins. Inside adipose, lipase enzyme in the plasma 
membrane of adipocytes breaks these TAGs to free fatty 
acids which eventually enter inside ER as fatty acyl-CoA. In 
ER, these fatty acyl-CoA are converted back to TAGs (re-
esterification) and stored in lipid droplets. Adipocytes also 
synthesize free fatty acids such as palmitic acid from acetyl-
CoA by the process of de novo lipogenesis. 
During fasting state, glucagon hormone is secreted from 
pancreatic alpha cells, which in turn activates lipolysis of 
stored TAGs in adipocytes. Free fatty acids released upon 
lipolysis are distributed to energy deficient tissues such as 
skeletal muscle. Here, these free fatty acids are oxidized into 
acetyl-CoA in mitochondria via β-oxidation pathway to 
generate energy in the form of ATP. 
2. Page 7. It is important not to confuse de novo lipogenesis with fatty acid 
resterification. The text should indicate where the fatty acids released 
by AT go e.g. muscle, to synthesise ATP in their mitochondria. 
• Have updated the introduction section 1.3 in the thesis (also 
mentioned in comment 1 by examiner 3). 
Chapter 3 Comparison of experimental models: SGBS vs primary 
subcutaneous adipocytes. 
3. Figure 16: could be labelled more intuitively easier and independent of 
the main text. Identification of clusters should be clearer. 
• Updated the figure legend and also added figures with magnified 
view.  
 
Figure 16: Transcriptome profiling of top 1000 differentially 
expressed genes in SGBS adipocytes. Heat map clustering 
(unsupervised) top 1000 significantly upregulated (red) or 
downregulated (blue) genes in SGBS (n = 2) when compared to SC (n = 
4) adipocytes. Enriched genes ontologies in up (lipid metabolism) or 
downregulated (membrane, extra-cellular matrix) set of genes in SGBS 
adipocytes are denoted on the right side of the figure.  For the 
experiments involving SC adipocytes, experiments were performed in 



































































adipocytes, experiments were performed in duplicates (SGBS_1 and 
SGBS_2) from the same SGBS adipocyte. 
4. Figure 17 does not permit reading the content of the enrichment map of 
gene ontologies. It is too small. 
• Have added magnified view of each ontology clusters for better 
understanding. Figure included in previous comments.  
5. Figure 18 it is difficult to read. Dark blue colours not appropriate to 
read inside boxes. 
• Have improved the contrast in the figure. Included in previous 
comments. 
6. Figure 19. Too small font 
• Have magnified the figure and made text sharper for better 
visualization. Included in previous comments. 
7. Page 67. PGC1a is not a transcription factor. It is a coactivator of 
several transcription factors. 
• Have corrected this in text in section 5.4 
• Revised text 
In all cell types in humans, mitochondrial biogenesis and 
adaptive thermogenesis are regulated primarily by upstream 
transcriptional coactivator PGC1α in conjunction with NRF1 
(nuclear respiratory factor 1) which is strongly activated by 
cAMP and cytokine pathways [17]. 
8. Figure 24 B. It is unclear how this experiment was performed. The graph 
should include information on the specific treatments. Also, some 
indication of increased mitochondria per/cell would have been helpful. 
• Have updated in the protocol section 2.8.  
• Updated version 
XF Cell Mito Stress test kit (Seahorse Bioscience) was used to 
measure mitochondrial function in adipocytes in a 24 well plate 
format. Data were reported as pmoles of oxygen consumed per 
minute or oxygen consumption rate. Cellular respiration 
parameters calculated are basal respiration, ATP production, 
proton leak, maximal respiration and spare respiratory capacity. 
As suggested by the manufacturer, 5 replicates of control, 
treatment conditions and negative controls were used. 
Oligomycin inhibits ATP synthase (complex V) and the decrease 
in OCR following injection of oligomycin correlates to the 
mitochondrial respiration associated with cellular ATP 
production. Carbonyl cyanide-4 (trifluoromethoxy) 
phenylhydrazone (FCCP) is an uncoupling agent that collapses 
the proton gradient and disrupts the mitochondrial membrane 
potential. As a result, electron flow through the ETC is 
uninhibited and oxygen is maximally consumed by complex IV. 
The FCCP-stimulated OCR can then be used to calculate spare 
respiratory capacity, defined as the difference between maximal 
respiration and basal respiration. Spare respiratory capacity is a 
measure of the ability of the cell to respond to increased energy 
demand. The third injection is a mix of rotenone, a complex I 
inhibitor, and antimycin A, a complex III inhibitor. This 
combination shuts down mitochondrial respiration and enables 
the calculation of non-mitochondrial respiration driven by 
processes outside the mitochondria. 
• We have used relative quantification of mitochondrial DNA as a 
surrogate marker of mitochondrial content. The results are 
presented in figure 24 C.  
Figure 24: SGBS and its browning phenotype. (A) UCP1 protein expression in 
differentiated SGBS and SC adipocytes at basal level and upon depletion of T3 and 
rosiglitazone (rosi) from differentiation medium. (B) Mitochondrial respiration 
measured as oxygen consumption rate in SGBS and SC adipocytes (detailed protocol 
discussed in section 2.8 (C) Mitochondrial DNA content measured the ratio of 
mitochondrial DNA (mtDNA) by nuclear DNA (nDNA). Data represented as mean ± 
SEM obtained from three different donors for SC adipocytes (in duplicates) and three 
independent trials for SGBS adipocytes.*P < 0.05, **P < 0.005. 
9. This differential differentiation occurred with a cocktail targeted for 
white or brown differentiation? 
• SGBS adipocytes show a high level of UCP1 mRNA and protein 
expression irrespective of the differentiation medium used 
(discussed in previous comments). On the other hand, in our 
experience, SC adipocytes show a minimal increase in UCP1 
expression when differentiated with the conventional adipogenic 
medium. Studies have observed moderate upregulation in UCP1 
expression after adding BMP4 to adipogenic cocktail [18], but 
does not equate with approximately 1500 higher fold induction 
of UCP1 in SGBS adipocytes. Thus, differential differentiation 
of SC towards white phenotype and SGBS towards brown 
phenotype seemed to be an inherent property, and not influenced 
by differentiation medium composition.  
10. How do you reconcile the increase in oxidative capacity and the 
increase in triglyceride deposition? Any insights of de novo lipogenesis? 
• RNA-sequencing data shows that key genes involved in various 
lipid metabolism genes are expressed higher in SGBS adipocytes 
when compared to SC adipocytes. These pathways include de-
novo lipogenesis (Figure 19), triglyceride biosynthesis as well as 
lipolysis. Based on these readouts, we cannot explain higher 
amount of TAG accumulation in SGBS adipocytes. Most 
importantly, RNA sequencing data is unable to predict 
information about the hormonal and post-translational regulation 
of lipid metabolism. However, higher TAG accumulation 
coupled with increased mitochondrial oxidative capacity 
suggests that SGBS adipocytes may have suppressed lipolysis 
which allows TAGs to accumulate inside the adipocytes. 
11. Is the increased browning of the SGBS cells relevant for the phenotype 
of the patient? 
• SGBS patients suffer from growth abnormalities, with no 
reported brown or beige phenotype in their AT.  
Chapter 4 Deficiency of FIT2 protein impairs triglyceride storage and 
insulin signalling in adipocytes.  
12. Figure 26. Shows that genes in OM are less expressed than in SC in both 
Non-Diabetics and Diabetics. However, this figure does not tell whether 
the Diabetic patients had lower level in absolute terms in comparison to 
non‐Diabetics. 
• FIT2 mRNA expression is lower in OM depot when compared 
to SC depot in both NT2DM and T2DM subjects. In absolute 
terms, mRNA expression in SC and OM depot from NT2DM 
subjects is similar to respective SC and OM depot from T2DM 
subjects. The expression trends differ more at the protein level. 
Compared to NT2DM subjects, T2DM subjects tend to have 
lower FIT2 expression in both OM (P < 0.05) as well as SC depot 
(non-significant). 
13. FIT2 is highly expressed in Brown AT. The role of this gene in BAT may 
also be relevant for the browning of the white AT as well as for the size 
of the lipid droplets and mobilisation of lipids required for 
thermogenesis. 
• Based on our results after FIT2 knockdown in adipocytes, it is 
unlikely that FIT2 protein will independently drive browning or 
differentiation (PPARγ and CEBPα remain unchanged upon 
FIT2 knockdown). In BAT, role of FIT2 protein would probably 
be similar to WAT i.e. TAG distribution and lipid droplet size 
determination. Absence of FIT2 protein drives the formation of 
larger lipid droplets as observed in adipocytes from AT specific 
knockout mice [19]. Typically, smaller lipid droplets undergo 
more efficient lipolysis and thus contribute towards maintaining 
adipocyte health [19].  
14. Figure 30: There seems to be a difference between the effect at mRNA 
and protein level. Is there any evidence for regulation at the level of 
protein degradation? 
• To our knowledge, there are no known post transcriptional or 
post translational modifications of FIT2. The difference between 
mRNA and protein expression may be implicated to the longer 
half-life of FIT2 protein. 
15. Any information about the promoters of FIT1 and FIT2? Their 
comparative analysis may help to understand their regulation and the 
possibility that may be regulated by insulin.  
• PPARγ is a known transcriptional regulator of FIT2 gene 
expression during adipogenesis [20]. In-silico predicted 
transcription factors of FIT2 gene include PPARα, PPARγ1, 
PPARγ2, CREB, ΔCREB, FOXC1, FOXO3a, FOXO3b, FOXF2 




ngene=n&B2=Search). Their role in-vitro or in-vivo has not 
been examined yet. 
• Predicted transcription factors for FIT1 include TBP, AML1α, 
TFIID, GATA-2, FOXF2, STAT5A and SREBP1C. (Predicted 
by SABiosciences' Text Mining Application 
http://www.sabiosciences.com/chipqpcrsearch.php?species_id=
0&nfactor=n&ninfo=n&ngene=n&B2=Search&src=genecard&
factor=Over+200+TF&gene=FITM1). Based on these details 
about transcription factors, FIT1 and FIT2 genes seem to have 
distinct transcriptional control. 
• In our experiments, FIT2 protein expression was unchanged 
upon 30 minute insulin stimulation. 
16. Any information about expression in FIT2 in macrophages? 
• FIT2 mRNA is expressed is very low in the macrophages. 
However, its protein expression has not been investigated in 
blood borne and plasma cells.  
Chapter 5: FTO protein knock down or chemical inhibition of FTO can 
increase energy expenditure in human adipocytes 
17. Page 107: It would be nice to explain well how these treatments (FCCP, 
rotenone, antimycin etc) work. 
• Have updated in the protocol section 2.8.  
• Updated version 
XF Cell Mito Stress test kit (Seahorse Bioscience) was used to 
measure mitochondrial function in adipocytes in a 24 well plate 
format. Data were reported as pmoles of oxygen consumed per 
minute or oxygen consumption rate. Cellular respiration 
parameters calculated are basal respiration, ATP production, 
proton leak, maximal respiration and spare respiratory capacity. 
As suggested by the manufacturer, 5 replicates of control, 
treatment conditions and negative controls were used. 
Oligomycin inhibits ATP synthase (complex V) and the decrease 
in OCR following injection of oligomycin correlates to the 
mitochondrial respiration associated with cellular ATP 
production. Carbonyl cyanide-4 (trifluoromethoxy) 
phenylhydrazone (FCCP) is an uncoupling agent that collapses 
the proton gradient and disrupts the mitochondrial membrane 
potential. As a result, electron flow through the ETC is 
uninhibited and oxygen is maximally consumed by complex IV. 
The FCCP-stimulated OCR can then be used to calculate spare 
respiratory capacity, defined as the difference between maximal 
respiration and basal respiration. Spare respiratory capacity is a 
measure of the ability of the cell to respond to increased energy 
demand. The third injection is a mix of rotenone, a complex I 
inhibitor, and antimycin A, a complex III inhibitor. This 
combination shuts down mitochondrial respiration and enables 
the calculation of non-mitochondrial respiration driven by 
processes outside the mitochondria. 
18. Any evidence of changes in the number of mitochondria? Results of 
Oxygen consumption after FCCP is compatible with increased number 
of mitochondria 
• We have evaluated mitochondrial DNA content and expressed it 
as a ratio of mitochondrial DNA: nuclear DNA (figure below). 
This serves as a surrogate marker for a number of mitochondria 
and remained unchanged with either FTO knock-down or 
inhibition suggesting the influence of FTO protein on 
mitochondrial function and not quantity. Figure attached.  











































Chapter 6: Transcriptomic Analysis reveals a role for extracellular matrix 
and fibrosis pathways in maintaining healthy human adipose tissue 
function in obese non diabetics. 
19. Fig 41 may benefit from a more clear explanation in the legend 
independent from the main text. 
• Included more comprehensive explanation in the figure legend. 
Figure included in previous comments. 
20. To what extent the difference could be explained by different in 
macrophage concentration? 
• Transcriptomic data does not enable us to predict the 
contribution of macrophage infiltration. Examiner’s concern is 
justified as ECM components are secreted mostly by 
preadipocytes during maturation and onsite macrophages [21, 
22]. Our aim was to investigate transcriptomic signatures using 
the whole tissue, and in future, we can perform tissue sectioning 
and imaging to study the probable influence of macrophage 
infiltration.  
21. Figure 46: may benefit from increased font that could make it easier to 
read. 
• Have enlarged figure and improved colour contrast for easier 















1. Shulman, G.I., Ectopic fat in insulin resistance, dyslipidemia, and 
cardiometabolic disease. N Engl J Med, 2014. 371(12): p. 1131-41. 
2. Wabitsch, M., et al., Characterization of a human preadipocyte cell strain with 
high capacity for adipose differentiation. Int J Obes Relat Metab Disord, 2001. 
25(1): p. 8-15. 
3. Sethi, J.K. and A.J. Vidal-Puig, Thematic review series: adipocyte biology. 
Adipose tissue function and plasticity orchestrate nutritional adaptation. J 
Lipid Res, 2007. 48(6): p. 1253-62. 
4. Virtue, S. and A. Vidal-Puig, It's Not How Fat You Are, It's What You Do with It 
That Counts. PLoS Biol, 2008. 6(9): p. e237. 
5. Hahn, P. and M. Novak, Development of brown and white adipose tissue. J 
Lipid Res, 1975. 16(2): p. 79-91. 
6. Mootha, V.K., et al., PGC-1alpha-responsive genes involved in oxidative 
phosphorylation are coordinately downregulated in human diabetes. Nat 
Genet, 2003. 34(3): p. 267-73. 
7. Merico, D., et al., Enrichment map: a network-based method for gene-set 
enrichment visualization and interpretation. PLoS One, 2010. 5(11): p. 
e13984. 
8. Green, H. and M. Meuth, An established pre-adipose cell line and its 
differentiation in culture. Cell, 1974. 3(2): p. 127-33. 
9. Todaro, G.J. and H. Green, Quantitative studies of the growth of mouse 
embryo cells in culture and their development into established lines. J Cell Biol, 
1963. 17: p. 299-313. 
10. Negrel, R., P. Grimaldi, and G. Ailhaud, Establishment of preadipocyte clonal 
line from epididymal fat pad of ob/ob mouse that responds to insulin and to 
lipolytic hormones. Proc Natl Acad Sci U S A, 1978. 75(12): p. 6054-8. 
11. Sugihara, H., et al., Primary cultures of unilocular fat cells: characteristics of 
growth in vitro and changes in differentiation properties. Differentiation, 
1986. 31(1): p. 42-9. 
12. Zhang, Y.Y., et al., Positional Cloning of the Mouse Obese Gene and Its Human 
Homolog. Nature, 1994. 372(6505): p. 425-432. 
13. Halaas, J.L., et al., Weight-Reducing Effects of the Plasma-Protein Encoded by 
the Obese Gene. Science, 1995. 269(5223): p. 543-546. 
14. Scherer, P.E., et al., A novel serum protein similar to C1q, produced exclusively 
in adipocytes. J Biol Chem, 1995. 270(45): p. 26746-9. 
15. Rupnick, M.A., et al., Adipose tissue mass can be regulated through the 
vasculature. Proc Natl Acad Sci U S A, 2002. 99(16): p. 10730-5. 
16. Hotamisligil, G.S., N.S. Shargill, and B.M. Spiegelman, Adipose expression of 
tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. 
Science, 1993. 259(5091): p. 87-91. 
17. Puigserver, P. and B.M. Spiegelman, Peroxisome proliferator-activated 
receptor-gamma coactivator 1 alpha (PGC-1 alpha): transcriptional 
coactivator and metabolic regulator. Endocr Rev, 2003. 24(1): p. 78-90. 
18. Park, A., W.K. Kim, and K.H. Bae, Distinction of white, beige and brown 
adipocytes derived from mesenchymal stem cells. World J Stem Cells, 2014. 
6(1): p. 33-42. 
19. Miranda, D.A., et al., Fat storage-inducing transmembrane protein 2 is 
required for normal fat storage in adipose tissue. J Biol Chem, 2014. 289(14): 
p. 9560-72. 
20. Kadereit, B., et al., Evolutionarily conserved gene family important for fat 
storage. Proc Natl Acad Sci U S A, 2008. 105(1): p. 94-9. 
21. Trayhurn, P., Hypoxia and Adipose Tissue Function and Dysfunction in Obesity. 
Physiological Reviews, 2013. 93(1): p. 1-21. 
22. Sun, K., et al., Fibrosis and adipose tissue dysfunction. Cell Metab, 2013. 18(4): 
p. 470-7. 
 
